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Abstract 
Lymphoedema is a chronic and incurable condition. It is characterised by impaired 
drainage of lymphatic fluid, resulting in excess accumulation of fluid, and can affect 
all regions of the body. The physical symptoms of lymphoedema vary, but can 
include swelling, heaviness, tightness, numbness and pain, among others. When 
severe, these symptoms can be debilitating and significantly impact on employment, 
social functioning, psychological wellbeing, and on a person’s ability to perform 
daily activities. Without treatment, the condition can progress and there is risk of 
serious complications, including infection. In Australia and other developed 
countries, lymphoedema most commonly develops following cancer treatment. Given 
the high number of people expected to develop lymphoedema each year and the 
widespread impacts on quality of life, the public health implications are clear.  
The primary aim of this PhD research was to consider the patient’s experience of 
lymphoedema and associated treatments, and how this influences long-term 
management of the condition.  In doing so, there were three components to this work. 
As the majority of the research exploring the impact of lymphoedema on quality of 
life has been conducted with women with breast cancer-related lymphoedema, the 
first component of this PhD research was to further understanding of the impact of 
lower-limb lymphoedema (LLL). The focussed review of the literature (subsequently 
published and included in Chapter 2 of this thesis) explored the impact of LLL on 
quality of life following gynaecological cancers. The review confirmed that many of 
the challenges faced by those with ULL are shared by those with LLL. Additional 
concerns of those with LLL included exacerbations of symptoms when required to sit 
or stand for long periods of time, increased concerns about sexuality and intimacy, 
difficulties finding appropriate footwear, and trouble performing self-care aspects of 
treatment.  
The second component of this PhD work aimed to describe the use of different 
treatment types by people with lymphoedema. Secondary data analysis from a study 
focusing on the use of complementary and alternative medicine (CAM) found that 
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people with lymphoedema used a wide range of complementary therapies to manage 
their symptoms. Interestingly, when rating the effectiveness of treatments, both CAM 
and mainstream treatments were considered to be effective (mean±SD: 5.2±1.6 and 
5.3±1.5, respectively, on a 7-point Likert scale). Despite the high perceived 
effectiveness of mainstream treatments, many people were using multiple treatments 
concurrently, and almost half (45%) had also used one of 22 CAM treatments. It is 
plausible that people with lymphoedema use a combination of treatments in order to 
manage different symptoms of lymphoedema. The effectiveness of different 
treatments for improving specific symptoms and patients’ reasons for continued use 
of multiple treatments were considered further in the final component of this work.  
The third component of this research involved the design and conduct of a cross-
sectional study to investigate the use of a range of treatments by people with 
lymphoedema, as well as the factors influencing ongoing treatment use. While 
intervention studies have provided information about the effect of treatments on 
reducing limb volume, little attention has been given to treatment effect on 
lymphoedema-related symptoms, or the burden of long-term treatment on patients. 
Non-adherence to treatment is considered to be the most important modifiable factor 
compromising treatment effectiveness for chronic conditions. The World Health 
Organisation adopts a five-dimensional approach to explaining the factors 
influencing treatment adherence; specifically, health care system factors, social and 
economic factors, treatment-related factors, condition-related factors and patient-
related factors. A primary objective of this cross-sectional study was to examine the 
relationship between these factors and use of lymphoedema treatment(s).  
The self-administered questionnaire developed for this study, was completed by 421 
eligible participants; adults aged 18-91 years diagnosed with primary or secondary 
lymphoedema, living in Queensland, New South Wales or Victoria. Similar 
proportions of participants had ULL (46%) and LLL (44%), while 10% had 
symptoms affecting multiple regions of the body. The questionnaire was used to 
collect information about a range of social and economic characteristics, 
lymphoedema characteristics, partcipants’ use, perceived effectiveness and 
acceptability of treatments, and reasons for ceasing treatment use. The study focussed 
on the most commonly prescribed mainstream treatments: compression garments, 
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self-administered massage, manual lymphatic drainage (MLD), prescribed exercises, 
complex physical therapy (CPT), compression bandaging, pneumatic compression 
pumps, laser therapy and surgery. In addition, open-ended questions allowed 
participants to provide information about additional treatments they had used. 
Descriptive analyses were used to examine and present the range of treatments used, 
as well as the acceptability and effectiveness of treatments. Bivariate analyses 
stratified by lymphoedema location were used to investigate subgroup differences in 
treatment use between those with upper- versus lower-limb lymphoedema. 
Multivariable logistic regression analyses were conducted to explore the complex 
relationships between healthcare team and system factors, social and economic, 
treatment-, condition- and patient-related factors, and lymphoedema treatment use.  
The majority of people with lymphoedema had used multiple treatments to manage 
their symptoms, with compression garments (86%), self-administered massage 
(79%), prescribed exercises (69%) and MLD (67%) used most commonly. Over half 
(62%) of all participants had used more than four treatment types, while 5% had used 
only one type of treatment. Patients’ continued use of treatment (considered an 
indicator of long-term use) varied widely across treatment types. For example, less 
than half of those who had used laser, CPT and/or bandaging reported continued use 
(43%, 32%, 30%, respectively), whereas 79%of participants who had ever used 
compression garments were currently using them. Participants reported experiencing 
improvements in swelling, heaviness and tightness following treatment, irrespective 
of the type of treatment. Across the range of lymphoedema-associated symptoms, 
compression garments, CPT, compression bandaging and MLD were reported as 
effective by higher proportions of participants than other treatments (40-60% 
reporting symptom improvements, compared with <30% reporting improvements in 
symptoms following exercises and self-massage).  
The cost, time and discomfort associated with treatment were considered 
unacceptable by a significant proportion of people with lymphoedema, and these 
factors represented common reasons for stopping treatment. For example, over half 
of the participants who used compression garments found the cost unacceptable. The 
time involved with treatment was most significant for intensive treatments (CPT, 
compression pumps and compression bandaging) and was reported as unacceptable 
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by 20-27% of participants. Around one in three people who had used compression 
bandaging (36%) and garments (31%) found the discomfort unacceptable. Also, 
between 26-36% stopped using CPT, compression garments, laser therapy or MLD 
because the treatment was too expensive, while 23-40% cited the effort involved as 
the reason they stopped using prescribed exercises, compression garments and 
bandaging, and self-massage. The time involved was a reason for ceasing use of self-
massage, prescribed exercises, MLD and CPT, for between 23-40% of those no 
longer using each treatment. Of note, these findings were consistent irrespective of 
sociodemographic characteristics.  
Results from adjusted multivariable analyses supported the hypothesis that continued 
use of treatment was associated with patient-reported acceptability and effectiveness. 
Acceptability of time and discomfort involved with undertaking treatment was 
associated (p<0.05) with continued use. That is, odds of continued use of MLD, 
compression garments, bandaging, self-massage and CPT was 2+ times higher for 
those who found the time and discomfort acceptable, compared with those who found 
time and discomfort unacceptable. Further, those who perceived the treatment as 
being effective at improving LE and its associated symptoms had higher odds (2+, 
p<0.05) of continued treatment use than those who did not perceive the same level of 
benefit for compression garments, self-administered massage, prescribed exercises 
and MLD.  
Previous research has found CPT, compression garments and bandaging contribute to 
significant volume reductions, and the current study has confirmed that these 
treatments are also perceived by patients to be effective for improving a range of 
other lymphoedema symptoms. However, this research shows that the cost and 
discomfort associated with these treatments were considered unacceptable to 
significant numbers of participants. Further, the effort involved and difficulties 
accessing treatment were raised by participants as additional reasons for 
discontinuing treatment. These are important considerations for health professionals 
supporting patients with long-term lymphoedema management.  
When research findings suggest particular treatments improve symptoms and 
complex treatment programs are prescribed, it is essential to consider the burden of 
treatment and the ability of patients to overcome treatment barriers, in order to 
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maximise treatment success. This study was the first to focus on the patient’s 
perspective of lymphoedema treatment effectiveness and acceptability. Physical 
responses to treatment are likely to vary between individuals, and the availability and 
accessibility of treatment differ according to patient-related factors (e.g., affordability 
of compression garments and MLD) and health-care system factors (e.g., adequately 
trained health professionals in regional areas). In addition, people may have difficulty 
performing self-management activities, and do not always have a support person 
available to assist long-term. It is necessary for health professionals to consider all of 
these factors to ensure appropriate treatment prescriptions are made. Future research 
is needed to determine the most effective and feasible treatment options for all 
aspects of this chronic condition. This research has shown that improvements in 
physical symptoms, function, mobility and visual appearance are important to the 
majority of people with lymphoedema, highlighting the need to consider these 
outcomes as additional measures of treatment effect in future efficacy and 
effectiveness research. Considering long-term treatment is required to prevent 
progression of lymphoedema and complications, it is important to consider the 
commitment required by patients and minimise the impact of the cost, time, effort 
and discomfort associated with treatment. 
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Chapter 1: Introduction 
1.1 BACKGROUND 
Lymphoedema is a chronic condition that can have a significant impact on quality of 
life. In Australia, and other developed countries, cancer treatment is the most 
common cause of lymphoedema 1. Although advances in cancer diagnosis and 
treatment have led to increased survival rates, a cancer diagnosis can have long 
lasting effects on patients. Current estimates suggest more than 8,000 patients are 
expected to develop secondary lymphoedema following cancer in Australia each year 
2. Lymphoedema is reported to be among the most serious and feared sequelae of 
cancer treatment 3–5, with some patients describing living with secondary 
lymphoedema as more distressing than their original cancer diagnosis 6.  
Over the past 50 years, considerable research has been done in the area of 
lymphoedema treatment. This has led to greater understanding and change of practice 
in some areas of lymphoedema management (e.g., patients are now often advised to 
use the affected limb in daily activities and exercise, compared to past advice to 
avoid exercise) 7,8. However, the quality of the research comparing the efficacy and 
effectiveness of various prevention and treatment options has been variable. 
The majority of lymphoedema treatment studies investigated whether treatments can 
reduce the degree of swelling, often measured by limb volume. Measurements of 
limb volume before and after treatment provide an objective measure of 
improvement, as well as enabling comparisons between treatment types. These are 
important qualities of outcome measures in intervention studies. However, less 
attention has been paid to the other common impacts of lymphoedema, including 
associated symptoms, loss of function, reductions in physical or emotional wellbeing 
and changes in appearance, and to whether treatments have any effects on these.  
The purpose of this research was to investigate the impacts associated with 
lymphoedema that are important to patients, and how these relate to treatment use 
and effectiveness. While previous research has focused on determining which 
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treatments yield the greatest limb volume reductions, this may have limited value in 
the translation of research into best practice. It was hypothesised that patients’ 
perceptions of treatment effectiveness, and the barriers they face in continuing long-
term treatment, are likely to play a significant role in the success of lymphoedema 
treatment.  
1.2 SCOPE OF THIS RESEARCH 
This PhD program of work focussed on adults (over 18 years) with lymphoedema 
and did not include children or adolescents. The burden of treatment for children 
with lymphoedema would impact on both the child and their parent (or other adult 
carer) and would need to be investigated separately. This research had three 
components: (1) a literature review of the quality of life of people with lower-limb 
lymphoedema (LLL) following gynaecological cancers 9; (2) secondary data analysis 
evaluating the use of complementary and alternative medicine (CAM) by people with 
lymphoedema 10, and; (3) the development, conduct and evaluation of a cross-
sectional study exploring the use, acceptability and perceived effectiveness of 
lymphoedema treatment. The latter cross-sectional study included patients with both 
primary and secondary lymphoedema, since treatment is the same irrespective of 
lymphoedema type. While some characteristics of lymphoedema may vary between 
the two groups, for example duration and severity, these possible differences were 
considered to be of interest in this study. Those with secondary lymphoedema 
following any type of cancer were included. The majority of lymphoedema-related 
studies have involved patients with breast cancer-related lymphoedema (BCRL) only, 
limiting the generalisability of research findings beyond breast cancer cohorts. This 
research gap was addressed by the first component of this research, which was a 
review of the literature on the quality of life of those who developed LLL following 
gynaecological cancers, and the cross-sectional study, by including patients who had 
been treated for any type of cancer.  
The cross-sectional study aimed to explore patients’ experiences of a range of 
treatment types. Mainstream treatments include compression bandaging, garments 
and pumps, manual lymphatic drainage (MLD), laser therapy and exercise. Surgery is 
generally only prescribed for those who do not respond to more conservative 
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treatment. These treatments are most commonly prescribed by health professionals, 
and are the focus of the majority of lymphoedema treatment research. While it is  
recognised that the prescription and use of CAM is increasing 11, these treatments 
have been given little research attention. The second component of this study, a 
report of the use of CAM by women with lymphoedema following breast and 
gynaecological cancers, aimed to provide an initial overview of the use of CAM by 
this patient group. While the cross-sectional study focussed on mainstream 
treatments, it also allowed patients to provide information about their use of other 
treatments including CAM.  
1.3 THESIS OUTLINE 
The details of this research program are divided into chapters, as follows: Chapter 2 
provides a comprehensive literature review of the research into lymphoedema 
management and concludes with a conceptual summary illustrating the issues 
potentially influencing lymphoedema treatment adherence and effectiveness. The 
first two components of this PhD research which culminated in the development and 
publication of two manuscripts are presented in Chapter 2. Chapter 3 describes the 
research objectives and design, as well as the methods for data collection and 
analysis. The results addressing each objective of the third component of this work 
are presented in Chapter 4. Finally, Chapter 5 discusses the findings from the cross-
sectional study, the public health significance of the findings and makes 
recommendations for future research.  
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In Australia, lymphoedema most commonly develops after treatment for cancer, and 
is one of the most feared side effects of cancer treatment 12. Treatment for the most 
common male and female cancers, prostate and breast cancer, respectively, place 
patients at risk of developing lymphoedema. Since one in four males and one in nine 
females are diagnosed with these cancers before the age of 85, the public health 
burden of lymphoedema in Australia is significant 13. In addition, lymphoedema is 
also a concern for other common cancers including melanoma and gynaecological 
cancers 2.  
Improving health outcomes and quality of life for those with lymphoedema requires 
an understanding of the longitudinal impact of the condition on patients, 
identification of the most effective treatments, and consideration of the burden 
associated with treatment, in the context of patients’ daily lives. This literature 
review begins by describing lymphoedema symptoms, incidence and prevalence, and 
risk factors. The physical, psychological and social impacts of lymphoedema on 
patients’ quality of life are then discussed, with the peer-reviewed publication that 
resulted from work undertaken in exploring the quality of life impacts of 
lymphoedema included in this section (manuscript 1). 
Improving symptoms and overall quality of life while living with lymphoedema often 
require patients to make a significant commitment to treatment and self-management, 
yet clear evidence-based treatment guidelines are lacking. In order to summarise the 
most current evidence relating to mainstream treatment effectiveness, a critique of 
existing literature and systematic reviews of lymphoedema treatment is presented. 
The use of CAM is also discussed, and the second manuscript written and published 
as part of this PhD follows.  
The impact of treatment adherence on treatment effectiveness is explored, and factors 
associated with treatment adherence are discussed, with consideration of relevant 
health behaviour models. A new conceptual model is presented, depicting 
associations between a range of factors and treatment adherence and illustrating how 
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these factors fit with other health behaviour models. The chapter concludes by 
highlighting the issues that have been identified in previous research as likely barriers 
to effective treatment and long-term lymphoedema management and highlighting 
gaps worthy of further research.   
PART ONE - LYMPHOEDEMA 
2.1 BACKGROUND 
Lymphoedema is a chronic condition characterised by impaired drainage of 
lymphatic fluid, commonly resulting in swelling and skin changes 14. Lymphoedema 
is referred to as primary or secondary lymphoedema depending on its origin. Primary 
lymphoedema is an inherited abnormality or disorder of the lymphatic system and 
typically manifests either at birth, in adolescence or at middle age 15,16. Secondary 
lymphoedema develops following trauma or injury, when the lymphatic system is 
damaged or blocked 17. While the most common cause of secondary lymphoedema 
worldwide is the parasitic infection filariasis, in Australia and other developed 
countries secondary lymphoedema most commonly develops following treatment for 
cancer.  
The International Society of Lymphology (ISL) details a four-stage classification 
system to describe lymphoedema status 18. Stage 0 refers to a sub-clinical condition 
where lymphatic transport is disrupted but there is no evidence of physical 
symptoms. Stage 1 represents swelling that decreases with elevation alone, and when 
the skin is compressed, an indentation may remain (“pitting oedema”). 
Lymphoedema that does not respond to elevation, is chronic in nature and where 
pitting is evident is categorised as Stage 2.  Stage 3 lymphoedema refers to severe 
swelling with the absence of pitting, and with possible skin changes including rashes, 
fibrosis, and seeping. Further, within these stages, when available, severity of 
lymphoedema is classified as minimal, moderate or severe, dependent on limb 
volume difference (<20% increase, 20-40% increase, >40% increase, respectively) 
compared with the unaffected limb, when available 18. In addition to swelling, 
physical symptoms of lymphoedema can include pain, stiffness, numbness, 
heaviness, tightness and reduced strength and range of motion in the affected limb 2. 
 Chapter 2: Literature Review 7 
People with lymphoedema commonly report worsening of symptoms in hot weather, 
or when the limb is overused or restricted to a certain position, for example, sitting 
all day without elevation 19,20. 
2.1.1 INCIDENCE AND PREVALENCE  
Primary lymphoedema can develop as a symptom of a range of congenital 
syndromes, making the incidence difficult to quantify. However, the prevalence 
worldwide is estimated at 0.1-2% 15. Secondary lymphoedema typically affects the 
limbs but can also develop in the trunk, head, neck and genital areas. While 
secondary lymphoedema incidence estimates vary widely (from 5 - 70% depending 
on cancer types), it is conservatively estimated that at least 20% of melanoma, breast, 
genitourinary and gynaecological cancer survivors will develop secondary 
lymphoedema following cancer treatment 2.  
In Australia, one in four males and one in nine females are at risk of developing 
prostate and breast cancers during their life, respectively 13. In addition, 1 in 18 
persons are at risk of developing  melanoma and 1 in 23 women are at risk of being 
diagnosed with any type of gynaecological cancer 13. Five year survival rates for 
these cancers vary between 67 - 92% 13,21. This highlights the public health burden 
associated with secondary lymphoedema, with more than 8,000 Australians expected 
to develop the condition each year 2. One study estimated a prevalence of 
lymphoedema in the general population of 1.33/1,000 3. However, this estimate was 
based on cases identified by an urban health authority and is likely to be an 
underestimation of the true prevalence, not accounting for unreported cases 17.  
2.1.2 RISK FACTORS 
A wide range of possible risk factors associated with the development of secondary 
lymphoedema following cancer treatment has been investigated 2,22,23. The current 
evidence highlights a number of factors that may increase lymphoedema risk, but 
does not enable prediction of who will or will not develop secondary lymphoedema. 
Radiotherapy and extensive surgical treatment, particularly resection of lymphatic 
vessels and lymph node removal, compromise the flow of lymphatic fluid, causing 
lymphoedema 24. Positive associations between chemotherapy and lymphoedema 
have also been reported in a number of studies 25–27. It is widely accepted that the use 
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of conservative treatment, such as sentinel lymph node dissection rather than full 
axillary clearance, reduces lymphoedema risk 28.  
Associations between patient- and disease-related factors and lymphoedema risk are 
less clear 2,29. Whilst some studies have reported that higher body mass index (BMI) 
increases risk of secondary lymphoedema 19,25,30, others have found no association 
31,32. Mixed findings have also been reported for the associations between 
lymphoedema risk and comorbid conditions, age and other demographic factors 2. 
Considering the discrepancies in findings of previous studies, as well as advances in 
cancer treatment, there is a clear need for continued research attention on this topic, 
particularly through prospective cohort studies. 
2.1.3 LYMPHOEDEMA PREVENTION 
Although lymphoedema prevention guidelines exist, these are based on physiological 
knowledge of the lymphatic system and common-sense reasoning, rather than 
scientific evidence 2,28. The broader principles that underpin prevention guidelines 
are: the production of lymph, which is proportional to blood flow, should be 
minimised, and additional blockages to lymph transport should be avoided 28. 
Patients are therefore advised to avoid situations and activities, which increase blood 
and lymph flow (e.g., excessive heat) or obstruct the lymphatic system (e.g., tight 
clothing or jewellery). Specific guidelines to prevent lymphoedema include: avoiding 
blood pressure readings and injections in the affected region, excessive heat, sunburn, 
flight or long-distance car travel, activities which may cause skin injuries (e.g., 
gardening), constrictive clothing and vigorous exercise 28. Avoidance of exercise has 
also been recommended previously. However, recent good quality evidence indicates 
that lymphoedema is neither initiated nor worsened by exercise 2. Considering the 
general health benefits of physical activity and the potentially positive impact of 
other recommended restrictions on patients’ daily life, it is important to determine for 
which factors there is, indeed, evidence of increased risk of lymphoedema and amend 
guidelines where necessary.  
2.2 IMPACT OF LYMPHOEDEMA ON QUALITY OF LIFE 
Previous research highlights the physical, psychological and social implications of 
lymphoedema and the impact on quality of life. As discussed above, physical 
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symptoms include pain, heaviness and tightness, and reduced range of movement. A 
review of the literature investigating psychological and social sequelae of 
lymphoedema following breast cancer reported many factors which contributed to 
reduced quality of life of those with lymphoedema 33. Frustration, distress, anxiety 
and depression were among the psychological symptoms found to impair quality of 
life. Reduced function, mobility and physical ability to perform simple daily 
activities (e.g., pulling up/down a zip, grocery shopping, exercise, and social 
activities) can be frustrating and lead to a perceived loss of control 33. For some 
patients, the chronic nature of secondary lymphoedema and the inability to hide 
physical symptoms and loss of function can make it even more distressing than the 
initial cancer diagnosis and associated treatment 6,7.  
The psychosocial impact of lymphoedema can adversely affect personal, social and 
work relationships. Adequate social support and pre-existing coping strategies within 
the families of those who have lymphoedema have been associated with improved 
social functioning and psychological wellbeing of patients 33. Unfortunately, a study 
of the experiences of women with lymphoedema found levels of support, acceptance 
and adjustment in intimate relationships varied widely 34. In addition, many patients 
report significant difficulty in and disruption to intimate and sexual relationships 
35,36. Social functioning can be limited if patients give up hobbies and restrict social 
activities 33,34, either to avoid worsening of symptoms (e.g., outdoor sporting 
activities) or to avoid uncomfortable social situations (e.g., friends reacting 
insensitively to swelling).  In some cases, people with lymphoedema have to adapt or 
change jobs or cannot work at all due to their symptoms 34. This can increase the 
financial burden on patients and their families and be a source of additional stress 
and frustration 6.  
The majority of the studies investigating the broader impacts of lymphoedema on 
quality of life has involved women with breast cancer and consequent upper-limb 
lymphoedema (ULL).  Many symptoms and their associated impact on daily life may 
be similar for patients with secondary ULL and LLL 37. However, evidence based on 
ULL cannot be directly transferred to LLL due to differences in limb size, volume 
and functions between the upper- and lower-limbs 3.  
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The limited research involving patients with LLL suggests patients can have 
difficulty walking and sitting, and performing self-management treatment 
components, such as massage and putting on compression stockings. Another 
concern, likely to be of particular importance to women with lymphoedema 
following gynaecological cancers, is the impact of the condition and associated 
symptoms on body-image, intimacy and sexual function 38.  
To progress the knowledge in this area, a systematic literature review of studies 
investigating the impact of LLL on quality of life was undertaken and formed the first 
component of this PhD research 9. The review was published in Expert Reviews of 
Pharmacoeconomics and Outcomes Research and is included below in Section 2.2.1. 
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2.2.1 QUALITY OF LIFE OF WOMEN WITH LYMPHOEDEMA FOLLOWING GYNAECOLOGICAL CANCER 
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PART TWO – LYMPHOEDEMA TREATMENT 
Lymphoedema is considered a progressive and incurable condition, requiring 
ongoing attention, self-management and long-term treatment 25,39,40. Without 
treatment, lymphoedema may progress and result in serious complications including 
infections and skin changes, reduced immunity and impaired mobility 29. Currently, 
there is no cure for lymphoedema. Treatment strategies aim to reduce swelling, 
prevent progression, reduce risk of infection and alleviate associated symptoms 2. 
Treatment effective in improving symptoms has been shown to reduce the impact of 
lymphoedema on daily activities, self-image and quality of life 34.  
A range of mainstream and CAM treatments for lymphoedema exist. Mainstream 
therapies including complex physical therapy (CPT), MLD, compression (bandages, 
garments and pumps), low-level laser and exercise, are the most widely prescribed 
forms of lymphoedema treatment 41. Surgery is typically only used for patients who 
are not responding to more conservative treatment 42. While CAM treatments are less 
often prescribed for lymphoedema treatment, emerging research suggests that many 
patients use a range of CAM treatments and perceive some to be effective at 
improving symptoms (see section 2.4). 
2.3 MAINSTREAM TREATMENT  
Although research has been undertaken investigating the effect of different 
mainstream treatment methods on lymphoedema, inconsistent treatment guidelines 
exist; there has been little progress in determining the most effective treatments. The 
range of available treatment options has resulted in a number of studies of 
lymphoedema treatment, most of which (n = 163) have been included in at least one 
of the more than 20 reviews conducted to summarise the effect of lymphoedema 
treatment. The following presents a critique of these reviews, beginning with a 
summary of findings for each treatment, followed by evaluation of the quality of the 
review process undertaken and identification of gaps in the research related to 
lymphoedema treatment. 
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2.3.1 LITERATURE SEARCH 
The reviews were identified through searches conducted in Medline, Pubmed, 
CINAHL, and Cochrane Database of Systematic Reviews. The main search terms 
were “lymphoedema or lymphedema”, “treatment or therapy” and “systematic review 
or literature review”. Additional search terms used were specific treatment strategies 
“complex physical therapy, complex decongestive therapy, manual lymph drainage, 
laser therapy, compression, surgery, massage, pneumatic pump, exercise” to ensure 
reviews assessing any lymphoedema treatment strategy were identified. In addition, 
internet searches were undertaken to identify any reviews commissioned by 
government and/or lymphoedema organisations but not published in journals, and 
therefore unavailable through electronic databases. The abstracts of 206 manuscripts 
were reviewed against the criteria below (see 2.3.2) and the full text versions of 23 
potentially suitable reviews were retrieved.  
2.3.2 INCLUSION CRITERIA 
Reviews were included if the following inclusion criteria were met: 
• A focus of the review was the effectiveness of lymphoedema treatment 
• The reviewers conducted and reported on electronic literature searches 
• Inclusion and exclusion criteria were defined and reported 
• The reviewers applied and described a method of assessing methodological 
quality of included studies. 
2.3.3 SEARCH RESULTS 
Seventeen reviews met the inclusion criteria outlined above, with six excluded 
because the review did not focus on the effect of lymphoedema treatment 
effectiveness. One review paper 43 was a focussed summary of findings from a more 
extensive review undertaken by Oremus et al. 44. The full review was included rather 
than the summary, leaving 16 reviews included in this critique. Fifteen reviews 
focussed on mainstream treatment types, while one review concentrated on self-
management strategies. Eleven reviews included studies of a range of lymphoedema 
treatment strategies. The remaining five reviews were single-focus, with two 
reviewing studies of pneumatic compression 45,46, and one each on the use of exercise 
47, surgery 48 and benzopyrones 49 to treat lymphoedema. The sixteen reviews were 
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published between 1998 and 2012 and included discussion of 158 primary studies of 
lymphoedema treatment, published between 1966 and 2011. An overview of review 
characteristics, including eligibility criteria and methods for assessing study quality, 
is presented in Table 2.1. 
Table 2.1 
Overview of included studies 
Review Search 
period 
Number 
of studies 
Eligibility Criteria Method for Assessing Study 
Quality 
Multi-focus reviews – including studies investigating a range of treatment types 
Megens  
1998 
1966-1997 13 Treated for BC 
Secondary LE in at least one arm  
IV=conservative treatment 
DV=limb size 
Sackett’s rules of evidence 
(adapted) 
Kligman  
2004 
1966-2002 9 RCTs or systematic review of 
RCTs 
Measured effect of treatment on 
arm volume, symptom control, 
QoL or cosmetic results 
Practice Guidelines 
Development Cycle 
Preston  
2004 
Up to 
2008 
3 RCTs only, >6 month follow-up 
LE limb >10% compared with 
normal limb, bilateral LE 
objectively assessed 
Cancer patients completed 
treatment >6 months prior 
CB studies – no CB within 6 
months prior 
Cochrane review criteria 
Moseley  
2007 
NS 36 Secondary LE following BC 
treatment 
Recurrent cancer or primary LE 
excluded 
Quality scale assessment tool  
Hayes  
2008 
2005-2007 19 Secondary LE following cancer 
treatment 
Treatment completed >6 months 
prior 
LE defined by authors’ objective 
assessments or diagnosed by HP 
NHMRC levels of evidence 
Devoogdt  
2009 
Up to 
2009 
15 RCTs, pseudo-randomised and 
non-randomised experimental 
trials 
Patients with arm LE 
Unclear criteria relating to 
treatment type and outcome 
measures 
NHMRC levels of evidence 
PEDro scores  
Karki 
2009 
1998-2008 14 RCTs 
Secondary LE after BC 
‘Physiotherapy treatments’ - diet, 
surgery and medical treatments 
excluded 
Internal validity criteria 
Level of evidence categories 
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Oremus 
2010 
1990-2010 36 RCTs or observational studies 
with comparison groups 
Secondary lymphoedema 
All treatment,  except surgery 
and drug therapy 
Jadad scale 
Newcastle-Ottawa scale 
McNeely 
2011 
1980-2009 25 RCTs 
conservative or dietary 
intervention 
>80% of participants with 
secondary LE following cancer 
LE vol as primary outcome 
Jadad scale (modified) 
Lasinski 
2012 
2004-2010 26 Complex decongestive therapy 
Patients with lymphoedema 
Case series if including >10 cases 
1 case report on genital LE due 
to paucity of literature 
PEP guidelines 
Ridner 
2012 
2004-2011 16 Primary or secondary LE 
Research results or expert 
opinion 
Lymphoedema self-care 
PEP guidelines 
Single focus reviews – including studies of a single treatment type 
Badger  
2003 
Up to 
2003 
15 RCTs only 
LE limb >10% compared with 
normal limb, bilateral LE 
objectively assessed 
Cancer patients completed 
treatment >6 months prior 
No CPT within 6 months prior 
Cochrane review criteria 
Rinehart-
Ayres 
2010 
Up to 
2007 
8 Secondary ULL following BC 
Treatment provided by HP using 
compression pump 
Measurements pre/post treatment 
 
Sackett’s rules of evidence 
Kwan 
2011 
2004-2010 15 RCT, cohort or case-control 
study, meta-analysis, or 
systematic review 
LE as primary or secondary 
outcome 
Classification of exercise as 
resistance, aerobic or physical 
therapy 
PEP guidelines 
Cormier 
2012 
2004-2010 19 Surgery for lymphoedema 
treatment 
>8 patients 
QADAS 
Feldman 
2012 
2004-2011 10 Research study 
Pneumatic compression 
Patients with lymphoedema 
>10 cases 
Bandolier strength of evidence 
guidelines 
BC: breast cancer; LE: lymphoedema; ULL: upper-limb lymphoedema IV: independent variable; DV: 
dependent variable; RCT: randomised controlled trial; CPT: complex physical therapy; CB:compression 
bandaging; QoL: quality of life; NHMRC: National Health and Medical Research Council; HP: health 
professional; QADAS: Quality Assessment of Diagnostic Accuracy Scale; PEP: Putting Evidence into 
Practice. 
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2.3.4 METHODOLOGICAL QUALITY 
Reviews were assessed against methodological quality criteria to evaluate rigour. The 
Cochrane Collaboration provides a tool for assessing risk of bias in the design and 
execution of randomised, controlled trials (RCTs) 50. The tool specifies factors that 
should be assessed for the risk of selection (sequence generation and allocation 
sequence concealment), performance (blinding of participants and personnel), 
detection (blinding of outcome assessment), attrition (incomplete outcome data), and 
reporting (selective outcome reporting) biases, as well as other potential sources of 
bias (any bias not assessed in other domains). The consideration of these factors by 
reviewers is summarised in Table 2.2. 
Only one of the sixteen reviews, a Cochrane Systematic Review 29, assessed studies 
against all of the above criteria, and reported the authors’ judgement of risk of bias 
for individual studies. Another Cochrane Systematic Review 49 appeared to assess 
studies for risk of selection, performance, detection and attrition bias, detailing 
randomisation and blinding processes, and describing reasons for participant 
withdrawals. However, the possibility of selective outcome reporting was not 
discussed, and the reviewers did not make any explicit judgement of risk of bias in 
individual studies. A further four reviews limited study inclusion to RCTs or non-
randomised experimental trials 51–54. Of these, three considered the impact of 
randomisation processes, blinding and attrition on the risk of bias in included studies 
51–53, and considered these factors when reporting results.  
The remaining ten reviews included observational, as well as experimental studies. 
There were numerous tools used to assess the methodological quality of 
observational studies, focusing on different strengths and weaknesses of study 
design. In order to critique the methods, results and conclusions of these reviews, 
they were assessed for their consideration of a number of factors relating to review 
protocol. These factors, and the reasons for their importance in reviewing the quality 
of available evidence, are described below: 
• study eligibility criteria – consideration of the inclusion and exclusion 
criteria and the influence these have on representativeness of the sample 
and generalisability of results;  
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• randomisation procedures (for RCTs) – identification of randomisation 
procedures, whether or not randomisation was successful, and whether 
there were any systematic differences between study groups at baseline; 
• methods for measuring lymphoedema – identification of the methods used 
to measure lymphoedema (e.g., water displacement method to measure 
limb volume), and the impact of different methods on the appropriateness 
of comparing results between studies; 
• adequate description of interventions – identification of treatment protocol 
and consideration of the impact of different protocols on results; 
• follow-up periods – ability to determine whether positive results were 
maintained over time, as well as identifying adverse effects; 
• details of patients lost to follow up – reasons for drop-outs and any 
differences between those who completed the intervention and those who 
withdrew from the study; 
• statistical pooling (meta-analysis) – consideration of heterogeneity in study 
design and appropriateness of combining results. 
An overview of each review and its consideration of these factors is presented in 
Table 2.3. Reviews taking these aspects of study design into account when reporting 
study results and forming conclusions about treatment effectiveness were considered 
to be of higher quality. 
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Table 2.2 
Reviewers’ consideration of Cochrane Collaboration criteria for assessing risk of bias 
Review 
Random 
sequence 
allocation 
Allocation 
concealment 
Blinding of 
participants and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome data 
Selective 
reporting 
Other sources of 
bias 
Badger 2003 X X X X X   
Preston  2004 X X X X X X X 
Oremus 2010 X X X  X X  
Rinehart-Ayres 2010 X
a Xa   Xb  X 
Devoogdt 2009 X X X X X  X 
McNeely 2011 X X  X X   
Karki 2009 X X X X X  X 
Megens 1998    X X  X 
Cormier 2012        
Moseley 2007        
Hayes 2008     X
c   
Kligman 2004    X    
Kwan 2011 X
d   Xe    
Lasinski 2012    X X
f   
Ridner 2012        
Feldman 2012        
adiscussed group differences at baseline, but not specifically random sequence allocation or allocation concealment (adequate randomization) 
b evaluated information about attrition of subjects (incomplete outcome data) 
ccommented on characteristics of those lost to follow-up for CPT but not other treatments 
dcommented on lack of randomization in one study, but not clear whether considered for all studies 
ecommented on blinding in some studies but not all 
flisted ‘no drop outs’ as a strength in two studies, not clear whether considered for all studies 
- - - Reviews above dashed line met more criteria and were considered higher quality reviews. 
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2.3.5 TREATMENT EFFECTIVENESS 
Where possible, review findings have been grouped according to treatment type, as 
classified by the review authors. The treatment types included in each review are 
presented in Table 2.4. Where review authors did not group studies according to 
treatment types, findings were grouped according to the following definitions of 
treatments (adapted from A. L. Moseley, Carati, & Piller, 2007)55: 
Complex Physical Therapy (CPT) – a period of intensive treatment or a treatment 
program involving at least two of the following: MLD, massage, compression 
bandaging, prescribed exercises.  
Manual Lymphatic Drainage (MLD) – light massage techniques applied by a health 
professional, to encourage removal of excess interstitial fluid, increase lymphatic 
transport and soften fibrotic induration. 
Self-massage – Similar massage techniques to MLD, applied by self or another 
person (e.g., partner). 
Laser therapy – low intensity wavelengths, either in a scanning or spot laser device.  
Pneumatic compression pump (PCP) – single- or multi-chambered pumps that 
envelop the limb, inflating and deflating with differing cycles and pressures.  
Compression bandaging (CB)– a gauze sleeve, soft cotton wrap or high density foam 
and 2-3 layers of short-stretch bandaging.  
Compression garments (CG) – compression sleeve or stocking with graduated 
pressure, from greatest compression at distal end of the limb to least compression at 
the proximal end.   
Prescribed exercises – progressive, resistive or sequential exercises prescribed with 
aim of varying total tissue pressure to encourage lymphatic drainage. 
Surgery – any surgical technique used to treat lymphoedema. 
Other – all other treatment types, including pharmaceutical and dietary interventions, 
heat therapy, elevation, electrical stimulation, ultrasound, and CAM therapies.  
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Table 2.3 
Assessment of study quality in lymphoedema treatment reviews 
Review 
Cochrane 
Criteria* 
Eligibility 
criteria 
Randomisation 
procedures 
Measurements 
of LE 
Intervention 
description 
Follow up 
periods 
Details of drop 
outs Meta-analysis 
Badger 2003 5/7 X X X X X X  
Devoogdt 2009 6/7 X X X X X   
Karki 2009 6/7  X X X X X  
McNeely 2011 4/7  X X X X X X 
Megens 1998 3/7 X  X X X X  
Oremus 2010 5/7 X X X X X X  
Preston  2004 7/7 X X X X X X  
Rinehart-Ayres 2010 4/7 X X X X X X  
Cormier 2012 0/7   X X X   
Feldman 2012 0/7   X X    
Hayes 2008 1/7   X  X X  
Kligman 2004 1/7   X X X   
Kwan 2011 2/7   X X X   
Lasinski 2012 2/7   X X X   
Moseley 2007 0/7 X   X X   
Ridner 2012 0/7   X X X   
- - - Reviews above dashed line met more criteria and were considered higher quality reviews, with reviews listed in alphabetical order. 
LE: Lymphoedema 
* Cochrane Criteria: Random sequence allocation; Allocation concealment; Blinding of participants and personnel; Blinding of outcome assessment; Incomplete outcome data; 
Selective reporting; Other sources of bias. Score out of 7 indicates how many of these criteria were met by each review.  
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Table 2.4 
Treatment types included in reviews 
Review CPT MLD CB CG SAM Laser PCP Exercises Surgery Other 
Megens  
1998 
X   X   X   X 
Badger  
2003 
         X 
Kligman  
2004 
X   X   X   X 
Preston  
2004 
 X X X       
Moseley  
2007 
X X X X  X X X  X 
Hayes  
2008 
X X    X X X X X 
Devoogdt  
2009 
X X X X   X X   
Karki 
2009 
 X X X  X X   X 
Oremus 
2010 
X X X X  X X X  X 
Rinehart-
Ayres 
2010 
      X    
Kwan 
2011 
       X   
McNeely 
2011 
 X X X  X X X  X 
Cormier 
2012 
        X  
Feldman 
2012 
      X    
Lasinski 
2012 
X X X        
Ridner 
2012 
    X  X X  X 
CPT: Complex physical therapy; MLD: Manual lymphatic drainage; CB: Compression bandaging; 
CG: Compression garments; SAM: Self-administered massage; PCP: Pneumatic compression pumps; 
Other: pharmacological therapies, ultrasound, microwave heating, electrical stimulation, dietary 
interventions, kinesiotaping and skin care. 
2.3.6 COMPLEX PHYSICAL THERAPY 
CPT, also known as Complex Decongestive Physiotherapy (CDT), is a two-phase 
treatment program combining multiple strategies. Foldi et al. (1989) originally 
described CDT as consisting of five parts of equal importance; skin care and hygienic 
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measures to eradicate infection, MLD, compression bandaging, and remedial 
exercises for a period of approximately four weeks, followed by prescription of a 
custom-made compression garment56. The compression garment is considered the 
second phase of treatment, prescribed with the aim of maintaining initial reductions 
in volume gained during the first phase of the treatment. Early studies of CDT 56 
suggested volume reductions could be achieved following the first phase in 95% of 
patients with ULL following treatment for breast cancer. Further, of the 177 patients 
(total at study commencement = 399) who completed the 3 year follow up period, 
54% were able to fully maintain volume reductions and 35% showed only partial 
relapse (lymphoedema did not return to pre-treatment volumes). Of note, the 10% of 
patients who had a full relapse had not complied with the maintenance phase of 
treatment56. However, since this early work, researchers internationally have 
combined multiple forms of various lymphoedema treatments to form an intensive 
period of treatment, called Complete Decongestive Therapy, Combined Physical 
Therapy, Decongestive Lymphatic Therapy or Complex Physical Therapy. For 
consistency, it will be referred to herein as Complex Physical Therapy (CPT), as 
defined by Casley-Smith & Casley-Smith 57.  
Seven reviews included studies investigating the effectiveness of CPT, with sample 
sizes ranging from 14-537. There was considerable variation in treatments 
prescribed, as well as outcome measures and reporting methods used. CPT was 
delivered for periods of five days to four weeks and follow up periods varied between 
1-13 months. The studies involved a range of treatment protocols, with MLD ranging 
from 30-60 minutes, daily to three times per week, and the use of compression being 
applied through bandages, garments, and/or pumps. Limb exercises and skin care 
were considered part of the CPT intervention in some studies, but not all.  
Outcome measures of treatment effectiveness were most commonly objective 
measures of limb circumference and/or volume, measured by circumferences from 1-
8 points on the limb (in some cases used to estimate volume using the truncated cone 
method)2,54,58,59, water displacement 2,54,58,59, and less often, perometry and tonometry 
2. Outcomes, when reported (some did not report actual results when they did not 
meet statistical significance criteria), were reported either as absolute reductions 
(mls) in limb volume or as percentage reductions compared with baseline measures.  
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Mean volume reductions reported in the seven reviews were 3-66% following 
treatment, although the clinical significance of these changes was unclear. 
Nonetheless, conclusions reached by the reviews suggest CPT is effective for treating 
patients with lymphoedema of varying degrees (mild, moderate or severe), early or 
late onset, recent or chronic, in patients with or without active cancer, and in 
palliative care 59. Results from studies of CPT with follow up periods indicated 
ongoing use of compression was required to maintain positive results 59. 
In addition to limb volume, some studies also explored the effect of CPT for 
improving subjective symptoms 44,54,55,59, with inconsistent results reported by the 
studies included in the reviews. Use of CPT was associated with reductions in pain, 
tightness, heaviness, pins and needles, cramps and tension, and improvements in 
quality of life scores 55,59 in some studies, while others found no difference in 
experiences of symptoms between treatment and control groups 44,54. Overall, the 
evidence suggests the use of CPT may improve symptoms and quality of life, 
although this is clearly an issue requiring further investigation. That is, clinically 
relevant outcomes including patients’ responses to treatment, changes in symptoms, 
adverse effects, and patient compliance need to be included in future studies 
evaluating effect of CPT 51,54.  
Despite differences in methods used to assess methodological quality, no review 
considered any studies of CPT to be high quality, and all discussed the 
methodological limitations of included studies. Limitations included: inconsistencies 
in defining and measuring lymphoedema 44,54,58,59; varied treatment protocols and 
bundling of interventions 44,59; lack of blinding of participants and assessors 51,58,59; 
small sample sizes 44,54,59; poorly stated exclusion criteria 55; questionable 
representativeness of samples 2; lack of follow up 44,59; lack of accounting for 
attrition bias 2; lack of measures of personal, treatment and behavioural factors 2; and 
lack of measures of symptoms and quality of life 51. While studies investigating the 
use of CPT have shown positive results, most reviews cautioned that these 
limitations need to be considered when interpreting findings.  
2.3.7 MANUAL LYMPHATIC DRAINAGE 
MLD refers to the use of massage on the limb and trunk, aiming to stimulate normal 
lymphatics, to encourage draining of excess fluid from the affected area 60,61. The 
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technique was first presented by Dr. Emil Vodder in 1936 60,61, as very specific hand 
movements, applying light pressure to the skin, in a distal to proximal manner. More 
recently, Vodder’s method has been modified by others, resulting in a range of 
techniques being referred to as MLD 61.  
Seven reviews included studies investigating the use of MLD. Of these reviews, only 
one referred to two studies investigating MLD use alone (with no other concurrent 
treatment), and these studies had very small samples of 12-17 people. All other 
studies included in the reviews combined MLD use with additional treatments, most 
often compression (bandaging, garments or pumps), aiming to determine whether 
MLD provided any additional benefit to patients beyond that achieved by 
compression (or other treatment) alone. Sample sizes in these studies varied widely 
(n = 11-357), as did treatment protocols. MLD techniques included the Vodder 
technique, Casley-Smith method, and other modifications, and were administered for 
30-80 minutes, 1-2 times per day, 2-7 days per week, for up to 12 weeks. Follow up 
periods were between 6 and 12 months.  
Results about MLD effectiveness conflicted across individual studies. Four reviews 
concluded that there was not sufficient evidence to support MLD effectiveness 
29,44,51,53. However, three reviews, including a meta-analysis of the addition of MLD 
to compression therapy compared with compression alone, suggested MLD provides 
additional benefit to patients 52,55,59.  Moseley et al. (2007) suggested MLD alone 
contributed to volume reductions of 104-156ml, and when used with compression 
demonstrated volume reductions of 47-250ml. It was reported these reductions 
equated to percentage reductions of 48%-84%. MLD was also shown to be effective 
in improving quality of life and associated lymphoedema symptoms, when used in 
conjunction with compression garments, bandages and/or pumps 55,59.  Findings from 
a meta-analysis 52 demonstrated a statistically significant benefit from the addition of 
MLD to compression therapy (SMD: 0.37; 95%CI: 0.07-0.67; p=0.02), but suggested 
this effect may be smaller than estimated by some individual studies, and should be 
considered in terms of the burden (time and financial) to patients. Conclusions from 
two reviews supporting MLD use suggested treatment should start with compression 
therapy, but when response is less than optimal or compression therapy is not well 
tolerated, MLD provides an appropriate alternative 52,59.  
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A number of issues are likely to contribute to the inconsistencies in findings between 
reviews. The use of different approaches for assessing methodological quality results 
in the identification of different weaknesses in study design and reporting. Whilst all 
reviews acknowledge the limitations of studies exploring MLD use, only two reviews 
differentiated between results based on study quality, showing that the studies 
reporting a significant effect of MLD were of low quality with inherent biases, while 
the higher quality studies found no additional benefit of MLD 51,53.  Further, 
differences in treatment protocols, study populations and study designs make 
comparisons inappropriate in many cases. The lack of methodological heterogeneity 
were cited in three reviews, as reasons for not undertaking meta-analyses 44,53,55. 
Although the meta-analysis performed by McNeely 52 reported no statistically 
significant heterogeneity (p=0.36) and low variability among studies (i-squared value 
of 14%), it is important to note the review included only 5 studies, all of which had 
varying treatment protocols. 
2.3.8 SELF-MASSAGE 
Self-massage, also referred to as simple lymphatic drainage (SLD), is the patient-
administered version of MLD.  One review included studies of self-management 
strategies, with self-massage being considered one component of self-management. 
Three of the sixteen studies included in that review (n=10-1449) investigated the use 
of self-massage, with other studies focussing on exercise, compression, weight 
reduction, skin care, and combined self-management programs 62. Findings from two 
cross-sectional surveys confirmed that self-massage is commonly used by patients 
(up to 66%) to manage their lymphoedema but did not report on effectiveness.  Only 
one intervention study investigated the use of self-massage and skin care, with 
reports of patients’ experiencing relief from symptoms and some reduction in arm 
volume after 3 months (size of reduction not reported).  
2.3.9 LASER THERAPY 
After findings in animal studies in wound healing suggested low level laser therapy 
(LLLT) accelerated regeneration of lymphatic vessels and stimulated lymphatic flow, 
LLLT using wavelengths of 650-1000nm was proposed for the treatment of 
lymphoedema 63. Laser therapy is applied to the affected area in either spot or 
scanning laser form. Five reviews included between 2-4 studies of LLLT. Individual 
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studies involved 8-64 participants, with intervention groups receiving laser therapy 2-
3x/week for 3-4 weeks, and control groups receiving either no treatment, sham laser 
or treatment with pneumatic compression. Volume reductions were achieved with 
both concentrated and scanning laser devices, and improvements in symptoms and 
quality of life were reported in 2 reviews 44,55. Actual volume reductions following 
treatment periods were summarised in three reviews 2,44,55, and ranged from 1-19%. 
Continued reductions (9-29%) were demonstrated 3 months to 3 years following 
treatment 55. Two reviews highlighted that when combined with exercise, treatment 
with LLLT demonstrated greater volume reductions than pneumatic compression 
44,52. However, these conclusions were based on results from a single study, limiting 
the strength of the evidence. 
Although there is some evidence to support LLLT effect, the studies showing the 
greater volume reductions were small and had varied treatment protocols. The largest 
study (n=64) found volume reductions of >200ml in 31% of participants who had 
received two cycles of laser, compared with 4% of participants who only received 
one cycle of laser treatment, but differences between mean limb volume before and 
after treatment were not significant 2.   
2.3.10 PNEUMATIC COMPRESSION 
Pneumatic compression pumps (PCP) consist of pneumatic cuffs attached to an 
electric pump, and wrap around the limb(s). The pump is designed to mimic the 
intermittent compression of vessels that normally occurs during muscle contraction 
(i.e., during exercise) 64. PCP vary in terms of timing (2 seconds-2 minutes), pressure 
(35-300mmHg) and compression type, which can be delivered by the pump 
uniformly through the whole cuff, sequentially via separate bladders inflating in 
sequence, or graded sequentially via different timing and pressure delivered through 
multiple bladders in the cuff. As there is no non-invasive way of measuring changes 
in lymph flow, the manner by which pneumatic compression works to move fluid, 
and which device is most suitable for lymphoedema treatment is not well understood 
64. It has been suggested that compression empties terminal lymphatics, allowing 
movement of fluid from the interstitium 64.  It is unclear whether pumps have any 
impact on fluid movement within the tissues, or assist with protein clearance 44,64. 
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Consequently, there is wide variation in the devices marketed for lymphoedema 
treatment. 
There has been considerable attention given to the use of pneumatic compression for 
lymphoedema treatment, with ten reviews summarising the available evidence. A 
range of pumps was used in the studies included within any given review, with one 
review identifying nine different devices across twelve studies. Both uniform and 
sequential pumps were used with pressures ranging from 40-150mmHg. Pumps were 
applied for 20 minutes to 6 hours/day, 1-3 times/day, once a week to daily, with the 
longest treatment period being 6 months. Studies assessed the use of PCP alone, 
compared their use with other treatment types, or assessed their effect when 
combined with other treatments.  
There is limited evidence to suggest pneumatic compression is effective in reducing 
limb volume in the short-term. Volume reductions (7-45%) have been reported 
following use of uniform and sequential PCP, with pressures between 40-160mmHg. 
Greater reductions have been achieved when the use of pumps was combined with 
other therapies, including MLD, compression garments or self-administered massage 
55. Volume reductions however have only been maintained with ongoing 
compression therapy, using pumps or compression garments 55,58.  
Two reviews evaluated use of pneumatic compression devices, suggesting PCP were 
well-tolerated in low to moderate pressure ranges, perceived as effective by patients, 
and associated with improvements in self-perceived emotional and physical health 
46,62. No adverse events during or after the use of PCP were reported, suggesting 
home use is a safe alternative for people unable to access other treatment.  
Four reviews found there was insufficient evidence to support efficacy of pneumatic 
compression, when compared with no treatment or other treatment types 45,53,54,62. 
The other six reviews presented evidence of demonstrated volume reductions 
following pump use, but drew attention to significant methodological limitations. 
Although over 20 studies have investigated the effect of PCP for treating 
lymphoedema, the use of many different pump types, small sample sizes, different 
treatment protocols, and combined treatment programs has contributed to lack of 
consensus between reviews about the overall evidence in support of pneumatic 
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compression compared with other treatments, or the most appropriate timing, 
pressure or compression type, for lymphoedema treatment.  
2.3.11 COMPRESSION BANDAGING AND GARMENTS 
Compression bandages and garments are commonly prescribed for the treatment of 
ULL and LLL. Bandages are usually applied to the affected limb by another person, 
while compression stockings and sleeves can be self-applied. Foldi et al. (1989) 
suggest bandages counteract elastic insufficiency (resulting from the destruction of 
elastic fibres in lymphoedema), increase tissue pressure and subsequently, increase 
lymph flow. However, unless the trunk has been decongested and normal lymphatics 
stimulated, it is suggested any fluid drained from the limb to the trunk through the 
use of compression can increase trunk edema, further reducing lymphatic drainage 
from the limb in the long-term 56. It has therefore been proposed compression therapy 
should be used in conjunction with MLD to prevent reaccumulation of fluid, rather 
than used as an initial treatment strategy 56. 
Between 2-6 studies (n = 19 - 150) investigating the use of compression bandaging 
and/or compression garments were included in any one of the nine relevant reviews. 
Studies compared either bandages with garments, compression alone (bandages or 
garment), as a component of a combined treatment strategy (e.g., compression 
garments with MLD or self-massage), or assessed differences between high- and low-
pressure bandages/garments.  
Compression bandaging alone 
Studies of compression bandaging included 29-90 participants, with bandages 
applied for a minimum of 24 hours and up to 19 days. Both low-pressure (20-
30mmHg) and high-pressure (44-58mmHg) bandages were used. Despite differences 
in the review approach undertaken, the conclusions regarding the effect of bandaging 
were consistent across all  reviews, suggesting the use of compression bandaging 
resulted in volume reductions in ULL and LLL, in the short and long-term 29,44,51,53,55. 
Volume reductions up to 38% were achieved when bandages were used alone. The 
two reviews that reported on follow-up periods noted reductions achieved by 
bandaging were maintained up to 6 months post-treatment 51,52.  
Compression garments alone 
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The use of compression garments to treat lymphoedema has been assessed in those 
with ULL and LLL. Sample sizes ranged from 19-150, garments (pressure: 30-
40mmHg) were prescribed for day-time use only or for 24-hour use, and study 
periods varied from 2 weeks to 15 months. Although volume reductions up to 24% 
were reported following the use of compression garments 52,55, the quality of the 
studies investigating compression use alone was considered low by the majority of 
reviews, suggesting these findings should be interpreted with caution. 
Compression (bandages or garments) combined with other treatments 
The majority of studies investigating the use of compression involved multi-
treatment interventions. Overall, review findings suggest there is evidence to support 
the effectiveness of compression garments and bandages, with greatest reductions (4-
60%) being achieved when compression was combined with other physical therapies 
53,55. However, the grouping of different treatments makes it particularly difficult to 
identify which components of the interventions are effective.  
2.3.12 EXERCISE 
Exercise prescription for lymphoedema treatment typically consists of aerobic or 
resistance training, or programs combining both. Types of exercise investigated 
include limb exercises (with and without weights), abdominal and back exercises, 
hydrotherapy, pole-walking, and dancing. Earlier guidelines for the management of 
lymphoedema suggested exercise, in particular repetitive movements, may exacerbate 
symptoms, but the current evidence suggests otherwise 2,7,44. Also, exercise has been 
found to have positive effects on physical and psychological factors 65. Studies have 
assessed lymphoedema status before and after completing different exercise 
programs, to determine which exercises are most beneficial to patients, as well as to 
monitor the presentation of any adverse effects.  
Seven reviews included between 1-15 studies of exercise interventions for the 
treatment of lymphoedema. Interventions evaluated in any one study included 
supervised and unsupervised exercise, full body and specific limb exercises, 
resistance and aerobic training. Studies included 10-141 participants with 
lymphoedema.  Although approaches used to review the relevant literature differed, 
conclusions were consistent across all reviews. Regardless of exercise type, exercise 
did not exacerbate lymphoedema, and in many cases was associated with 
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improvements in symptoms and quality of life. There is some suggestion from small 
trials that resistance training, hydrotherapy and limb exercises can contribute to 
volume reductions (12-101ml), but much larger trials are needed to confirm these 
findings 55. Identified weaknesses in the majority of exercise trials included small 
samples, moderate adherence (47-70%), evaluations completed by multiple 
therapists, lack of blinding of assessors, and difficulties measuring unsupervised 
exercise 47.  
One review separated studies into exercise types and assessed findings based on 
study quality 47. The recommendations from that review suggested resistance exercise 
was likely to be effective (highest current available level of evidence for exercise 
interventions), benefits were balanced with harms for combined resistance and 
aerobic exercise, and effectiveness was not established (lowest level of evidence) for 
other exercise (e.g., limb exercises). These recommendations are based on the weight 
of the available evidence and highlight the need for high quality research in this area, 
addressing the limitations of previous studies.  
2.3.13 SURGERY 
Surgical procedures used to treat lymphoedema include excisional procedures, 
lymphatic reconstruction and tissue transfer procedures. Excisional debulking 
procedures are an aggressive form of surgery, involving the removal of excess skin, 
adipose tissue and fibrous connective tissue, resecting the skin and soft tissue, and 
covering with a skin graft 48. Reported complications following excisional procedures 
include hematoma, skin/flap necrosis, infection, deep vein thrombosis, loss of limb 
function and destruction of lymphatic vessels 48. More recently, liposuction has been 
used to remove subcutaneous fat, reducing overall limb size 48,66.  Lymphatic 
reconstruction procedures are microsurgical procedures used to create anastomoses 
between lymphatic channels, lymph nodes and veins. Lymphaticovenular 
anastomosis (LVA) involves making small incisions to enable the creation of fine 
connections between lymphatics and subdermal venules. The procedure is less 
invasive than other forms of lymphoedema surgery and can be performed using local 
anaesthesia 48. Tissue transfer procedures involve the transplanting of normal lymph 
nodes and vessels to the lymphoedematous area. Most commonly, lymph nodes from 
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an unaffected thigh are transplanted to the affected upper or lower-extremity, with 
anastomoses created between the normal lymph tissue and existing lymph vessels 48.  
Studies of surgical procedures for the treatment of lymphoedema were only included 
in two reviews. Prospective studies included between 9-42 participants, while 
retrospective studies assessed outcomes of 9-1800 lymphoedema patients following 
surgical treatment for lymphoedema. The overall quality of study design and 
reporting was low, with most lacking comparison groups, having unreported 
participant rates, lacking selection criteria and absence of symptom assessment 48. 
Nonetheless, significant volume reductions were achieved using excisional (18-
118%), lymphatic reconstruction (2-59%) and tissue transfer procedures (up to 
100%). Only one retrospective study of 9 patients who were treated with tissue 
transfer procedures reported an increase in limb volume of 13%. Although positive 
results were obtained following surgery, continued use of conservative treatment 
(e.g., compression garments) was required to maintain benefits long-term.  
2.3.14 OTHER TREATMENT FOR LYMPHOEDEMA 
Other treatments proposed and investigated for lymphoedema include 
pharmacological interventions, ultrasound, microwave heating, electrical stimulation, 
dietary interventions, kinesiotaping and skin care 2,44,49,52–55,58,62. Four reviews 
included fifteen studies investigating the use of pharmacological treatments. 
Synthesis of the available evidence and resulting conclusions were consistent; the 
evidence does not support the use of benzopyrones or other pharmacological 
interventions for lymphoedema treatment 2,49,54.  
Dietary interventions have been prescribed on the premise that reducing body fat may 
improve lymphoedema. Overall, studies suggested those who undertook dietary 
interventions resulting in weight loss, also demonstrated reduced arm volumes 2,44,52.  
Conclusions made in the relevant reviews were that positive effects on lymphoedema 
were found following dietary interventions, and that health benefits are likely to 
extend beyond limb volume reductions, but suggest more research is needed to 
investigate long-term maintenance 2,44,52. The paucity of research relating to the other 
treatment types precludes any conclusions being made regarding their use by 
lymphoedema patients.  
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2.3.15 KEY FINDINGS RELATING TO EFFECT OF MAINSTREAM TREATMENTS 
A tabulated summary of review findings relating to each treatment type is presented 
in Table 2.5. For each treatment, the conclusions made in each review were 
considered to reflect an improvement in lymphoedema (‘yes’) following treatment, 
no improvement in lymphoedema (‘no’), or inconsistent results precluding any solid 
conclusions being made.  
When considering these findings alongside review protocols, there was no obvious 
explanation for the differences in the findings between reviews.  Thirteen different 
methods, scales and sets of guidelines were used by reviewers to assess 
methodological quality of their included studies, with some reviewers using multiple 
scales. Although there was variation in the assessment of study quality and reporting 
of study details, these discrepancies did not impact significantly on the key findings 
reported between reviews and are therefore reported here. 
The following key findings summarise the current available evidence, and identify 
the gaps needing further research attention: 
• There is agreement among reviews that CPT is effective at reducing limb 
volume. The most effective components of CPT cannot be identified based 
on the current level of evidence. Further, factors influencing effectiveness 
are not well understood. It appears ongoing therapy is required to maintain 
initial reductions achieved by an intensive period of CPT. 
• Reported effect of MLD on lymphoedema is inconsistent. MLD appears to 
be effective when used with compression therapy, but the available 
evidence does not support its use as a stand-alone treatment strategy.  
• Limb volume reductions have been demonstrated following use of low-
level laser therapy in some studies, but these results should be considered 
preliminary, with larger, better designed trials needed to support this 
evidence.  
• Volume reductions have been achieved with the use of PCP, with greater 
reductions demonstrated when the use of pumps was combined with other 
treatments.  
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• Significant volume reductions have been demonstrated following the use 
of compression bandaging and garments in combined treatment programs, 
but the contribution of compression therapy alone, in reducing limb 
volume, is not well understood.   
• More evidence is needed to determine whether exercise contributes to 
volume reductions, and if so, whether reductions are maintained long term.  
• Use of surgical treatment for lymphoedema has resulted in significant 
volume reductions, but has the potential for complications and requires 
continued use of conservative treatment to maintain improvements.  
2.3.16 LIMITATIONS OF REVIEWS OF MAINSTREAM TREATMENT LITERATURE 
There was significant variation in review methodologies. Reviews had different 
inclusion criteria based on time periods, treatment types, study populations, selection 
criteria, and study design, although some overlap did exist, with multiple reviews 
including the same studies. Where crossover was evident and discrepancies between 
authors’ conclusions existed, results from primary studies were assessed to determine 
the most appropriate conclusions. 
Overall, the quality of studies investigating treatment for lymphoedema has been 
poor, both in terms of study design and reporting. There is suggestion the apparent 
lack of fundamental aspects of study design in some studies may be a result of poor 
reporting practices rather than inherent flaws in the research 44, but this cannot be 
assumed where the authors have not described methods adequately. The majority of 
studies have been cohort, case-control and cross-sectional studies, with few well-
designed RCTs. Inconsistent methods for measuring lymphoedema, multiple 
outcome assessors, lack of blinding, small samples, and lack of follow-up periods 
were all cited as methodological limitations. Conducting inappropriate data analyses 
and the reporting of unadjusted results were also evident in many studies, increasing 
the potential for biased results 2,29,52,53. These limitations of the majority of the 
studies included in previous reviews have led to underpowered results, a lack of 
generalisable findings and difficulties comparing results from studies of different 
treatments. 
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Table 2.5 
Summary of treatment effectiveness results from included reviews 
Review CPT MLD CB CG SAM Laser PCP Exercisesa Surgery 
Badger 2003*          
Preston 2004  No Yes Yes      
Oremus 2010 Yes Inconsistent Yes Yes  Yes Inconsistent No  
Rinehart-Ayres 2010       Yes   
Devoogdt 2009 Yes Inconsistent Yes No   Inconsistent Yes  
McNeely 2011  Yes Yes Yes  Inconsistent Inconsistent No  
Karki 2009  Yes Yes Yes  N/A** No   
Megens 1998 Yes   Yes   Yes   
Cormier 2012         Yes 
Moseley 2007 Yes Yes Yes Yes  Yes Yes Yes  
Hayes 2008 Yes Yes    Yes Yes Yes Yes 
Kligman 2004 No   Yes   No   
Kwan 2011        No  
Lasinski 2012 Yes Inconsistent Yes       
Ridner 2012     Yes  No No  
Feldman 2012       Inconsistent   
Yes: Review concluded treatment resulted in improvements in lymphoedema; No: Review concluded treatment did not improve lymphoedema; Inconsistent: Review 
concluded the results from individual studies of treatment effectiveness were inconsistent; Blank: Treatment was not included in review 
 
*Review of pharmaceutical treatments only – did not include any mainstream treatments **Decreases in lymphoedema between groups were not analysed 
a For exercise interventions, no change in lymphoedema is considered a positive finding (i.e., no exacerbation of lymphoedema following exercise) 
CPT: Complex physical therapy; MLD: Manual lymphatic drainage; CB: Compression bandaging; CG: Compression garments; SAM: Self-administered massage; PCP: 
Pneumatic compression pumps;  
 Chapter 2: Literature Review 46 
2.4 COMPLEMENTARY AND ALTERNATIVE MEDICINE 
All of the reviews discussed above focussed on mainstream treatments, considered by health 
professionals’ to be the most common forms of lymphoedema treatment 41. However, the use 
of CAM therapies, in addition to or as a substitute, for mainstream therapies is commonly 
reported by cancer patients 67–69. Although research on the use of CAM for lymphoedema 
treatment is limited, individual studies have investigated the use of acupuncture and the Sun 
Ancon Chi Machine 70,71, with positive effects on self-reported symptoms 70, and limb 
volume, respectively 71. 
To explore the use of CAM therapies in more detail, secondary analysis using data from a 
cross-sectional study investigating the use of mainstream and CAM treatments by women 
with lymphoedema (n=95) following breast or gynaecological cancer was undertaken as part 
of this postgraduate research. The resulting peer-reviewed, published manuscript 10 describes 
the use, as well as perceived effectiveness, of mainstream and CAM therapies for the 
treatment of lymphoedema. The following manuscript outlines the common and varied use of 
a range of treatment types and reports the high perceived effectiveness of treatment by 
patients. These findings provide new information about patients’ perceptions of lymphoedema 
treatment and highlight the need for further investigation into the reasons why patients choose 
to use such a wide range of treatments, many of which have received little research attention 
and thus have little evidence for their effectiveness.  
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2.5 LYMPHOEDEMA TREATMENT SUMMARY 
Despite the large number of studies investigating mainstream lymphoedema 
treatment (n = 158), progress towards identifying the most effective treatments has 
been slow. The use of compression therapy alone, and combined with MLD, has been 
supported by RCTs 49,52. Also of clinical importance, and supported by two well-
designed and reported RCTs, is the finding that exercise does not exacerbate 
lymphoedema 72,73. This evidence is important as previous lymphoedema prevention 
and management guidelines recommended that people with lymphoedema should 
avoid exercise to prevent worsening of symptoms.  
Future research, aiming to confirm or refute findings of previous studies, must 
address their limitations to improve the quality of the evidence surrounding 
lymphoedema treatment effectiveness. Large, well-designed RCTs are needed, with 
sufficient numbers to enable subgroup analyses (i.e., to determine whether particular 
treatments are more effective at treating ULL compared with LLL, or mild versus 
severe lymphoedema). It has been suggested in several reviews that experimental 
interventions should be compared to ‘standard lymphoedema treatment’ 44, but it is 
evident from the wide range of treatment protocols in the reviewed studies that there 
is little consensus on what ‘standard lymphoedema treatment’ involves. In all studies, 
treatment protocols should be described in enough detail to enable replication in 
other study populations. Where blinding of participants and health professionals 
administering treatment is not possible due to the nature of the intervention, the 
blinding of outcome assessors would at least strengthen study design.  
There is evidence of improvements in lymphoedema following the use of a range of 
different treatments, but regardless of treatment type, ongoing management is 
required to manage chronic symptoms. It is possible different treatments are more 
appropriate at different stages of the trajectory. Further, long-term outcomes are 
likely to be influenced by patients’ adherence to treatment, yet little research 
attention has been given to adherence or factors influencing adherence. In addition to 
measuring objective changes in limb volume, the effect of treatment on patients’ 
symptoms, as well as the time, cost and effort involved in undertaking lymphoedema 
treatment and self-management, should be considered. The following section 
summarises the available research in the area of treatment adherence.  
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PART THREE – LYMPHOEDEMA TREATMENT ADHERENCE 
2.6 TREATMENT ADHERENCE 
Early diagnosis, rapid initiation of treatment and high adherence to treatment (which 
often includes daily self-management tasks for patients) have been reported to 
optimise lymphoedema treatment success 74, and lack of any treatment has been 
associated with lymphoedema progression 2.  Whilst research on adherence to 
lymphoedema treatment is limited, adherence is considered an important aspect of 
the long-term management of many chronic conditions. Non-adherence to medical 
treatment is a common and persistent problem, reducing treatment effectiveness, 
impacting on patients’ quality of life, and increasing health service costs 75,76. 
Whether the patient is required to take medication, attend regular appointments with 
health professionals or continue self-management behaviours to treat their condition, 
their adherence to the prescribed treatment program is often important to achieve 
optimal results 77.  
Non-adherence (also called non-compliance) was first recognised by Hippocrates, as 
a potential threat to the spread of infectious disease 78. In the 1950’s, non-compliance 
was again recognised by three physiologists as being a significant problem in 
effectively treating tuberculosis 78. Following this recognition, researchers began to 
further explore the factors associated with non-compliance. Although the terms 
“compliance”, “concordance” and “adherence” have been used interchangeably in the 
literature, their differences are defined here for clarity.  “Compliance” is defined as 
conforming to a treatment program as prescribed by a health professional 79.  
Negative connotations associated with the word “compliance”, implying patients 
should submit to doctor’s advice and play only a passive role in managing their 
treatment, have led to the use of other terms. In the “concordance model”, developed 
by members of the Royal Pharmaceutical Society of Great Britain, the patient is seen 
as an active decision maker and the aim is for the patient to make informed, 
considered choices about treatment for their condition 76. Similarly, it is suggested 
the term “adherence” reduces the power attributed to the health professional in the 
professional-patient relationship, and describes a process where the patient is an 
active participant in decisions relating to their treatment. The meaning of adherence 
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changes depending on the treatment requirements for a given health issue. While 
some acute conditions will only require adherence to a short term prescribed 
pharmacological treatment in order for treatment to be successful, a treatment 
protocol for a chronic condition may have several elements, including physical 
therapies, lifestyle changes and medications 77. The increasing popularity of 
terminology that acknowledges the patient’s involvement in their care reflects the 
growing understanding of the complexity of treatment adherence as a theoretical 
concept. 
Treatment adherence is used here as an umbrella term to describe the process where 
the choices and behaviour of the patient correspond to what has been agreed upon 
with their health care provider regarding their treatment 77,79. This definition 
acknowledges the importance of considering the patient’s perspective and individual 
situation when developing the treatment program. There is argument that one of the 
greatest factors hampering progression in adherence research is the absence of the 
patient’s perspective 76,80. While it is useful to measure “compliance” when assessing 
treatment effectiveness (e.g., what level of compliance with a prescribed treatment is 
required to achieve the desired improvement in symptoms), research into factors 
associated with long-term adherence provides important information about what it is 
that determines whether or not patients continue with treatment in the context of their 
daily lives, subsequently optimising treatment effectiveness and improving quality of 
life. 
The World Health Organisation (WHO) adopts a multidimensional approach in 
describing the factors that influence long-term adherence. The five dimensions 
include healthcare team and system factors, socio-economic factors, treatment-related 
factors, condition-related factors and patient-related factors 77. A summary of these 
dimensions follows.  
2.6.1 HEALTHCARE AND SYSTEM FACTORS 
Sufficient evidence exists to suggest the patient-provider relationship plays an 
important role in influencing treatment adherence 79,81. Although communication is 
often the focus of research in this area, Palmer (2006) suggests equal importance lies 
in the ability of the provider to assess the transfer of knowledge to the patient, the 
development of skills for self-management, and the organisation of appropriate 
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follow-up care. While clarity of treatment advice has been correlated with short-term 
adherence, there is little evidence of its significance in improving long-term 
treatment adherence for chronic conditions 77. 
2.6.2 SOCIAL AND ECONOMIC FACTORS 
Many long-term treatment strategies come at a significant cost to patients. Not 
surprisingly, studies of treatment for chronic conditions have identified relationships 
between poverty, unemployment, illiteracy, and reduced adherence 79. Associations 
between non-adherence and other social factors, including race and age, have been 
reported, but findings have not been conclusive across different settings. The impact 
of these factors on treatment adherence needs to be evaluated for specific conditions. 
2.6.3 CONDITION-RELATED FACTORS 
The nature of the health condition and its impact on a patient’s daily life are likely to 
influence adherence. While severe symptoms may require more intensive treatment, 
they can also make it more difficult to adhere to complex interventions. Symptom 
severity may influence the patient’s perception of risk and their prioritisation of 
treatment over other demands 77. 
2.6.4 PATIENT-RELATED FACTORS 
A number of patient-related factors have been identified as influencing adherence to 
health behaviours 79. A person’s attitudes towards their condition, including their 
perceived risk of the condition worsening (perceived seriousness), their belief that 
they have the ability to treat it (self-efficacy), and the values they hold around their 
health and aspects of their life that are impacted on by the condition, are all likely to 
influence their motivation to continue complex treatment strategies. 
2.6.5 TREATMENT-RELATED FACTORS 
Factors that are consistently associated with adherence in the literature concern 
specific aspects of the treatment program itself 77. The complexity, time involved, 
and duration of the treatment period, influence the likelihood that patients will 
continue to adhere to the treatment as prescribed. A combination of these factors can 
simultaneously impact on the ability of patients to adhere to treatment, requiring 
continual assessment of barriers and the development of strategies to address these. 
This approach recognises the patient as being integral to the adherence process, but 
54 
54 Chapter 2: Literature Review 
also acknowledges the wider influences on a person’s ability to continue with long-
term treatments. 
2.7 THEORETICAL MODELS IN TREATMENT ADHERENCE RESEARCH 
Non-adherence is considered the most important modifiable factor that compromises 
treatment effectiveness 77. Research in treatment adherence has involved 
investigating a range of treatment-, patient- and condition-related factors described 
above, in many different contexts and settings. While in research settings, extensive 
efforts may be placed on achieving optimal adherence to interventions (e.g., intensive 
follow-up of patients), in practice, long-term self-management is dependent on 
individuals making the decision to continue treatment 81.  Researchers have applied 
numerous conceptual models in their studies aiming to explain the associations 
between relevant factors and a patient’s likelihood to adhere to treatment 77,79,82. 
2.7.1 BIOMEDICAL MODEL 
A paternalistic biomedical approach may suggest treatment adherence is a passive 
process whereby patients follow the directions of the health professional, and success 
is dependent on patient characteristics (e.g., personality and sociodemographic 
factors) 77,82. However, research based on the biomedical approach has failed to 
identify any particular sociodemographic or individual personality characteristics 
which differentiate those who adhere to treatment from those who do not 82. 
Although this evidence contradicts the main hypothesis of the biomedical model, it 
has urged consideration of other factors and exploration of their role in influencing 
adherence behaviour.  Findings from this research suggest disease and treatment 
characteristics have greater influence on whether a patient is likely to adhere, 
motivating the development of technical solutions to treatment adherence barriers 82.  
Interventions aiming to improve adherence based on principles of the biomedical 
model are often referred to as technical interventions, where steps are taken by health 
professionals to reduce the demand on the patient. One strategy is the simplification 
of treatment regimens or programs (i.e., simplifying dosage or packaging of 
medications), aiming to increase the likelihood of patients complying with prescribed 
treatment by making it easier to do so. Although many studies of chronic conditions 
have found this to be effective 83, the evidence indicates over a period of time that the 
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effectiveness of technical interventions decreases 75, suggesting it may be more 
appropriate for the treatment of acute conditions than those requiring long term 
management. Behaviour theorists propose external factors and the cognitive 
processes of patients (described below in Section 2.7.2) play a significant role in 
determining health promoting and disease management behaviours, which are largely 
ignored by the biomedical model 77,82. 
2.7.2 PSYCHOSOCIAL MODELS 
A number of psychosocial models, including the Health Belief Model (HBM), 
Theory of Reasoned Action (TRA) and Theory of Planned Behaviour (TPB) present 
frameworks for further understanding additional factors relating to a person’s 
thoughts, attitudes, and beliefs, and the impact these have on the likelihood of a 
person performing a particular behaviour 82,84. Besides knowledge, an individual’s 
thoughts and beliefs about their ability to perform the behaviour (self-efficacy) as 
well as factors in their environment may influence attitudes towards specific 
behaviours (e.g., societal or cultural norms, or treatment barriers).  
The HBM was developed by a group of social psychologists in the 1950’s and is 
commonly used in the development of health education, health promotion and 
behavioural interventions 85. The HBM suggests the likelihood of a person taking 
action towards addressing a health problem is dependent upon perceived threat and 
outcome expectations. The level of perceived threat is influenced by perceived 
susceptibility (i.e., risk of contracting an illness) and perceived seriousness (i.e., 
consequences of leaving a health problem untreated) of the health problem. The 
perceived benefits of the behaviour and perceived barriers to taking action combine 
to form a person’s outcome expectations associated with performing a particular 
behaviour. The model has been used in research on preventive health strategies, 
diagnosis seeking and screening behaviours, and to explore adherence to prescribed 
medical treatment. In a review of 46 interventions based on the dimensions of the 
HBM, “perceived barriers” was the strongest predictor of a range of health 
behaviours across settings 86. Despite the successes of interventions designed 
according to the HBM, the effect size of the behavioural improvements is often small 
82. A limitation of the model in understanding treatment adherence is that the model 
only assists in understanding the variation in health behaviour attributable to 
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individuals’ attitudes and beliefs. This does not allow for consideration of other 
influences, such as economic or environmental factors, habitual behaviour and 
behaviour undertaken for non-health-related reasons 84,86. In addition, the HBM 
suggests a person’s motivation to engage in a given health behaviour is dependent on 
their perceptions of their own susceptibility and the seriousness of a health problem. 
Other behavioural theorists propose there are more factors involved in influencing 
motivation than these aspects of perceived risk.  
Fishbein and Ajzen (1975) argue that social norms also influence motivation, and 
developed the TRA, and the later extended TPB87. The TRA proposes a person’s 
actions are determined by their attitude towards certain behaviours and subjective 
norms (what it is the individual believes others think they should do, and whether 
they are motivated to comply). In practice, this model suggests if a person thinks 
undertaking a particular behaviour will benefit their health and they feel social 
pressure to do so, they are more likely to intend to and to actually undertake that 
behaviour. The theory was developed further to the TPB, incorporating perceived 
behavioural control to the model as an additional influence on behavioural intentions. 
This aspect of the model is similar to the concept of self-efficacy (a person’s belief in 
their ability to perform a behaviour), proposing that even if a person intends to 
behave in a particular way, the behavioural intention is only likely to result in the 
desired behaviour if they believe they have power and control over both intrinsic 
factors (e.g., problem solving skills) and external factors (e.g., accessibility). 
However, the TPB appears to be most effective in predicting preventive health 
behaviours and those with strong social influences, such as smoking and sun 
protection 85,88. It is expected the influence of social norms on personal decisions 
around an individual’s medical treatment would be less, and disease- and treatment-
related factors not adequately accounted for by this model would have greater impact 
on treatment adherence. 
2.7.3 TRANSTHEORETICAL MODEL 
The Transtheoretical model (TTM) was developed by Prochaska and colleagues in an 
attempt to integrate the field of health behaviour theory, which had fragmented into 
over 300 theories by the 1980’s 89. The model describes the stages of change people 
go through when adopting new health behaviours (precontemplation, contemplation, 
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preparation, action, maintenance). The constructs from the TTM are often combined 
with constructs from other behavioural models. For example, an intervention may be 
developed based on the HBM, but taking into account the ‘stages of change’ of their 
target population, recognising that the needs of those who are only contemplating 
changing their behaviour are different from those who are actively engaging in the 
desired behaviour.  An important construct of the TTM is decisional balance, also 
described as the process of weighing up the pros and cons of changing behaviour. 
Studies of the TTM across a range of behaviours and settings have found the results 
from this process shifts as a person moves from one stage to the next (i.e., as a person 
moves from the contemplation stage to action, the pros of engaging in the behaviour 
outweigh the cons). This model suggests it is necessary to consider the factors that 
are perceived by patients as pros and cons of initially undertaking treatment and of 
continuing treatment long-term, as well as the way individuals weigh the importance 
of these factors. 
2.7.4 DECISIONAL BALANCE MODEL OF TREATMENT SATISFACTION 
Research towards a treatment satisfaction tool to be used with patients with varying 
chronic conditions led to the development of the Decisional Balance Model of 
Treatment Satisfaction 90. The study confirmed that two of the three most common 
dimensions on which patients evaluate their treatment relate to barriers, specifically 
the side effects of treatment and the convenience of use 90. The third dimension found 
to be commonly self-evaluated by patients, and influencing treatment satisfaction, 
was treatment effectiveness. This model emphasises the importance of understanding 
the role of patient perceptions when exploring treatment adherence or developing 
interventions to improve adherence should not be minimised. The value a person 
places on different treatment attributes is likely to have significant influence on their 
decision to continue or cease a treatment program 90. 
Many other theoretical models have been devised, often with overlapping 
components, but as yet, no single model appears to be superior to others in 
explaining treatment adherence. Despite the study of over 200 variables (including 
sociodemographic and condition-related factors) to determine associations between 
patient satisfaction and treatment adherence since the 1970’s, there have been no 
conclusive findings regarding the most important predictors of adherent behaviour 
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76,80. Further, successful strategies to overcome barriers to adherence in one particular 
setting have often been unsuccessful in other settings 82. Findings from studies 
investigating patient adherence suggest the fragmentation of research, absence of a 
single model or theory able to integrate the findings of different studies, and 
inconsistent definitions of relevant terminology, have delayed understanding, 
measurement and resolution of non-adherence 75,76. The slow progress in all areas of 
this research highlights the complex nature of treatment adherence as a research 
outcome.  
As the prevalence of chronic diseases has increased over the past 50 years, there has 
been a push for greater reliance on self-management practices and more research into 
patient satisfaction with health care and medical treatment and services 91. Despite 
this, and many attempts at improving adherence with complex interventions, non-
adherence rates remain largely unchanged, with medical treatment adherence for 
some chronic conditions estimated as low as 51% (chronic obstructive pulmonary 
diseases) and 55% (asthma) 75. The development of appropriate strategies to improve 
long-term adherence to treatment for a particular condition first requires an 
understanding of the factors influencing the patient’s ability to commence, and then 
continue a treatment program.  
 
2.8 ISSUES IN LYMPHOEDEMA MANAGEMENT 
Due to the chronic nature of lymphoedema and serious consequences of progressive 
disease, long-term adherence to interventions which improve lymphatic flow appears 
necessary to manage lymphoedema effectively 55,57,92–96. Accessibility of treatment, 
associated costs and the time and/or discomfort involved with treatment are 
considered unacceptable to some, potentially influencing adherence and treatment 
effectiveness 95,97. The evidence relating to factors influencing lymphoedema 
treatment adherence is summarised below, categorised according to the five 
dimensions affecting adherence to long-term therapies defined by the WHO 77.  
2.8.1 HEALTHCARE AND SYSTEM FACTORS 
Effective lymphoedema management is often dependent on access to appropriate 
treatment programs within the health care system and the availability of experienced 
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health professionals. Several issues have been identified as barriers to the provision 
of effective treatment, including delayed diagnostic and treatment pathways, and 
limited lymphoedema knowledge and understanding amongst health professionals.  
The structure of the health care system influences the duration, cost and availability 
of lymphoedema treatment. For example, lymphoedema management has never 
belonged to one specific medical speciality 98, resulting in varied treatment pathways 
being prescribed by health professionals from different disciplines 3,34. Over the past 
decade, multidisciplinary centres have been established to treat lymphoedema, 
involving dermatologists, surgeons, nurses, physiotherapists, occupational therapists, 
podiatrists, dieticians and orthotists 98. A clinical perspective analysis of a 
multidisciplinary lymphoedema centre  reported the benefits of a holistic approach 
towards treatment include: access to multidisciplinary assessment and standardised 
diagnostic procedures; combined treatment plans based on knowledge and experience 
of a range of health professionals; higher continuity of treatment and improved 
patient satisfaction and compliance; enhanced opportunities for education, training 
and research; and increased awareness of lymphoedema across disciplines 98. 
Although the establishment of such centres requires considerable resources, research 
into cost-effectiveness indicates the diagnosis and adequate treatment of 
lymphoedema in its early stage can significantly reduce both direct and indirect costs, 
compared with treatment for advanced lymphoedema resulting from delayed or 
missed diagnoses 99. While the traditional model of impairment-based rehabilitation 
relies on patients or health professionals recognising symptoms of lymphoedema and 
seeking appropriate treatment, this approach can result in lymphoedema reaching an 
advanced stage before treatment is initiated 99. Findings from an analysis of the costs 
involved in treating advanced versus early stage lymphoedema have suggested that 
implementing a surveillance program following cancer treatment to enable early 
detection and treatment of lymphoedema could reduce total health care costs  
associated with lymphoedema by more than half 99.  
Health professionals have identified a lack of support and training as a barrier to 
providing treatment. A study exploring knowledge, diagnostic procedures and 
treatment prescribing practices of health professionals treating lymphoedema in 
Australia (including physiotherapists, occupational therapists, registered nurses and 
remedial massage therapists) found that only the minority felt they had received 
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adequate training from their professional body 41. Likewise, health professionals 
involved in a study in the UK felt they did not know how to treat complex wounds 
and expressed frustration over not always having access to multidisciplinary care, 
particularly for patients with more advanced lymphoedema and associated 
complications 100. While the majority of health professionals in the Australian study 
indicated they sourced additional information regarding lymphoedema treatment 
from patient organisations, journal articles, books, postgraduate courses and the 
internet 41, other studies have identified limited lymphoedema knowledge, 
inappropriate prescribing practices (e.g., diuretics), and dismissive attitudes towards 
patients’ symptoms as common issues in this setting 3,34,37.  
Patients and health professionals identify confusion over treatment advice, and 
concern and frustration over delayed access to treatment, as barriers to effective 
lymphoedema management 34,37,101,102. Health professionals specialising in 
lymphoedema care in the UK raised a number of concerns about the care of 
lymphoedema patients within the health care system 100. They believed the apparent 
lack of professional knowledge and interest in treating lymphoedema patients, 
negative views about the likely effectiveness of treatment, and the belief that treating 
patients with lymphoedema was time consuming and expensive, delayed referral to 
appropriate services and resulted in patients developing irreversible complications 
100.  
A lack of understanding amongst health professionals is considered another potential 
barrier to providing adequate care 3,28,40. Patients have described dismissive and 
insensitive attitudes from health professionals 28, including being told “it’s nothing”, 
“you have to live with it” or “it will clear up” 37. Clinicians who trivialise the impact 
of lymphoedema underestimate the long-term and debilitating nature of the condition 
28. Evidence suggests few patients receive psychological support as part of their 
treatment, despite clear reductions in quality of life 3, and acknowledgment that 
psychosocial factors have a significant impact on patient compliance and the 
provision of effective lymphoedema care 100.  
Patients’ confusion about treatment can be a result of receiving inconsistent advice 
from health professionals 65. Between 25-38% of participants in three different 
studies felt the lymphoedema information they received was inadequate 37,102,103. 
Breast cancer patients gave examples of receiving conflicting advice regarding use of 
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their arm, with some suggesting they should rest the affected arm and others advising 
to use the arm as much as possible 65,101.  Professional perceptions that lymphoedema 
is not painful conflict with patients’ reports of lymphoedema symptoms, suggesting a 
lack of understanding about the patients’ experiences of the condition 3. These issues 
can negatively influence patient-professional relationships, patients’ beliefs about the 
possibilities for effective treatment 100, and subsequently impact on compliance and 
treatment effectiveness. 
2.8.2 SOCIAL AND ECONOMIC FACTORS 
Social and economic factors may impact on patients’ likelihood to adhere to long-
term treatment, due to the significant cost and complex nature of lymphoedema 
treatment strategies. The only study directly exploring relationships between social 
and economic factors and adherence to an intervention aiming to treat lymphoedema, 
found no significant relationships 104. However, this study involved participants 
completing a daily, home-based exercise program, and did not include the more 
commonly prescribed and costly interventions, such as CPT and compression 
garments.  
The financial burden associated with lymphoedema treatment is considerable, with 
studies finding the cost of compression garments and consultation fees a concern to a 
large number of patients 37,41,105,106. In addition to the direct costs of different 
treatments, patients often have transport costs and some are required to take leave 
from work to undergo intensive treatment 100.  
Additional social factors found to influence adherence in other settings include age, 
education level, living arrangements, and levels of social support 77. Although few 
studies have explored these factors in the context of lymphoedema management, the 
following findings suggest more research attention to this issue is warranted. Issues 
influencing adherence may differ across age groups, with health professionals 
drawing particular attention to the issues faced by young patients, including dealing 
with stigma, unattractive compression garments, and intensive treatments which can 
be intrusive and difficult to schedule in their busy lives 100. With respect to education 
levels, patients with higher education levels have been found to experience more fear 
of using the affected limb 107, and are more likely to express anger over receiving 
inadequate information, and source their own information about treatment 101.  
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Living arrangements may influence lymphoedema management in multiple ways. 
Living location often determines access to health services and availability of health 
professionals trained in lymphoedema care 106. Further, those who live alone may 
have difficulty with self-care, including use of compression garments and skin 
hygiene 100. Health professionals specialised in lymphoedema treatment reported 
associations between poor housing and living alone, and recurrent infections and 
deterioration of lymphoedema 100. Level of social support is also suggested to impact 
on compliance with treatment and levels of psychological distress 108. 
2.8.3 CONDITION-RELATED FACTORS 
Symptoms of lymphoedema may influence adherence in a number of ways. While 
physical and psychological difficulties can prevent people from undertaking 
treatment and unexpected changes in symptoms may cause them to stop treatment, 
symptoms can also act as a motivator to continue treatment, particularly if the patient 
fears worsening of their condition 34,65,103,109. The chronicity of the condition may 
also influence treatment use, adherence and effectiveness. Patients who experience 
acute exacerbations may need to alter treatment based on the symptoms they 
experience at different stages of the condition trajectory.  
Research exploring the impact of symptoms on lymphoedema treatment adherence is 
limited, but suggests lymphoedema severity, location (upper-limb versus lower-limb) 
and type (cancer related versus non-cancer related) may be related to adherence and 
treatment effectiveness 34,95,109. The relationship between symptom severity and 
adherence is unclear. Severe symptoms may physically prevent patients from 
completing treatment as prescribed, for example, those with severe swelling may 
have difficulty applying compression garments, and self-massage can be particularly 
hard for those with truncal swelling 100,110,111. Further, there is evidence to suggest 
those with more severe swelling experience greater fear of activity or movement of 
the effected limb 107, and that those who experience changes in symptoms following 
physical activity may withdraw from the activity unless they can be reassured that 
their lymphoedema is not progressing 65. However, other studies suggest patients 
with more lymphoedema symptoms, lower overall quality of life, and those with 
lymphoedema of longer duration, were more likely to adhere to prescribed treatment 
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95,103. These ambiguous findings highlight the need for greater research attention on 
the relationship between condition-related factors and adherence. 
2.8.4 PATIENT-RELATED FACTORS 
Patient-related factors likely to influence adherence to lymphoedema treatment 
include level of knowledge, attitudes, beliefs and perceptions, relating to both the 
patients’ condition and past illness and treatment experiences. Research suggests 
knowledge and education are beneficial to patients, increasing their sense of control 
over their condition and facilitating self-care 79,100,108,110. However, several studies 
have described the detrimental impact of providing inadequate information 100,101,112. 
Findings suggested patients who received inappropriate advice regarding their 
lymphoedema, or who had a poor understanding of the prescribed treatment program, 
were less likely to continue with treatment 100. Further, patients who felt they had a 
lack of information or inaccurate information had increased levels of fear, confusion 
and other negative emotional responses, impacting on decisions regarding arm care 
and adherence to treatment 101,112. 
Patients’ attitudes and beliefs about their condition and treatment are likely to play an 
important role in determining whether they continue long-term treatment. These 
beliefs may be influenced by previous experiences, the beliefs of family, friends or 
trusted health professionals, patients’ coping mechanisms, and their understanding 
about lymphoedema and the risk of progression 20,37,79,100,104,107,112,113. In a study 
involving breast cancer patients with lymphoedema, some reported concerns about 
worsening symptoms and complications as motivating them to continue with 
treatment long-term 20. Confirming this, several women with LLL following 
treatment for gynaecological cancers said they were motivated to continue with time-
consuming massage and exercise routines if they had seen someone with severe LLL 
37. However, others, described as using more passive coping and avoidance 
strategies, did not adhere to treatment despite knowing how to manage their swelling, 
with the hope that the swelling would just ‘go away’ 113. It is unclear from the limited 
research whether factors such as lymphoedema severity or levels of lymphoedema 
knowledge are associated with patients’ perceived seriousness of the condition, but 
there is suggestion the more the condition is felt to be a threat to life, the greater the 
urge to treat it 97.  
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Patients’ perceptions of treatment effectiveness reflect the subjective improvements 
in symptoms following treatment. Evidence suggests those who perceive their 
treatment to be effective are more likely to continue with it 112. Further, previous 
experiences of ineffective treatment are considered to be a major factor influencing 
treatment adherence 100. The role of perceived effectiveness in lymphoedema 
treatment adherence has not been explored adequately, but these findings highlight 
the importance of considering patients’ perceptions in addition to objective measures 
when investigating treatment effectiveness. 
2.8.5 TREATMENT-RELATED FACTORS 
The cost, duration and discomfort associated with commonly prescribed 
lymphoedema treatment strategies can be a significant burden to patients 20,34,114. It is 
unclear whether treatments prescribed and administered by health professionals are 
required on a regular basis to obtain best results or whether intensive periods of 
treatment (e.g., CPT) followed by self-management strategies are equally effective. 
Patients commonly undertake a number of different treatments simultaneously 10, 
which can make it particularly difficult to isolate which are most effective. Patients 
face many barriers to treatment adherence, whether they are undertaking intensive 
treatment or long-term maintenance strategies such as self-massage and wearing 
compression garments.  
Undertaking CPT treatment is costly, time-consuming, and can be exhausting and 
traumatic for patients 20,92,114. Patients may be required to travel long distances to 
access treatment, take periods of time off work, and be unavailable to care for family 
3,114. Self-care strategies to manage lymphoedema can also be burdensome to patients 
and difficult to complete successfully 103. Studies of the use of compression garments 
and compression bandaging have found difficulties applying bandages and garments 
can result in improper use and lower compliance 100,115. Additional barriers to the 
long-term use of compression garments include the cost, appearance, discomfort, and 
difficulties accessing correct-fitting garments 37,79,95,116. Estimates of adherence to 
self-care vary widely, with studies reporting 45-97% of participants completing some 
type of self-care to manage their lymphoedema 37,116. These ranges apply to different 
self-care strategies (i.e., compression, massage and exercises), and small sample 
sizes, varying study designs, and the use of different outcome measures preclude the 
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drawing of conclusions about whether patients are more likely to continue with any 
one aspect of self-care. 
2.9 SUMMARY AND IMPLICATIONS 
Lymphoedema is a chronic and incurable condition, which can have a significant 
impact on daily activities and quality of life. Evidence of the impact of ULL 
following breast cancer suggests women can experience a range of physical 
symptoms, as well as significant psychological impacts, and difficulties with 
employment, social situations and personal relationships. The review of the impact of 
LLL on quality of life described in Section 2.2.1 filled a gap in the research, and 
found those with LLL may experience many of the same adverse effects as those with 
ULL, with additional challenges identified, particularly with extended use of the 
lower-limbs (e.g., standing or sitting for long periods) and difficulties with intimacy 
and sexual function. It is likely lymphoedema would have a similar impact on the 
quality of life of men, but this area requires further research attention.  
People with lymphoedema use a range of mainstream and CAM therapies to treat 
their condition (described in Section 2.4), with many using a number of treatments 
concurrently. Reductions in limb volume have been demonstrated following a range 
of treatments, but the most effective treatments are yet to be clearly identified. 
Lymphoedema treatment studies to date have assessed the effectiveness of treatment 
interventions mostly by examining objective patient outcomes (e.g., limb volume 
reductions), and rarely consider the importance of the patient’s subjective response to 
treatment, the burden of treatment to patients or the impact of non-adherence on 
treatment success 100,117,118. This is not uncommon in studies of healthcare quality, 
which have historically focused on clinical perspectives rather than patient 
perceptions 119. In addition, while lymphoedema is a chronic condition, many patients 
report acute exacerbations (e.g., in hot weather or following long-distance travel), 
and the treatment needs across different stages of the trajectory are rarely considered 
in intervention studies. It is plausible that different treatments are effective for 
different symptoms, and that optimal management of the condition long-term 
requires use of a range of treatments for some people.  
Non-adherence is considered the most important modifiable factor compromising 
treatment effectiveness 77. As reviewed in Section 2.7, many health behaviour models 
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have been applied in research exploring adherence to treatment for chronic 
conditions. While interventions developed based on the biomedical model have 
improved adherence to some medical treatments, the success of such interventions 
appears to decrease over time. This suggests their suitability may be limited for 
managing chronic conditions which require ongoing commitment for self-care from 
the patients. On the other hand, behaviour theorists who take into account the 
cognitive processes largely ignored by the biomedical model, may not adequately 
consider the impact of economic and environmental factors on patients’ ability to 
adhere to a long-term treatment program.  
It is clear that no single model has been identified as predicting adherence across 
different settings, and that many interrelated factors likely influence treatment use. 
The following conceptual summary presents the range of factors associated with 
treatment adherence for lymphoedema, as reviewed in Chapter 2. Factors are grouped 
according to the domains defined by the WHO, and their relevance to different 
theoretical models is represented by the symbols, as per the key.  
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Conceptual model of factors influencing treatment adherence and effectiveness 
Condition-, treatment- and patient-related factors, as well as social, economic and 
health care system factors all contribute to the long-term treatment burden. In 
addition, these factors are likely to be interrelated. For example, a person’s 
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perceptions and expectations of treatment (patient-related factors) may be influenced 
by the severity of their condition and/or the complexity and cost of treatment 
(expecting greater effectiveness from more complex or costly treatments). Evidence 
from treatment adherence for other chronic conditions suggests this treatment burden 
influences treatment adherence, and subsequently treatment effectiveness, but these 
relationships have not been explored in any detail in the context of lymphoedema 
management.  
The role of social and economic factors in treatment adherence has differed across 
different settings. For some conditions, levels of adherence to medical treatment has 
been associated with poverty, unemployment, illiteracy, race and age 77,79, while for 
lymphoedema, the only study exploring these associations found sociodemographic 
factors were not associated with adherence 104. It is possible the treatment burden is 
significant regardless of sociodemographic profile. However, considering the only 
study exploring associations between lymphoedema treatment adherence and 
demographic factors involved a self-care exercise program and did not include the 
more costly and complex treatments (e.g., compression garments and MLD), there is 
a clear need to explore these associations further.  
Effective treatment is likely to improve the quality of life of patients and reduce 
health care costs.  Findings from previous lymphoedema treatment research suggest 
treatment outcomes are optimal when lymphoedema is diagnosed and treated early. 
However, even when identified early, lymphoedema is considered incurable and 
requires ongoing management, highlighting the importance of improving treatment 
adherence. The evidence of treatment effect is building 2 and will be strengthened by 
future RCTs to confirm the positive findings from previous studies, but there is a 
lack of attention on the treatment burden and influence this has on long term 
treatment outcomes. To address this, the third component of this program of research 
involved designing and conducting a cross-sectional study to explore: the use of 
treatment by lymphoedema patients and which treatments are most likely to be 
continued long term; and associations between continued treatment use and 
condition-, patient-, and treatment-related factors, as well as sociodemographic and 
health care system factors.   
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Chapter 3: Research Design 
This research used a quantitative approach to investigate the relationships between 
lymphoedema treatment adherence and range of demographic and psychosocial 
factors. This chapter details the methods used to address the aim and objectives of the 
research, describes the stages of questionnaire development, and outlines the 
procedures used for data collection and data analysis. The ethical considerations of 
the research are detailed in section 3.6. 
3.1 AIM AND OBJECTIVES 
The aim, objectives and hypotheses of the third component of this PhD research are 
as follows: 
AIM 
To assess the use, acceptability and perceived effectiveness of lymphoedema 
treatment strategies to people with lymphoedema, in order to explore issues related to 
lymphoedema treatment adherence. 
OBJECTIVES 
1. To describe the treatment strategies undertaken by people with 
lymphoedema, and determine which are continued long term. 
2. To describe the clinically relevant level of change in lymphoedema 
symptoms (by people with lymphoedema). 
3. To describe the acceptability of lymphoedema treatment options by people 
with lymphoedema. 
4. To assess the perceived effectiveness of lymphoedema treatment to 
alleviate the physical symptoms of lymphoedema.  
5. To assess the relationships between personal characteristics, lymphoedema 
characteristics and the use, acceptability and perceived effectiveness of 
lymphoedema treatment strategies. 
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H1: There will be differences in the lymphoedema treatment types used by 
lymphoedema patients with different sociodemographic characteristics. 
H2: There will be differences in the lymphoedema treatment types used by 
people with different lymphoedema type (primary or secondary), location 
(region of the body affected) and duration.   
H3: The proportion of people with lymphoedema currently using a 
particular treatment will be higher for those who find the cost of that 
treatment acceptable. 
H4: The proportion of people with lymphoedema currently using each 
treatment will be higher for those who find the time associated with that 
treatment acceptable.  
H5: The proportion of people with lymphoedema currently using each 
treatment will be higher for those who find the discomfort associated with 
that treatment acceptable.  
H6: The proportion of people with lymphoedema currently using each 
treatment will be higher for those who find the treatment effective for 
improving their symptoms.  
3.2 RESEARCH DESIGN AND METHODS 
As treatment adherence has been identified as an important component of overall 
treatment effectiveness 77, the ideal research design for investigating the significance 
of adherence in lymphoedema management would involve the addition of adherence 
measures in longitudinal studies investigating lymphoedema treatments. The benefits 
of a longitudinal study would include the ability to investigate patterns of treatment 
use over time, as well as changes in the condition and whether these impact on long-
term treatment use. However, due to time and resource limitations it was not possible 
to adopt this type of design for this study.  
Instead, a cross-sectional study of adults diagnosed with lymphoedema was 
conducted, to explore issues related to adherence for a range of lymphoedema 
treatments. As part of this research, a participant-administered questionnaire assessed 
the factors contributing to treatment burden, as detailed below: 
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• Condition-related factors  
o lymphoedema type (primary or secondary; upper-limb, lower-limb or 
upper- and lower-limb), time since lymphoedema diagnosis, 
lymphoedema patterns (single episode, recurrent or persistent), and 
cancer type for those with secondary lymphoedema following cancer.  
• Patient-related factors 
o perceived effectiveness of treatment options to treat the physical 
symptoms of lymphoedema;  
o perceived acceptability of the cost, time and discomfort associated 
with treatment 
• Treatment-related factors 
o specific treatments undertaken including duration of treatment;  
o cost of undertaking treatment; 
o time involved for treatment sessions; 
o discomfort associated with each treatment; and 
o ability to perform treatment as prescribed 
• Social and economic factors 
o demographics: age, gender, number of children, income, education 
level, employment status, living arrangements 
• Health care system factors 
o health professional who diagnosed lymphoedema; 
o health professional who prescribed treatment; and 
o private health insurance 
3.3 DEVELOPMENT OF THE QUESTIONNAIRE – PHASE ONE 
The questionnaire was developed in consultation with senior researchers, based on 
the objectives of this project (see Appendix A). No previously developed tools for 
the assessment of lymphoedema treatment adherence or satisfaction were identified 
in the literature. 
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Due to the lack of evidence in the literature to support the use of one particular model 
to examine factors influencing treatment adherence 79, research questions were 
developed based on the conceptual summary of the gaps in the literature (Figure 3.1). 
Although the burden of treatment on patients has been acknowledged in previous 
lymphoedema research, no studies to date have explored this burden from the 
patient’s perspective. Further, the extent to which the treatment burden influences 
adherence and treatment effectiveness remains unclear. The aspects of the conceptual 
summary investigated by the current study are highlighted below (Figure 3.1), with 
variables grouped according to the WHO’s five dimensions77. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Factors in the conceptual summary investigated by the current study 
 
The questionnaire was constructed in 2 phases. Initially, questions were developed to 
collect information about patients’ lymphoedema status, treatments used, and the 
acceptability and perceived effectiveness of treatments used. Demographic 
information was collected using questions originally developed for a prospective 
longitudinal cohort study that included lymphoedema as a primary outcome 120. Two 
independent researchers and a physiotherapist reviewed the questionnaire and 
provided feedback about the face validity of the questionnaire. To improve clarity, 
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changes were made to incorporate this feedback into the questionnaire. It was 
determined throughout this process that the most feasible way to collect information 
on the use, acceptability and effectiveness of treatments was to create a section of the 
questionnaire for each different treatment type being assessed. This way, only 
participants who used a particular treatment were required to complete the relevant 
questions. To further ensure the face validity of the tool, the questionnaire was 
completed by two women with lymphoedema to determine whether questions were 
easily understood and interpreted in the way intended by the researcher. The primary 
change following feedback from these women was further clarification of treatment 
types (i.e., providing explanations of each treatment type to prevent 
misunderstandings due to the differing terminology used by health professionals and 
patients, for example, massage versus MLD). 
3.3.1 TREATMENT TYPES 
Treatment types explored by the questionnaire included those identified as the most 
commonly prescribed treatment strategies by health professionals for the 
management of lymphoedema 41,55, as well as those considered in the literature to be 
‘mainstream’ or ‘conventional’ treatment options 2,55. The nine treatment types were 
defined as CPT, MLD, self-administered massage, laser therapy, pneumatic pumps, 
compression bandaging, compression garments, prescribed exercises and surgery 
(defined in Section 2.3.5). 
3.3.2 QUESTION TYPES 
Forced-choice questions were used to collect information about demographic 
characteristics (age, gender, marital and parental status, household income, education 
level, employment status, living arrangements and private health insurance), when 
applicable cancer type and treatment (surgery, chemotherapy, radiotherapy, hormone 
therapy), lymphoedema type (upper- or lower-limb, and primary or secondary), the 
use of lymphoedema treatments (CPT, MLD, self-massage, compression garments, 
compression bandaging and PCP, laser therapy, exercise, surgery), reasons for 
discontinued use of treatment, and the need and availability of another person to 
assist with lymphoedema treatment. Additional questions asked participants to 
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provide information on characteristics of their lymphoedema (location, duration, 
diagnostician, persistence of symptoms).  
Likert scales were used to measure the acceptability and perceived effectiveness of 
lymphoedema treatments used by participants, the importance of symptom 
improvement and the importance of other lymphoedema-related factors (visual 
appearance, ability to wear normal clothing, improvement in function and mobility). 
Four aspects of acceptability (cost, time required per treatment session, duration of 
total treatment period, and discomfort) were measured using a scale labelled 
‘unacceptable’, ‘somewhat unacceptable’, ‘neutral’, ‘somewhat acceptable’ and ‘very 
acceptable’. The Likert scale used to measure how much a treatment helped with a 
range of lymphoedema-related symptoms was labelled according to ‘helpfulness’ as 
‘not at all’ , ‘very little’, ‘a little’, ‘quite a lot’, and ‘very much’, with a ‘not 
applicable’ option provided for those who did not experience a particular symptom. 
The importance of symptom improvement and other related factors to participants 
were measured with a Likert scale labelled ‘not important at all’, ‘unimportant’, 
‘neutral’, ‘quite important’, and ‘very important’.  
A seven point rating scale used in a previous study of breast cancer patients was used 
to ask participants to rate their ‘overall health’ and ‘overall quality of life’ during the 
past week, with one end of the scale labelled ‘very poor’ and the other ‘excellent’.  
As this research was informing a broader understanding of the patients’ perspectives 
regarding treatment adherence, limited open questions were asked to enable 
participants to provide additional information about reasons for discontinuing use of 
lymphoedema treatments, and the level of change in their lymphoedema that would 
be considered as an acceptable treatment outcome.  
3.3.3 PHASE TWO QUESTIONNAIRE REVIEW 
Prior to data collection through Lymphoedema Association of Victoria (LAV), 
participant responses from 134 questionnaires were reviewed to explore the ways in 
which people responded to different types of questions and to determine whether the 
information gained from the questionnaires was suitably addressing the research 
questions.  
A number of changes were made to the questionnaire before further distribution: 
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• Age requested in years rather than date of birth 
• Injury and trauma (as possible causes of lymphoedema) were combined  
• Self-administered massage was renamed ‘self-massage’ and treatment 
descriptions were amended to reflect difficulty participants appeared to 
have in determining which treatment sections to complete (i.e., if 
participants completed CPT which included compression bandaging, 
whether they should also complete the section on compression bandaging 
separately) 
• An open question was added to each treatment section - ‘In your own 
words, please tell us what this treatment entails (i.e., tell us what was 
prescribed, how often you attended sessions, how long each session was 
and the length of the total prescribed treatment period). This modification 
was made because in the initial data collection, a number of participants 
had recorded elsewhere on the page what their treatment involved.  On 
review of this information, there were significant differences in what had 
been prescribed to different patients. The importance of knowing what was 
involved in the treatment that participants were rating as effective and 
acceptable was evident.  
• Cost was defined as ‘financial cost’ (in question about acceptability) 
• Time was divided into two categories (in question about acceptability) – 
‘Time required per session/day’ and ‘Duration of total prescribed treatment 
period’ 
• Likert scale relating to how much a treatment helped with symptoms was 
changed to combine ratings that appeared too similar (and were not 
clinically meaningful). The scale was reduced to three categories of 
helpfulness “very little/little”, “somewhat/moderately” and “quite a 
lot/very much”.  
• The order of reasons for discontinued use was changed to list ‘no longer 
needed (treatment was effective)’ as the first reason, being the only 
positive reason provided as an option. Several participants appeared to not 
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see it among the more negative reasons provided, providing it as their own 
reason in an open-ended question. 
• An ‘other’ treatment option was included, providing space for participants 
to list any additional treatment type they had used and complete the same 
questions to rate the acceptability and perceived effectiveness of that 
treatment. 
• The answer options for questions relating to the need for another person’s 
help to complete treatment were expanded from ‘yes/no’ to ‘yes, all the 
time’, ‘yes, sometimes’ and ‘no’. 
• Likert scale relating to the importance of a treatment improving particular 
symptoms had three labels changed – ‘unimportant’ to ‘not very 
important’, ‘neutral’ to ‘does not bother me’, and ‘quite important’ to 
‘important’. 
• Height and weight (when diagnosed with lymphoedema, at heaviest since 
diagnosis, current weight) questions were added. 
• A final open-ended question was added to ask for any additional 
information participants wanted to provide relating to their lymphoedema 
or treatment use (examples of participant responses are detailed in 
Appendix B). Many participants from the initial round of data collection 
provided additional information, indicating a wish to share their own 
experiences of having lymphoedema and associated treatment.  
In addition to these changes, the questionnaire was reformatted as a booklet to make 
it more readable (due to increased spacing between questions) and more easily 
completed. The questions relating to each treatment type were presented on two 
pages (left and right side when the booklet was open), improving the clarity of the 
format and questionnaire design. This was considered important given the substantial 
size of the questionnaire, at 30 pages in length. The questionnaire included an 
introduction to the research project, initial questions regarding background 
demographic characteristics of participants, questions relating to the research 
questions, further demographic questions and a final acknowledgement of the 
participants’ effort in completing the questionnaire. 
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3.4 METHODOLOGICAL CONSIDERATIONS ASSOCIATED WITH QUESTIONNAIRE 
CONSTRUCTION 
Many cross-sectional studies rely on self-reported measurements using rating scales. 
The subjective nature of these scales necessitates the need to report the psychometric 
properties, to demonstrate that the tool is both reliable and valid 121. The types of 
reliability and validity to be considered are dependent on the type of measurement 
tool. 
3.4.1 VALIDITY 
A tool is considered valid if it is shown to measure what it intends to measure. There 
are several ways to assess validity, including face, content, criterion-related, and 
construct validity 122,123. Determining which should be considered when developing a 
new tool depends on the measure of interest, the type of tool being developed, and 
the research context. 
Face validity refers to whether a tool appears to be measuring what it is supposed to 
measure ‘on face value’. Experts in the field (i.e., clinicians and other researchers) 
and clients are typically involved in this consultation process, and their 
interpretations of the measures are compared with those of the researcher. They may 
also be asked whether the tool is adequately measuring all aspects of a given concept, 
to determine content validity 124,125. 
Criterion-related validity is further divided into predictive and concurrent validity. 
Predictive validity refers to how well the results from one tool predict the results of a 
future measure of the same variable, and concurrent validity involves the comparison 
of the results to another type of measure taken at the same time point, usually 
considered the gold-standard tool. Concurrent validity is therefore only considered 
when there is a pre-existing tool measuring the same construct, most often with the 
aim of determining whether a given construct can be measured as, or more 
efficiently.  
Construct validity refers to the extent to which the measure reflects the theoretical 
constructs underpinning the hypothesis, and includes both convergent and 
discriminant validity. Assessing convergent and discriminant validity involves 
examining whether the measure is similar to other measures it would be expected to 
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be similar to (convergent) as well as different from other measures it would be 
expected to be different from (discriminant). Examining convergent and discriminant 
validity is another way of determining whether the tool is adequately capturing the 
measure of interest, without inadvertently including unrelated concepts. 
3.4.2 REPEATABILITY 
The repeatability or consistency of a measurement tool indicates to what degree the 
tool is expected to produce the same result if repeated at different time points. Unlike 
systematic error, where the scores of individuals in a given sample are influenced 
either positively or negatively (e.g., measurements taken by two different clinicians 
resulting in one set of observed scores being higher than another), this type of 
measurement error is random. Repeatability of a tool must be measured using 
identical administration methods and within a time frame where the health condition 
would not be expected to change, but allowing enough time so that the participants 
will have forgotten previous questionnaire responses 123.  
Kappa is used to estimate the proportion of agreement beyond that which could occur 
by chance. In contrast to measuring proportions of agreement between two time 
points, Kappa accounts for the prevalence of different responses across categories. 
For categorical variables with three or more possible response categories, using a 
weighted Kappa takes into account the size of the difference in responses between 
time points (i.e., weighting cases where a response has moved three categories, 
compared to responses moving one category from one time point to the next). Kappa 
values of 0.5 and 0.7 indicate moderate agreement and good agreement, respectively 
123.  
3.5 VALIDITY AND REPEATABILITY OF THE QUESTIONNAIRE 
In this study, the face validity, content validity and repeatability of the questionnaire 
were investigated, and are described in more detail below.  
3.5.1 FACE VALIDITY 
As described in Section 3.3, face validity of the questionnaire was ensured through 
reviews by independent researchers, a physiotherapist and people with lymphoedema. 
The time taken to complete the questionnaire, appropriateness of questions and 
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clarity were considered by those reviewing the questionnaire. Participant responses 
from 134 questionnaires were reviewed to explore the ways in which people 
responded to different types of questions. Changes made to the questionnaire (see 
Section 3.3.3) prior to distribution through LAV were reviewed by two researchers 
and a physiotherapist. 
3.5.2 CONTENT VALIDITY 
Six participants completed the questionnaire twice, one week apart. To assess content 
validity, participants were asked three additional questions relating to the 
questionnaire during the first data collection session. Participants were asked 
questions relating to the acceptability and effectiveness of treatment methods, and 
about the importance of improvement in lymphoedema-related factors (i.e., 
improvement in visual appearance), to determine whether there were any aspects of 
these concepts they felt were not addressed by the questionnaire (see Appendix C). 
Additional open-ended questions were used within the questionnaire to provide 
participants with the opportunity to give further information about reasons for 
ceasing treatment. 
Participants indicated two aspects of ‘acceptability’ they felt had not been addressed 
by the questionnaire, those being the ‘frequency’ of treatment, and unavailability of a 
particular treatment type in their local area. Two participants described symptoms 
(one symptom each) that had not been included in the list of symptoms used to assess 
treatment effectiveness, namely ‘pitting’ and ‘heat in legs’. In terms of the 
importance of improvements in lymphoedema-related factors, one participant 
reported the questionnaire did not include “ability to do things I want to do in daily 
life” [sic], and another responded “normality of tissues and softness of skin”. 
Remaining participants indicated all other factors they felt were important relating to 
acceptability, effectiveness or importance had been included. 
3.5.3 REPEATABILITY 
Data from the six participants who repeated the questionnaire were entered into the 
statistical package, Statistical Package for the Social Sciences (SPSS), Version 18. 
The limited sample size prevented formal statistical testing of repeatability, but 
visual inspection of the data suggested question responses were consistent.  
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There were no clinically significant differences in the responses between time points 
for the outcome variables of interest. These included the treatment (e.g., have you 
used compression garments to treat your lymphoedema) and current treatment (e.g., 
are you currently using this treatment?) variables, acceptability of cost, time, duration 
and discomfort, and the effectiveness variables relating to each symptom. The 
responses to the variables relating to the importance of improvement in 
lymphoedema status were not significantly different between time points. Any 
changes in Likert scale responses were no more than one category (on a 5 point scale) 
apart between time points.  
3.6 ETHICS 
The study was deemed low risk as there was no foreseeable risk of harm or 
discomfort to participants. No sensitive information was collected. There was still a 
need however to gain ethical approval as the study gathered new information from 
participants which may have led to some inconvenience in terms of the time taken to 
participate in the study. This was minimised by the use of a self-administered 
questionnaire which could be completed and returned at an appropriate time by 
participants. Ethics approval was obtained by Queensland University of Technology 
Human Research Ethics Committee, approval number: 0900000984. 
3.7 PARTICIPANTS 
Eligible participants were adults aged 18 years and over with lymphoedema. The age 
range was not limited and there were no exclusions based on cancer or treatment 
types. Data was collected using a convenience sampling approach (see Figure 3.2). 
Specifically, the initial survey was distributed to:  
• people with lymphoedema attending a patient information session at the 
22nd Congress of the ISL in Sydney in 2009 (70 questionnaires 
distributed); and 
• members of the Lymphoedema Association of Queensland (LAQ) (n=250) 
in 2010. LAQ is a self-help organisation offering support, information and 
education to anyone affected by lymphoedema including those with 
primary or secondary and ULL or LLL. 
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The modified survey was distributed to: 
• members of the LAV in 2010 (n=710).  
To maintain the privacy of LAQ and LAV members, all member details were 
retrieved and prepared for the mail-out by the respective state association 
committees. The surveys to LAQ were mailed as a one-off distribution and included 
instructions to return completed surveys in reply-paid envelopes within two weeks. 
The method of distribution was reviewed prior to the LAV mail-out, which included 
a reminder post-card sent 2 weeks after the surveys (see Appendix D). Distribution of 
the survey through the state-wide lymphoedema associations was the most feasible 
way of recruiting participants diagnosed with lymphoedema. A limitation of this 
sampling approach is possible bias introduced by participants being members of the 
associations; they may be more informed and more likely to be active seekers of 
treatment than those with lymphoedema in the general population.  
Of the 70 questionnaires distributed at ISL, 24 (34%) were returned. No details were 
known about attendees who did not complete the questionnaire. Of the mail-out 
distributions through LAQ and LAV, both had similar response rates (44% and 43%, 
respectively). Respondents who were ineligible for inclusion included health 
professionals who were members of LAV but did not have the condition, those who 
had not been formally diagnosed with lymphoedema and parents of children with 
lymphoedema.  
70 questionnaires distributed at ISL patient information session 
24 questionnaires returned (34%) 
 
250 questionnaires sent to LAQ members 
8 replied - ineligible 110 (44%) - returned and eligible to participate  
 
710 questionnaires sent to LAV members 
43 replied - 
ineligible 10- too unwell 
8 – wrong address or 
deceased 
307 (43%) – 
returned and eligible 
to participate 
Figure 3.2 Questionnaire distribution and response rates. 
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3.8 DATA MANAGEMENT  
Data was collected using the mailing lists of the LAQ and the LAV. Questionnaire 
packages were labelled by members of LAQ and LAV, and member details were not 
provided to the researcher. Returned questionnaires were allocated a sequential ID 
number, and hard copies were stored in a locked filing cabinet. Data files were kept 
on a password-protected personal drive accessible by the researcher only. The initial 
questionnaire returned by LAQ members and patients attending the ISL patient 
information session is herein described as the ‘first questionnaire’, and this cohort 
described as ‘LAQ+’. The ‘second questionnaire’ refers to the revised questionnaire 
distributed to, and returned by, members of LAV. This group of participants is 
described as ‘LAV’. 
Master copies of both the first and second questionnaires were assigned 
comprehensive codes, and data was entered into Statistical Package for Social 
Sciences (SPSS), Version 18.0, by the researcher and a research assistant. After 
entering data from three of each of the questionnaires, the researcher was consulted 
to ensure the research assistant was interpreting and entering data correctly (e.g., 
consistency of data entry when participants had provided a written response instead 
of ticking one of the boxes provided, or had responded inconsistently). On 
completion of data entry, a random subset of 10% of the dataset (42 participants, 533 
variables) was re-entered for data verification. There were 24 discrepancies noted in 
22, 386 variables entered (i.e., 99.89% accurate) so the original data entry was 
accepted.  
3.9 DATA CLEANING 
Frequencies were run for all variables and checked against the coding manual to 
identify any invalid or out-of-range values or inconsistent data (e.g., response “no” to 
“do you have children?” but a number of “2” in “how many children do you have?”). 
Where data was missing for a given variable, other related variables were checked 
and hard copies of questionnaires were accessed, to determine whether data could be 
entered (i.e. if participants did not answer the question “have you used complex 
physical therapy to treat your lymphoedema?” but completed all other questions 
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related to that treatment, it was assumed the participant did the treatment and the 
response “yes” was entered for the original question).  
3.10 VARIABLE DEFINITIONS 
The main outcome and independent variables are defined below. 
3.10.1 OUTCOME VARIABLES 
The main outcome variables for these analyses were use of treatment, current use of 
treatment, acceptability of treatment, and perceived effectiveness of treatment. 
The use of treatment was a dichotomous, categorical variable, defining the number of 
people who had ever used a particular treatment type. The proportion of people 
currently undertaking treatment (dichotomous, categorical variable) was also 
assessed.  
Measuring the acceptability of treatment involved multiple outcome variables 
including, acceptability of financial cost, time involved each session/day, the duration 
of the total prescribed treatment period, and discomfort. All acceptability variables 
were ordinal categorical variables, with five levels of acceptability (very acceptable, 
somewhat acceptable, neutral, somewhat unacceptable, and unacceptable).  
Perceived effectiveness of treatment was assessed by participants rating how much 
each treatment helped to treat symptoms of lymphoedema. The first questionnaire 
listed 10 different symptoms which were identified from the literature (swelling, 
heaviness, tightness, aching, tenderness, stiffness, weakness, numbness, pain, and 
range of movement) and included five levels of effectiveness (not at all, very little, a 
little, quite a lot, very much). Following review of the questionnaire responses (see 
section 3.3.3), tingling was added as a symptom and effectiveness was collapsed to 
three levels, ‘very little/little’, ‘somewhat/moderately’, and ‘quite a lot/very much’.  
3.10.2 INDEPENDENT VARIABLES 
Objective five explored the impact on these overall results of a range of socio-
demographic, condition-related and treatment-related variables. This section 
considers the transformations of the independent variables from the data collected in 
the questionnaire, to the variables used in analysis.  
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Social and economic characteristics 
Information about the social and economic characteristics of participants was 
collected using questions from previous studies involving people with cancer, 
including those who developed secondary lymphoedema following cancer treatment. 
Following review of the raw data, some variables were transformed to maximise use 
of available data, and statistical power for multivariate analysis. Specifically; 
• Age was collected to the nearest year, and was retained as a continuous 
variable. For bivariate analysis, age was recoded into 10 year age groups, 
then further collapsed to combine groups with too few participants. The 
resulting four age groups (under 55 years, 55-64 years, 65-74 years, and 75 
years and over) enabled comparison of the outcome variables between 
younger and older age groups.  
• Number of children was collapsed into a dichotomous yes/no variable to 
determine those who had children. The majority of participants in the study 
were over 55 years and had adult children if any, so the ages of children 
were not considered relevant for this study.  
• Living arrangements were combined to create three categories: living 
alone; living with a partner, friends or relatives; and other (including 
nursing home and hostel accommodation). 
• Private health insurance was reduced to a yes/no variable.  
• Education levels were collapsed from nine original categories to four: year 
12 or less; trade or business certificate/apprenticeship; associate or 
undergraduate diploma; and bachelor degree or higher.  
• Household income was collected in $10,000 income levels and was 
combined according to previous research in socioeconomic status and 
health outcomes 126. The income categories used in bivariate and 
multivariable analyses were <$20,799, $20,800 - $36, 399, $36,400 - 
$51,999, and >$52,000, with an additional category for those who did not 
know or did not want to answer the question.  
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These variable transformations were conducted to improve model stability in 
multivariate analyses and enable meaningful comparisons between the independent 
and dependent variables.  
Lymphoedema characteristics 
Diagnosis of lymphoedema, presence of lymphoedema at the time of completing the 
questionnaire, lymphoedema type (primary or secondary), and the development of 
lymphoedema following cancer (yes/no) were collected as dichotomous variables.  
Considerable information was collected about the location (right and left side, hand, 
arm, breast, trunk, leg, foot, and groin), date of diagnosis, diagnosing health 
professional, duration (>3 months, yes/no) and characterisation (single episode, 
recurrent, and persistent) of lymphoedema. Following review of the data, location of 
lymphoedema was collapsed into three categories: upper only (including hand, arm, 
breast); lower only (including foot, leg, groin); and full body or other (where the parts 
of the body involved did not fit into either upper only or lower only). Health 
professionals were recoded as either medical practitioners (including general 
practitioners and specialists) or allied health professionals, with an additional 
category for others. The vast majority of participants (79%) had persistent 
lymphoedema, so those with single episode or recurrent lymphoedema were 
combined for multivariate analysis. 
In addition to lymphoedema characteristics, data were collected about participants’ 
other medical conditions using a standard question from previous research 127. The 
question specified 15 medical conditions and provides three answer options: yes, no, 
and don’t know. These variables were combined to create a single comorbidities 
variable, with five categories ranging from no conditions to 4 or more conditions.  
3.10.3 EFFECT MODIFYING VARIABLES 
This study included participants with all lymphoedema types and lymphoedema 
affecting all areas of the body. Review of the literature identified some differences in 
the impact of lymphoedema between those with ULL and LLL and highlighted 
potential barriers to treatment specific to lymphoedema location (e.g. requiring help 
from another person to massage lower-limbs). In addition, available treatment could 
differ based on the affected region, with those with lymphoedema of the trunk and 
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groin being unable to apply compression garments. For this reason, results were 
explored for subgroup differences to determine whether lymphoedema location was 
an effect modifying variable for the associations between treatment use and other 
independent variables.  
It is recognised that there could also be subgroup differences in other relationships of 
interest in this study. This particular relationship was explored because of the 
differences in impact highlighted by the literature review and suggestion in previous 
research of potential treatment challenges for lymphoedema affecting different 
regions. It was considered important to explore these differences further and 
determine whether recommendations should differ based on lymphoedema location.  
3.10.4 CONFOUNDING VARIABLES 
Many of the independent variables described above in Section 3.10.2 were possible 
confounders of the relationships between the other independent variables and 
outcomes explored to address Objective 5. Multivariable regression models were 
used to adjust for these inter-relationships. The methods for these analyses are 
described in the Data Analysis section below (see Section 3.12.5). 
3.11 STATISTICAL CONSIDERATIONS 
3.11.1 CLINICAL IMPORTANCE 
The clinical importance of the results was considered in addition to statistical 
significance. At the bivariate level, results for the use, acceptability and effectiveness 
were considered clinically important if there was ≥ 10% difference between groups. 
For multivariable analyses, odds ratios (OR) ≤ 0.5 or ≥ 2.0 were considered clinically 
important.  
3.11.2 SAMPLE SIZE 
The sample size required to compare proportions for research question five was 
calculated using the two proportions equation 128. To be able to detect a 10% 
difference between groups with 80% power and a significance level of 5%, where 
50% of the referent group had the outcome of interest (e.g., 50% of those with 
secondary lymphoedema using MLD compared with 60% with primary 
lymphoedema), it was calculated that 195 participants would be required in each 
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group. Actual proportions of lymphoedema patients using different types of 
treatments differed widely, so sample size calculations were based on the assumption 
that at least 50% of the sample would be expected to have used the treatments 
reported by health professionals as most commonly prescribed. Statistical power was 
limited for outcomes related to treatments less commonly used by participants.  
3.11.3 ASSUMPTIONS OF TESTS AND MODELS 
Prior to conducting bivariate and multivariable analyses, the relevant assumptions 
were tested.  
The distributions of continuous variables are assessed for normality to ensure 
appropriate summary statistics are used. The only continuous independent variable 
was age, which was assessed for normality using the following criteria: 
• mean within 10% of median; 
• mean ± three standard deviations approximates the minimum and 
maximum values observed; 
• skewness and kurtosis coefficients within ± 3; and 
• histogram approximately symmetrical and bell-shaped.  
The distribution of age did not meet the above criteria, so results are expressed as 
medians with minimum and maximum values. 
The chi-square test for the comparison of proportions within categorical variables 
assumes the following: 
• observations are independent; 
• categories are mutually exclusive; and 
• all expected cell counts are five or more. 
An expected cell count of over five is considered a conservative rule 129, and as such, 
an expected cell count of over two was used for this analysis. The study was a cross-
sectional study with no repeated measures, and study participants were unlikely to be 
related. Therefore, observations were considered to be independent. For all variables, 
care was taken during the questionnaire design stage to ensure categories were 
mutually exclusive and exhaustive.  
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The absence of collinearity is assumed for logistic regression. It was considered 
possible that some of the independent variables were measuring the same or very 
similar concepts. These variables were tested for collinearity to determine the degree 
of redundancy prior to multivariable modelling. Correlations between variables 
measured on Likert scales were examined using Pearson’s correlation coefficient. 
Categorical variables suspected to be measuring similar concepts (ie. characterisation 
of lymphoedema and duration of lymphoedema) were checked at the bivariate level 
using cross-tabulations of counts and percentages, to consider the similarity of the 
variables qualitatively. The phi coefficient for 2x2 tables, Cramer’s V for nominal 
variables with 3 or more categories, and Kendall’s Tau-b (τb) for ordinal variables 
were used to statistically test collinearity. If the correlation was above 0.7 or below -
0.7, variables were entered into the model separately to assess the change in 
estimates, as recommended by Tabachnick and Fidell 130. If the correlation was above 
0.9 or below -0.9, the variables were considered to be measuring the same concept.  
The following rationale describes the variables tested for collinearity. Lymphoedema 
duration and characterisation were likely to be strongly correlated (i.e. a high 
proportion who had lymphoedema for more than 3 months were likely to describe 
their lymphoedema as ‘persistent’) so these variables were tested for their degree of 
redundancy. Household income, employment status and education level are all 
measures of socioeconomic status. Although these variables are usually considered 
independent, they often have an effect on one another 126. For example, education 
level influences employment status and both variables influence household income. 
As measuring the acceptability of the cost of treatment was an important part of this 
research and could be influenced by socioeconomic status, it was important to 
determine the strength of association between these variables.  
It was considered possible the ‘treatment effectiveness’ variables (for a range of 
symptoms) could be highly correlated and measuring the same concept. The same 
was possible for ‘acceptability’ variables. Although the questionnaire asked 
participants to rate the effectiveness and acceptability of different aspects of 
treatment, these variables were tested to determine whether they would need to be 
entered into separate models due to collinearity.  
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3.12 ANALYSIS 
3.12.1 DATA ANALYSIS –  LYMPHOEDEMA TREATMENT USE 
Determine which treatment strategies are undertaken by people with lymphoedema, 
and which are continued long term. 
Frequencies and proportions of participants who reported using each treatment were 
calculated and reported. The second questionnaire included a question asking 
participants to describe what each treatment entailed. Responses were coded 
according to whether or not the participant’s description matched the definition of 
each treatment used for this study (see Table 3.1). 
Table 3.1 
Treatment types and description of treatments 
Treatment Description 
Complex Physical Therapy a period of intensive treatment, or a 
treatment program involving at least two of 
the following; MLD, massage, compression 
bandaging, prescribed exercises 
Manual Lymphatic Drainage session times with a health professional of 
the procedure of massage techniques used to 
drain lymphatic fluid 
Self-massage massaging of self or by another person (e.g., 
partner, NOT health professional) or the 
time/how often massage was undertaken. 
Laser therapy description of laser machine or how often 
sessions were attended. 
Pneumatic pumps description of pump, brand, or sessions 
attended 
Compression bandaging description of bandaging technique or type 
of bandage  
Compression garments description of garment, stocking, brand of 
compression garments, or an activity/time 
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period in which CG are commonly 
prescribed (i.e., for air travel).  
Prescribed exercises physical activity program or limb exercises 
or a source (i.e., brochure) where participant 
obtained details of appropriate exercises 
Surgery surgical procedure used to treat 
lymphoedema or associated complications 
 
These data were used to calculate the proportions of participants using each treatment 
whose description met the defined criteria. If the description met the criteria for 
another treatment type and no information had been provided for that treatment, the 
data was moved to its more appropriate treatment type (i.e., if the participant had 
completed questions in MLD but described performing the massage themselves, data 
was moved to self-massage). The range of responses provided for each treatment was 
assessed and examples are provided in the results. However, for all further analyses, 
all participants who indicated they had used each treatment were included in the 
analyses. The frequencies and proportions of participants who were currently using 
each treatment were also calculated and reported.  
Participants who did not continue with a particular treatment were asked to indicate 
the reasons for stopping. On the first questionnaire, seven possible reasons were 
listed, and an open question was included for participants to respond with additional 
reasons. After reviewing responses to the open question, an eighth reason for 
stopping (stopped due to side effects) was included in the second questionnaire. 
Frequencies and proportions of participants indicating each reason for stopping were 
calculated and reported for each treatment type.  
3.12.2 DATA ANALYSIS – IMPORTANCE OF IMPROVEMENT IN LYMPHOEDEMA 
STATUS 
To describe what level of change in lymphoedema status is perceived as important by 
people with lymphoedema. 
The importance of improvement in physical symptoms was assessed using 5 
categories (“not important at all”, “not very important”, “does not bother me”, 
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“important” and “very important”). The number of participants who had each 
symptom was calculated by using responses to either questions on effectiveness or 
importance of improvement in symptoms. As importance was the outcome of 
interest, proportions of participants who had the symptom and indicated 
improvement in that symptom was either “important” or “very important” were 
calculated and presented.  
Other factors related to lymphoedema status were considered for their importance to 
participants, including improvement in visual appearance, ability to wear normal 
clothing, improvement in function and improvement in mobility. Frequencies and 
proportions of participants responding “quite important” or “very important” were 
calculated.  
3.12.3 DATA ANALYSIS – ACCEPTABILITY OF TREATMENT 
To describe the acceptability of lymphoedema treatment options by people with 
lymphoedema. 
Acceptability of the cost, time, duration and discomfort were assessed for each 
treatment. The number and proportion of participants indicating each response (5 
categories – “unacceptable” “somewhat unacceptable” “neutral” “somewhat 
acceptable” or “very acceptable”) were calculated.  
3.12.4 DATA ANALYSIS – PERCEIVED EFFECTIVENESS OF TREATMENT 
To assess the perceived effectiveness of lymphoedema treatment, to treat the physical 
symptoms of lymphoedema. 
The proportions of participants with each symptom who indicated each treatment was 
effective “quite a lot/very much” for that symptom were calculated and reported.  
3.12.5 DATA ANALYSIS – FACTORS INFLUENCING TREATMENT USE 
To assess the relationships between personal characteristics, lymphoedema 
characteristics and the use, acceptability and perceived effectiveness of 
lymphoedema treatment strategies. 
Bivariate Analyses 
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Bivariate analyses were conducted to determine whether any personal/demographic 
or lymphoedema characteristics were crudely associated with each of the outcome 
variables (use, current use, acceptability and perceived effectiveness). This was done 
using crosstabulations and chi squared tests, as all variables were independent 
categorical variables.  
Impact of lymphoedema location on bivariate analyses 
Lymphoedema location was considered a possible confounder and/or effect modifier 
of the relationships between the independent variables and outcomes of interest. 
Firstly, bivariate analysis was used to assess relationships between lymphoedema 
location and outcome variables. Confounding variables are associated with both the 
independent and outcome variable and cause a shift in the results. After establishing 
associations with outcome variables, lymphoedema location was tested for 
associations with all independent variables, using crosstabulations of counts and 
percentages, and chi squared tests of association. 
Crude relationships between independent variables and treatment use variables were 
stratified by the potential effect modifying variable ‘lymphoedema location’ to 
establish whether the pattern of association was different within subgroups. When 
stratified crosstabulations revealed subgroup differences, effect modification was 
documented. Differences in independent variables with less than 20 cases were not 
documented due to the resulting oversensitivity.  
Multivariable analyses 
Binary logistic regression analyses were used to assess the adjusted relationships 
between personal and lymphoedema characteristics and the use of treatment, as well 
as the current use of treatment. Four treatment types had insufficient sample sizes to 
undertake multivariable analyses. Included treatments in multivariable analyses were 
compression garments, self-administered massage, prescribed exercises, MLD, 
compression bandaging and CPT. OR and 95% confidence intervals were generated 
to identify which characteristics influenced the use of treatment.  
Two thematic blocks were defined and entered into the model separately. All models 
included age, due to the known association between age and many health-related 
outcomes. If variables were found to be related (e.g., education and income), they 
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were removed and entered one at a time to examine changes in effect size indicative 
of confounding. The categories of variables with the highest number of participants 
or the most clinical relevance were defined as the referent groups. Where variables 
had over 10% missing data, a ‘missing’ category was defined and included.  
Table 3.2 
Modelling blocks defined for logistic regression analyses 
Block Variables 
Block 1 – Personal characteristics age, gender, children, living arrangement, 
private health insurance, education level, 
employment, income 
Block 2 – Lymphoedema characteristics age, lymphoedema type, lymphoedema 
location, lymphoedema after cancer, 
characterisation of lymphoedema, duration, 
co-morbidities, diagnosing health 
professional 
 
To prevent exclusion of potentially important variables, those with p-values <0.25 
and/or considered clinically important were retained for the hybrid models 131. Final 
models included any variables found to be statistically significant (p<0.05) or 
clinically significant (OR <0.5 or >2.0) in the hybrid models. Model fit was assessed 
using the Omnibus Tests of Model Coefficients (p<0.05 indicating independent 
variables in Block 1 were better predictors of the outcome than Block 0, where it is 
assumed all participants respond in the way the majority respond to the dependent 
variable) and Hosmer and Lemeshow Test (p>0.05 indicating support for the model). 
The Cox and Snell, and Nagelkerke R square values were used to assess the amount 
of variation in the outcome explained by each model, with the values between 0 and 
1 suggesting the percentage of variability explained by the variables in the model 
132,133.  
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Chapter 4: Results 
This chapter presents the results relating to each objective outlined in Section 3.1. 
Key characteristics of the sample are described first, providing details of participants 
from the first and second stages of recruitment to enable comparison of the two 
groups. Descriptive results are presented to address the objectives related to the use, 
importance of improvement in lymphoedema, acceptability of treatment, and 
perceived effectiveness of treatment. Finally, the results from the multivariable 
models testing the associations between acceptability, effectiveness and current 
treatment use, are presented for compression garments, self-administered massage, 
prescribed exercises, MLD, compression bandaging and CPT.  
4.1 SAMPLE CHARACTERISTICS 
The demographic and lymphoedema characteristics of the 133 eligible participants 
who responded to the initial questionnaire (the majority from Queensland, who will 
be referred to as LAQ) were compared with those of the 288 participants who 
completed the final questionnaire (LAV). There were no significant differences 
between LAQ and LAV participants for age, gender, child responsibilities, living 
arrangements, private health insurance status, education level, or household income 
(see Table 4.1). The majority of participants in both LAQ and LAV groups (82% and 
86%, respectively) were aged 55 years or older, with a median age of 66.0 years 
(min=18.0, max=91.0), and most participants (95% in both groups) were female. 
Approximately half of the participants in both groups lived with partners, friends or 
relatives (49% LAQ and 53% LAV), and around 10% had children living at home 
(14% LAQ and 11% LAV). Education levels were consistent between groups, with 
around 40% finishing Year 12 or less, 20% completing TAFE or diploma level 
qualifications, and 27% completing bachelor (or higher) degrees and the majority of 
participants had private health insurance (77% in both groups).  
The majority of participants had secondary lymphoedema (84% LAQ and 76% LAV) 
and of these, most had developed lymphoedema following cancer treatment (86% 
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LAQ and 81% LAV). Proportions of participants diagnosed with different cancer 
types were similar in both LAQ and LAV groups, at 68% and 70% for breast cancer, 
15% and 16% for gynaecological cancers, and 16% and 13% diagnosed with other 
cancers, respectively. The vast majority (96%) had surgical treatment for cancer, 
around one third had also received radiation treatment, and one third had received 
both radiation and chemotherapy. One in four participants who had been diagnosed 
with cancer received hormone therapy.  
Participants from LAQ and LAV were similar for lymphoedema location, duration 
and characteristics. Of the 45% with ULL, 43% (45% LAQ and 42% LAV) had 
unilateral ULL, and 2% (4% LAQ and 2% LAV) had bilateral ULL. The proportions 
of those with unilateral and bilateral lymphoedema were more evenly spread for 
those with LLL, with 21% with unilateral LLL (23% LAQ and 21% LAV) and 22% 
with bilateral LLL (19% LAQ and 24% LAV). A further 5% of participants had full 
body lymphoedema, and 6% had lymphoedema in another area of the body (i.e., 
affected areas of the body did not fit any of the descriptions above). The majority of 
participants had lymphoedema for more than 3 months (84% of all participants, 79% 
LAQ and and 87% LAV), and described their lymphoedema as ‘persistent’ (78% of 
all participants, 80% LAQ and 78% LAV).  
Over half of the study participants had two or more other medical conditions (60% 
total, 59% LAQ and 60% LAQ), with around 20% reporting four or more conditions. 
Participants’ rating of their overall health and quality of life (on a scale of one to 
seven, with one labelled ‘very poor’ and seven labelled ‘excellent’) did not differ 
between groups, with a median overall health rating of 5.0 (min=1, max=7) and 
median overall quality of life rating of 5.0 (min=1, max=7). The majority rated their 
overall health and quality of life between 5.0 and 7.0 on the 7 point rating scale (68% 
and 70.5%, respectively).  
Considering the similarities between the samples, participants were considered 
representative of Lymphoedema Association members in Australia, and it was 
considered appropriate to pool the data for all further analyses. 
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Table 4.1 
Sociodemographic and lymphoedema characteristics of all eligible study participants  
 Queensland Victoria Total 
Age  median (min,max) 65.0 28.0, 86.0 67.0 18.0, 91.0 66.0 18.0, 91.0 
 n (%) n (%) n (%) 
Age Group       
Under 55 years 24 (18.0) 38 (13.2) 62 (14.7) 
55-64 years 37 (27.8) 85 (29.5) 122 (29.0) 
65-74 years 44 (33.1) 105 (36.5) 149 (35.4) 
75 and over/missing 28 (21.1) 60 (20.8) 88 (20.9) 
Gender 
Female 126 (94.7) 273 (94.8) 399 (94.8) 
Male 7 (5.3) 15 (5.2) 22 (5.2) 
Children  
None 34 (25.6) 67 (23.3) 101 (24.0) 
Children under 14 years 6 (4.5) 10 (3.5) 16 (3.8) 
Children over 14 years 80 (60.2) 160 (55.6) 240 (57.0) 
Children of unknown ages 16 (12.0) 55 (19.1) 71 (16.9) 
Children living with you  19 (14.3) 33 (11.5) 52 (12.4) 
Living arrangement 
Living alone  44 (33.1) 69 (24.0) 113 (26.8) 
Living with 
partner/friends/relatives 
65 (48.9) 154 (53.5) 219 (52.0) 
Couple living with children 17 (12.8) 36 (12.5) 53 (12.6) 
Other/Missing 7 (5.3) 29 (10.0) 36 (8.6) 
Private health insurance 
No 30 (22.6) 48 (16.7) 78 (18.5) 
Yes, hospital only 14 (10.5) 50 (17.4) 64 (15.2) 
Yes, extras only 5 (3.8) 10 (3.5) 15 (3.6) 
Yes, hospital and extras 83 (62.4) 163 (56.6) 246 (58.4) 
DVA card - - 2 (0.7) 2 (0.5) 
Missing 1 (0.8) 15 (5.2) 16 (3.8) 
Highest education qualification 
Year 12 or less 54 (40.6) 120 (41.7) 174 (41.3) 
Trade or business cert/ 
Apprenticeship 
14 (10.5) 32 (11.1) 46 (10.9) 
Associate or Undergrad 
diploma  
17 (12.8) 25 (8.7) 42 (10.0) 
Bachelor degree or higher 36 (27.1) 80 (27.8) 116 (27.6) 
Other/Missing 12 (9.0) 31 (10.8) 43 (10.2) 
Household income 
<$20 799 24 (18.0) 45 (15.6) 69 (16.4) 
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$20 800 – 36 399 21 (15.8) 40 (13.9) 
 
61 (14.5) 
$36 400 – 51 999 24 (18.0) 31 (10.8) 55 (13.1) 
$52 000+ 31 (23.3) 55 (19.1) 86 (20.4) 
Do not know/Do not want to 
answer question/Missing 
33 (24.8) 117 (40.6) 150 (35.6) 
Lymphoedema type 
Primary 22 (16.5) 70 (24.3) 92 (21.9) 
Secondary  111 (83.5) 218 (75.7) 329 (78.1) 
Secondary lymphoedema followed cancer  
Yes 91 (82.0) 177 (81.2) 272 (82.7) 
Diagnosed with cancer 
Yes 92 (69.2) 184 (63.9) 276 (65.6) 
Cancer type 
Breast 63 (68.5) 130 (70.7) 193 (69.9) 
Gynecological 14 (15.2) 30 (16.3) 44 (15.9) 
Other 15 (16.3) 24 (13.0) 39 (14.1) 
Cancer treatment 
Surgery 90 (97.8) 176 (95.7) 266 (96.4) 
Chemotherapya (noradiation) 5 (5.4) 21 (11.4) 26 (9.4) 
Radiationb 34 (37.0) 59 (32.1) 93 (33.7) 
Chemo and radiation 28 (30.4) 59 (32.1) 87 (31.5) 
Hormone therapy 27 (29.3) 47 (25.5) 74 (26.8) 
Other treatment 12 (13.0) 15 (8.2) 27 (9.8) 
Lymphoedema location 
Unilateral Upper  60 (45.1) 122 (42.4) 182 (43.2) 
Unilateral Lower 30 (22.6) 60 (20.8) 90 (21.4) 
Bilateral Upper 5 (3.8) 5 (1.7) 10 (2.4) 
Bilateral Lower 25 (18.8) 69 (24.0) 94 (22.3) 
Full Body 5 (3.8) 16 (5.6) 21 (5.0) 
Other 8 (6.0) 16 (5.6) 24 (5.7) 
Diagnosing health professional 
Medical practitioner 85 (63.9) 186 (64.6) 271 (64.4) 
Allied health  27 (20.3) 46 (16.0) 73 (17.3) 
Massage Therapist 4 (3.0) 9 (3.1) 13 (3.1) 
Other (self, family) 4 (3.0) 13 (4.5) 17 (4.0) 
Missing 13 (9.8) 34 (11.8) 47 (11.2) 
Lymphoedema for >3 months 
Yes 105 (79.0) 249 (86.5) 354 (84.1) 
Lymphoedema characterised 
Single episode 3 (2.2) 2 (0.7) 5 (1.2) 
Recurrent 10 (7.5) 26 (9.0) 36 (8.6) 
Persistent 107 (80.5) 224 (77.8) 331 (78.6) 
Missing 13 (9.8) 36 (12.5) 49 (11.6) 
Current lymphoedema 
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Yes 126 (94.7) 273 (94.8) 399 (94.8) 
Medical conditionsc 
0 17 (12.8) 47 (16.3) 64 (15.2) 
1 37 (27.8) 67 (23.3) 104 (24.7) 
2 33 (24.8) 68 (23.6) 101 (24.0) 
3 19 (14.3) 39 (13.5) 58 (13.8) 
4 or more 27 (20.3) 67 (23.3) 94 (22.3) 
       
Health and QoLd  medi
 
min, max median min, max median min, max 
Overall health rating 5.0 1.0, 7.0 5.0 1.0, 7.0 5.0 1.0, 7.0 
Overall QoL rating 5.0 1.0, 7.0 5.0 1.0, 7.0 5.0 1.0, 7.0 
aChemotherapy without radiation; b Radiation without chemotherapy; c Includes: heart attack, angina, 
high blood pressure, high cholesterol, other heart condition, stroke, diabetes, asthma, chronic bronchitis, 
emphysema of the lungs, stomach or duodenal ulcer, migraine headaches, osteoporosis, rheumatoid 
arthritis, depression; dmeasured using a 7-point visual analogue scale; QoL: Quality of life 
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4.2 OBJECTIVE ONE – LYMPHOEDEMA TREATMENT USE 
Determine which treatment strategies are undertaken by people with 
lymphoedema, and which are continued long term. 
At least two thirds of participants had used compression garments (86%), self-
massage (79%), prescribed exercises (69%), or MLD (67%) to treat their 
lymphoedema (see Table 4.2). In addition, compression bandaging and CPT were 
used by 45% and 42% of participants, respectively. Between 3 to 18% had used laser 
therapy, PCP, and/or had surgery to treat their lymphoedema (18%, 12%, 3%, 
respectively), while less than 3% had used a range of other treatments, including 
whole body exercise, medication, CAM therapies, and electrotherapy.  
Over half (62%) of all participants had used more than four lymphoedema treatment 
types, while 5% had used only one type of lymphoedema treatment. Of those who 
had only used one or two treatment types (n=70), over half had used compression 
garments (61%), and at least one quarter had used self-massage (31%), MLD (30%) 
and prescribed exercises (24%). In this group (using one or two treatments), fewer 
participants had used bandaging (11%), CPT (7%), surgery (1%), and no participants 
had used laser or PCP. Participants’ descriptions of treatments varied (see Appendix 
E for examples of treatment descriptions). The defined criteria matched participants’ 
descriptions more often for some treatments (e.g., compression garments and laser 
therapy) than others (e.g., CPT) (see Table 4.2).  
Patients’ continued use of treatment varied widely across treatment types. Over three 
quarters (79%) of the participants who had ever used compression garments were 
currently using them at the time of the study. Over half of the participants who used 
self-massage (68%), prescribed exercises (64%) and MLD (58%) reported current 
use, while less than half were currently using laser (43%), and around one third were 
currently using CPT and/or bandaging (32% and 30%, respectively). Of note, over a 
quarter of all participants (27%) reported current use of more than four treatment 
types, at the time of the study. Similar proportions reported current use of three 
treatments (20%), two treatments (21%) or a single treatment (22%), and 11% were 
not currently using any treatment. Of those who reported current use of more than 
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four treatments, the majority were using compression garments (93%), self-
administered massage (92%), prescribed exercises (83%) and/or MLD (80%). 
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Table 4.2  
Use of lymphoedema treatments by all study participants 
 
 
 
 
 
 
 
 
 
 
 
 
 Used treatment Among those who used treatment, 
proportion whose description met 
defined criteria 
Among those who used treatment, 
proportion who currently used treatment 
 n (%) n (%) n (%) 
Complex Physical Therapy 176 (41.8) 62 (63.2) 57  (32.4) 
Manual Lymphatic Drainage 285 (67.3) 143 (78.6) 166  (58.0) 
Self-massage 332 (78.9) 173 (79.0) 227 (68.4) 
Laser Therapy 77 (18.3) 29 (90.6) 33 (42.9) 
Pneumatic Pumps 51 (12.1) 11 (73.3) 6 (11.8) 
Compression bandaging 188 (44.7) 81 (78.6) 57  (30.3) 
Compression garment 362 (86.0) 214 (90.3) 284 (78.5) 
Prescribed exercises 291 (69.1) - - 185 (63.6) 
Specific LE exercises - - 153 (77.3) - - 
Whole body exercise - - 17 (8.6) - - 
Surgery 14 (3.3) 5 (50.0) - - 
Othera 38 (9.0) - - - - 
Whole body exercise 11 (2.6) - - - - 
Medication 6 (1.4) - - - - 
CAM 9 (2.1) - - - - 
Massage 2 (0.4) - - - - 
Body flow 5 (1.1) - - - - 
Specific LE exercises 4 (1.0) - - - - 
a Other treatment questions only included in second questionnaire (LAV) and definitions not provided;  LE: lymphoedema, CAM: complementary and alternative 
medicine. 
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4.3  OBJECTIVE TWO – IMPORTANCE OF CHANGE IN LYMPHOEDEMA STATUS 
Describe what level of change in lymphoedema status is perceived as important 
by people with lymphoedema. 
Participants reported improvements in physical symptoms following treatment were 
important in order for them to continue use of a particular treatment. Of the 15 
lymphoedema-associated symptoms, more than 60% of those with swelling, 
heaviness, tightness and reduced range of movement reported improvements in those 
symptoms as very important. Further, 64% of all participants said improved function 
of the affected limb was very important. No less than 40% of participants who had 
each symptom said improvements in that symptom were very important outcomes of 
treatment.  
Table 4.3 
Importance of improvement in lymphoedema symptoms 
Symptom  
na 
Very important 
n (%) 
Important 
n (%) 
Not importantb 
n (%) 
Swelling 418 301 (72.0) 83 (19.9) 37 (8.1) 
Heaviness 375 236 (62.9) 93 (24.8) 92 (12.3) 
Tightness 375 225 (60.0) 97 (25.9) 99 (14.1) 
Aching 323 183 (56.7) 88 (27.2) 150 (16.1) 
Tenderness 286 140 (49.0) 76 (26.6) 205 (24.5) 
Stiffness 261 134 (51.3) 71 (27.2) 216 (21.5) 
Weakness 254 112 (44.1) 67 (26.4) 242 (29.5) 
Numbness 225 101 (44.9) 56 (24.9) 264 (30.2) 
Tinglingc 143 57 (39.9) 43 (30.1) 188 (30.1) 
Pain 275 157 (57.1) 68 (24.7) 196 (18.2) 
Range of movement 328 209 (63.7) 68 (20.7) 144 (15.5) 
Improved visual appearance 421 181 (43.0) 129 (30.6) 111 (26.4) 
Able to wear normal clothing 421 220 (52.3) 123 (29.2) 78 (18.5) 
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Improved function 421 268 (63.7) 102 (24.2) 51 (12.1) 
Improved mobility 421 170 (59.0) 70 (24.3) 48 (16.7) 
anumber of participants with symptom; all participants (n=421) were asked questions related 
to factors below the dotted line. 
bnot important includes those who responded ‘does not bother me’, ‘not applicable’ or 
missing. 
cTingling only included on second questionnaire – total 288 LAV participants 
 
4.4 OBJECTIVE THREE – ACCEPTABILITY OF TREATMENT 
Describe the acceptability of lymphoedema treatment options by people with 
lymphoedema. 
4.4.1 ACCEPTABILITY OF COST, TIME AND DISCOMFORT 
At least half of the participants who used compression garments (57%) or surgery 
(50%) to treat their lymphoedema found the associated financial costs unacceptable 
(see Appendix F for descriptive results). Between 25 and 40% reported the cost of 
MLD, CPT, compression bandaging, and laser therapy as unacceptable (36%, 34%, 
30% and 28%, respectively), while less than 20% found the cost of  PCP (16%), 
prescribed exercises (5%) and self-administered massage (4%) unacceptable.  
One in five participants found the time associated with each treatment session for 
compression bandaging, PCP and CPT, unacceptable (20%, 22% and 27%, 
respectively). Between 10 and 20% reported the time involved in using compression 
garments (17%), prescribed exercises (16%), self-administered massage (16%), MLD 
(12%) and laser therapy (12%) as unacceptable (see Appendix F).  
The duration of the total treatment period was reported as unacceptable by 20 to 25% 
of participants who used compression bandaging, garments, laser therapy, and CPT 
(25%, 22%, 22% and 21%, respectively). Between 7 and 18% of participants who 
used MLD (18%), self-administered massage (14%), prescribed exercises (13%) and 
PCP (7%) found the duration of the prescribed treatment period unacceptable (see 
Appendix F).  
About half of the participants (57%, n=8) who had surgery to treat lymphoedema 
found the discomfort unacceptable (see Appendix F). Around one in three 
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participants who used compression bandaging (36%) and garments (31%) reported 
the discomfort as unacceptable. The discomfort associated with CPT was 
unacceptable to 21% of participants, while less than 10% of those who used PCP, 
prescribed exercises, MLD, self-administered massage or laser therapy reported 
unacceptable discomfort (10%, 7%, 5%, 5% and 5%, respectively).  
 
Figure 4.1 Unacceptability of the cost, time, duration and discomfort associated with 
treatment.  
4.4.2 REASONS FOR CEASING USE OF TREATMENT 
Those who stopped using treatments indicated a number a reasons for doing so (see 
Table 4.4). Reasons are ranked from highest to lowest for each treatment, and the 
reasons (excluding ‘no longer needed’) reported by the highest proportions of 
participants (across different treatments) are shaded in the table. As some participants 
who reported stopping the use of treatment because the treatment was ‘no longer 
needed’ had also provided other reasons for ceasing treatment use, all participants 
remained in the multivariable analyses.  
Between 26-36% stopped using CPT, compression garments, laser therapy, and MLD 
(26%, 27%, 30% and 36%, respectively) because the treatment was ‘too expensive’. 
The effort required for the continued use of prescribed exercises, compression 
garments and bandaging, and self-administered massage was reported as a reason for 
ceasing treatment by 23 to 34% of participants (23%, 23%, 25%, and 34%, 
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respectively). Between 23 to 40% reported self-massage, prescribed exercises, MLD 
and CPT as too time consuming (40%, 31%, 26%, and 23%, respectively).  
At least one in four participants who stopped using prescribed exercises (26%) and 
self-massage (31%) did so because they felt the treatment did not improve symptoms, 
while 21% of participants who no longer used compression garments ceased use due 
to associated side effects.  
Additional Reasons for ceasing treatment use 
Participants’ responses to open-ended questions about their reasons for stopping 
treatment were reviewed and grouped into themes. A number of themes coincided 
with the reasons listed in the questionnaire (e.g., cost, time, effort, ineffective), but 
additional themes included access to treatment, discomfort, inability to perform 
treatment, treatment being a reminder of the condition, treatment not being 
recommended on a long-term basis, and forgetting the treatment.  
Access to treatment was a significant issue for a number of participants who had 
stopped using CPT and/or MLD (see Appendix G for additional examples of 
participants’ reasons for ceasing use). Participants described barriers to accessing 
services (i.e., living in rural areas) and dissatisfaction with treating practitioners who 
they felt were not adequately trained in lymphoedema management (i.e., feeling 
adequate lymphoedema training was unavailable).  
“As a country resident (150km from Melbourne) access is restricted. Local 
hospital physio has been trained but does not have time for CPT.” (response 
to Q.15h, CPT) 
“I have not been able to find another physio offering this service – plenty of 
people who think they know – really shonky, and very worrying!” (response 
to Q.16h, MLD)  
Difficulties accessing treatment were also reported by participants who had stopped 
using laser therapy, PCP, bandaging, and compression garments.  
Discomfort associated with treatment was discussed by a considerable number of 
participants who had stopped using compression bandaging and garments. 
Participants described particular difficulties in hot weather, pain, and ill-fitting 
garments.  
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“Found them very uncomfortable they ride down and then dig in under the 
knee causing pain.” (response to Q.21h, compression garments) 
Reasons associated with discomfort were also described by participants who had 
stopped using prescribed exercises, PCP, and CPT.  
Some participants who were not currently performing self-massage reported being 
unable to do so. Participants described not having another person who could assist 
them, while others felt this was too burdensome on a long-term basis.  
“My husband did complete the 1 month as directed but found it very hard 
and time consuming to continue with the lymphoedema ‘milking’ process of 
my legs. It was very effective though. Trying to do it myself seemed 
ineffective.” (response to Q.17h, self-massage) 
Being reminded of lymphoedema was also discussed as a reason for no longer using 
self-massage to treat symptoms. A number of participants stated they were no longer 
using PCP because long-term use was not recommended by their treating health 
professional.  
“Told not to use outside of complex physical therapy, which I only had for 
10 sessions in 1 month. Would like to have more.” (response to Q.19h, 
pneumatic pumps) 
 
 Chapter 4: Results 106 
Table 4.4 
Proportions of participants who used each treatment, who reported different reasons for ceasing use of each treatment 
CPT 
(n=114/176)* 
MLD 
(n=107/285)* 
Self-massage 
(n=82/332)* 
Laser 
(n=44/77)* 
Pumps 
(n=44/51)* 
Bandaging 
(n=121/188)* 
Garments 
(n=60/362)* 
Exercises 
(n=91/291)* 
Not needed 
38 (33.3) 
Expensive 
39 (36.4) 
Time 
33 (40.2) 
Expensive 
13 (29.5) 
Not needed 
10 (22.7) 
Not needed 
38 (31.4) 
Not needed 
20 (33.3) 
Time  
28 (30.8) 
Expensive 
30 (26.3) 
Time 
28 (26.2) 
Effort  
28 (34.1) 
No improvement 
9 (20.5) 
No improvement 
9 (20.5) 
Time 
29 (24.0) 
Expensive 
16 (26.7) 
 
No improvement 
24 (26.4) 
Time 
21 (18.4) 
Not needed 
27 (25.2) 
No improvement 
25 (30.5) 
Not needed 
7 (15.9) 
Expensive 
5 (11.4) 
Effort 
28 (23.1) 
Effort 
15 (25.0) 
Effort 
21 (23.1) 
Effort 
21 (18.4) 
Effort 
23 (21.5) 
Not needed 
23 (28.0) 
Effort 
4 (9.1) 
Effort 
3 (6.8) 
No improvement 
17 (14.0) 
Side effects 
9/43 (20.9) 
Not needed 
14 (15.4) 
No improvement 
17 (14.9) 
No improvement 
20 (18.7) 
Expensive 
8 (9.8) 
Time 
4 (9.1) 
Time 
3 (6.8) 
Expensive 
16 (13.2) 
Time 
9 (15.0) 
Stopped improving 
7 (7.7) 
Stopped improving 
15 (13.2) 
Stopped improving 
13 (12.1) 
Stopped improving 
8 (9.8) 
Stopped improving 
2 (4.5) 
Stopped improving 
1 (2.3) 
Stopped improving 
13 (10.7) 
No improvement 
9 (15.0) 
Side effects 
2/57 (3.5) 
Side effects 
4/61 (6.6) 
Side effects 
2/73 (2.7) 
Symptoms worse 
4 (4.9) 
Symptoms Worse  
1(2.0) 
Symptoms worse 
0 (0.0) 
Side effects 
5/71 (7.0) 
Stopped improving 
9 (15.0) 
Symptoms worse 
3 (3.3) 
Symptoms worse 
3 (2.6) 
Symptoms worse 
1 (0.9) 
Side effects 
3/62 (4.8) 
Side effects 
0 (0.0) 
Side effects 
0 (0.0) 
Symptoms worse 
5 (4.1) 
Symptoms worse 
8 (13.3) 
Expensive 
2 (2.2) 
CPT: Complex physical therapy; MLD: Manual lymphatic drainage; * Number of participants who stopped using treatment/Total number who had ever used treatment 
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4.4.3 ASSISTANCE WITH TREATMENT 
Almost half of all participants (42%) reported needing assistance from another 
person to complete their prescribed lymphoedema treatment. Of these, one in five did 
not have a support person available to assist them with treatment.  
4.5 OBJECTIVE FOUR – PERCEIVED EFFECTIVENESS OF TREATMENT 
Assess the perceived effectiveness of lymphoedema treatment to treat the 
physical symptoms of lymphoedema.  
4.5.1 IMPROVEMENT IN SYMPTOMS 
At least one in five, and up to 60% of participants (who experienced each symptom) 
perceived their lymphoedema treatment (regardless of treatment type) as effective in 
treating their swelling (26 to 60% across treatment types), heaviness (23 to 50%) , 
tightness (23 to 52%), and aching (20 to 40%) (see Table 4.5). 
4.5.2 EFFECTIVENESS OF LYMPHOEDEMA TREATMENT TYPES 
Proportions of patients who experienced each symptom and who found treatment 
effective for improving their symptoms are presented in Table 4.5 and Table 4.6. In 
Table 4.5, the four symptoms for which the highest proportions of participants 
reported improvements following treatment are shaded. The four treatments 
perceived as effective for improving symptoms by the highest proportions of 
participants are shaded in Table 4.6. At least one in two participants who used 
compression garments, CPT, compression bandaging, and/or surgery to treat their 
lymphoedema, perceived the treatment as effective in reducing swelling (60%, 60%, 
52% and 50%, respectively). Half of those who used CPT also found it effective at 
improving heaviness (50%) and tightness (52%).  
Overall, CPT, compression garments, compression bandaging and MLD were 
perceived as effective at improving a range of lymphoedema symptoms, by 18 to 
60% of participants reporting improvements in any one symptom (see Table 4.6). 
Self-administered massage and prescribed exercises consistently had the lowest 
proportions of participants reporting the treatments as effective at improving 
symptoms.  
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Table 4.5 
Proportions of participants who reported each treatment as effective for treating lymphoedema symptoms 
Garments 
n (%)a 
 
Self-massage 
n (%)a 
Exercises 
n (%)a 
MLD 
n (%)a 
Bandaging 
n (%)a 
CPT 
n (%)a 
Laser therapy 
n (%)a 
Pumps 
n (%)a 
Surgery 
n (%)a 
Swelling Swelling Swelling Swelling Swelling Swelling Tightness Swelling Swelling 
216 (60.0) 86 (26.1) 78 (26.9) 132 (46.2) 98 (52.1) 105 (59.7) 34 (46.6) 22 (43.1) 7 (50.0) 
Heaviness Heaviness RoM Tightness Heaviness Tightness Swelling Stiffness Heaviness 
153 (46.6) 71 (23.4) 58 (24.6) 112 (42.3) 79 (46.7) 86 (51.5) 27 (35.1) 11 (32.4) 5 (38.5) 
Tightness Tightness Tightness Heaviness Tightness Heaviness Heaviness Tightness Tightness 
138 (42.9) 71 (23.2) 65 (24.3) 109 (41.6) 78 (44.6) 83 (50.3) 22 (30.6) 16 (32.0) 5 (35.7) 
Aching  Aching  Heaviness Aching  Aching  Aching  Aching  Heaviness Tingling 
108 (38.7) 53 (20.0) 64 (24.3) 88 (38.4) 51 (32.1) 60 (40.5) 19 (28.8) 15 (30.6) 2 (33.3) 
Tenderness Tenderness Stiffness Stiffness RoM RoM Stiffness RoM RoM 
74 (29.7) 34 (14.6) 43 (22.5) 53 (27.6) 44 (27.3) 53 (35.6) 13 (23.6) 14 (29.8) 4 (30.0) 
Pain Pain Aching  Tenderness Stiffness Stiffness Tenderness Aching  Stiffness 
63 (26.7) 33 (14.3) 50 (21.9) 57 (27.5) 31 (24.8) 41 (33.1) 13 (23.2) 12 (26.1) 3 (30.0) 
RoM RoM Pain RoM Tenderness Tenderness RoM Tenderness Aching  
69 (23.8) 38 (14.1) 33 (16.6) 61 (26.6) 32 (23.2) 41 (31.3) 14 (21.2) 8 (19.0) 3 (27.3) 
Stiffness Numbness Tenderness Pain Pain Tingling Pain Pain Pain 
51 (22.5) 24 (12.6) 30 (15.1) 53 (26.4) 30 (22.9) 17 (30.9) 12 (20.3) 7 (18.4) 2 (20.0) 
Tingling Stiffness Weakness Numbness Tingling Numbness Tingling Numbness Tenderness 
24 (20.2) 25 (11.3) 26 (14.0) 35 (21.6) 12 (21.8) 27 (25.5) 4 (19.0) 6 (18.2) 2 (20.0) 
Weakness Tingling Numbness Tingling Numbness Pain Numbness Weakness Numbness 
44 (19.7) 13 (10.7) 18 (11.0) 20 (19.8) 21 (19.8) 30 (23.3) 6 (13.0) 5 (14.7) 1 (14.3) 
Numbness Weakness Tingling Weakness Weakness Weakness Weakness Tingling Weakness 
36 (18.7) 22 (10.2) 11 (10.4) 34 (18.0) 23 (18.4) 25 (20.7) 5 (9.8) 1 (12.5) 1 (12.5) 
Shading highlights the four symptoms for which the highest proportions of participants reported improvements following treatment; aProportions of patients who used the treatment 
and had the symptom; RoM – Range of movement; MLD – manual lymphatic drainage; CPT – complex physical therapy 
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Table 4.6 
Proportions of participants who reported improvement in lymphoedema symptoms following use of different treatments 
Swelling 
n(%)a 
Heaviness 
n(%)a 
Tightness 
n(%)a 
Aching 
n(%)a 
Tenderness 
n(%)a 
Stiffness 
n(%)a 
Weakness 
n(%)a 
Numbness 
n(%)a 
Tingling 
n(%)a 
Pain 
n(%)a 
RoM 
n(%)a 
CG CPT CPT CPT CPT CPT CPT CPT SURG CG CPT 
216 (60.0) 83 (50.3) 86 (51.5) 60 (40.5) 41 (31.3) 41 (33.1) 25 (20.7) 27 (25.5) 2 (33.3) 63 (26.7) 53 (35.6) 
CPT CB LAS CG CG PCP CG MLD CPT MLD SURG 
105 (59.7) 79 (46.7) 34 (46.6) 108 (38.7) 74 (29.7) 11 (32.4) 44 (19.7) 35 (21.6) 17 (30.9) 53 (26.4) 4 (30.0) 
CB CG CB MLD MLD SURG CB CB CB CPT PCP 
98 (52.1) 153 (46.6) 78 (44.6) 88 (38.4) 57 (27.5) 3 (30.0) 23 (18.4) 21 (19.8) 12 (21.8) 30 (23.3) 14 (29.8) 
SURG MLD CG CB CB MLD MLD CG CG CB CB 
7 (50.0) 109 (41.6) 138 (42.9) 51 (32.1) 32 (23.2) 53 (27.6) 34 (18.0) 36 (18.7) 24 (20.2) 30 (22.9) 44 (27.3) 
MLD SURG MLD LAS LAS CB PCP PCP MLD LAS MLD 
132 (46.2) 5 (38.5) 112 (42.3) 19 (28.8) 13 (23.2) 31 (24.8) 5 (14.7) 6 (18.2) 20 (19.8) 12 (20.3) 61 (26.6) 
PCP LAS SURG SURG SURG LAS PE SURG LAS SURG PE 
22 (43.1) 22 (30.6) 5 (35.7) 3 (27.3) 2 (20.0) 13 (23.6) 26 (14.0) 1 (14.3) 4 (19.0) 2 (20.0) 58 (24.6) 
LAS PCP PCP PCP PCP CG SURG LAS PCP PCP CG 
27 (35.1) 15 (30.6) 16 (32.0) 12 (26.1) 8 (19.0) 51 (22.5) 1 (12.5) 6 (13.0) 1 (12.5) 7 (18.4) 69 (23.8) 
PE PE PE PE PE PE SAM SAM SAM PE LAS 
78 (26.9) 64 (24.3) 65 (24.3) 50 (21.9) 30 (15.1) 43 (22.5) 22 (10.2) 24 (12.6) 13 (10.7) 33 (16.6) 14 (21.2) 
SAM SAM SAM SAM SAM SAM LAS PE PE SAM SAM 
86 (26.1) 71 (23.4) 71 (23.2) 53 (20.0) 34 (14.6) 25 (11.3) 5 (9.8) 18 (11.0) 11 (10.4) 33 (14.3) 38 (14.1) 
Shading highlights the four treatments for which the highest proportions of participants reported improvements in symptoms; aProportions of patients who used the treatment 
and had the symptom; CG – Compression garments; CPT – Complex physical therapy; CB – Compression bandaging; SURG – Surgery; MLD – Manual lymphatic drainage; 
PCP – Pneumatic compression pumps; LAS – Laser therapy; PE – Prescribed exercises; SAM – Self-administered massage 
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4.6 OBJECTIVE FIVE – FACTORS INFLUENCING THE USE, ACCEPTABILITY AND 
EFFECTIVENESS OF LYMPHOEDEMA TREATMENT 
Assess the relationships between personal characteristics, lymphoedema 
characteristics and the use, acceptability and perceived effectiveness of 
lymphoedema treatment strategies. 
Bivariate relationships between factors in the conceptual model described in section 
2.9 were explored one by one to examine the crude relationships between socio-
demographic and condition-related factors and the use, acceptability and 
effectiveness of treatments. As described in section 3.12.5, bivariate results were then 
stratified by lymphoedema location to explore confounding and effect modification 
of the crude relationships. Multivariable regression modelling was then used to 
control for confounding. Six treatments were used by an adequate number of 
participants to enable these analyses. Results are presented for each of these six 
treatment types; compression garments (n=362), self-massage (n=332), prescribed 
exercises (n=291), MLD (n=285), compression bandaging (n=188), and CPT 
(n=176). Where the only significant differences occurred in “other” categories of an 
independent variable, these results were not considered meaningful, and are not 
further discussed.  
Before conducting the multivariable analyses, independent variables were tested for 
collinearity, according to the rationale described in Section 3.11.3. Lymphoedema 
characterisation and lymphoedema duration were moderately correlated (V=0.51), but 
appeared to be measuring different concepts (i.e., symptoms coming and going, 
characterised as recurrent lymphoedema, may have only been short-term but could 
also be long-term), hence both variables were retained for multivariable analyses.  
Relationships between income, education level and employment status were 
associated at the low to moderate level (all correlation coefficients were less than 
0.5). These variables were entered into multivariable models in the thematic block 
described in Section 3.12.5, along with the other personal characteristics variables.  
Effectiveness variables for 11 symptoms were moderately to highly correlated 
(r=0.34 to r=0.90 depending on symptoms). Effectiveness variables were entered one 
at a time into multivariable models of compression garment use (the treatment used 
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by the highest number of participants) to examine whether there were differences in 
the relationships between other independent variables and the outcomes, depending 
on symptom-specific differences. The relationships did not change, so for all further 
multivariable analyses, effectiveness of the treatment for reducing swelling 
(experienced by the highest number of participants) was used as a surrogate measure 
of effectiveness. 
Acceptability variables (cost, time, duration and/or discomfort) were moderately 
correlated (τb=0.51 to τb=0.69), indicating those who found some aspect of treatment 
acceptable/unacceptable also found other aspects of the treatment 
acceptable/unacceptable. However, considering the differences between the cost, 
time and discomfort associated with treatment are clear, it was assumed that although 
these variables were related there was no overlap in the constructs these variables 
were measuring. On the other hand, acceptability of time and duration were 
correlated (τb=0.72) and it was considered that participants may have confused 
treatment session time and the total duration of a treatment period, so these variables 
were not included in the same model. As ‘duration’ was only added to the second 
questionnaire, treatment session time (included in both questionnaires and asked of 
all participants) was used to represent ‘acceptability of time’ in the multivariable 
models.  
Bivariate Results 
The crude associations between independent variables and treatment use are 
presented below, according to treatment type. Only those associations that remained 
clinically and/or statistically significant after controlling for confounding are 
discussed in text.  
The impact of lymphoedema location on bivariate associations 
All bivariate associations were stratified by lymphoedema location to identify 
subgroup differences. Results indicating effect modification are presented in 
Appendix H, and are described below. Treatment use was different across a number 
of independent variable categories when stratified by lymphoedema location, and 
varied between treatment types. Results are documented for those with full 
body/other lymphoedema (see Appendix H), but are not discussed in terms of effect 
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modification due to the very few participants in this category (<20 using any 
treatment type). 
Compression garments 
Significantly less people with ULL in the older age group (70% of participants over 
75 years) were using compression garments than the younger age groups (86%, 65-74 
year; 90%, 55-64 years; 84%, under 55 years). However, this was not the case for 
those with LLL, for whom compression garment use was similar across age groups 
(86-92%). The association between household income and garment use also differed 
between those with ULL and LLL. While a lower proportion of people with ULL in 
the lowest income group (77%) used garments compared with higher income groups 
(91%, 86%, 92%, in order of ascending income groups), there was no association 
between household income and garment use for those with LLL (90%, 96%, 91%, 
91%, respectively).  
Self-massage 
The association between private health insurance and self-massage use differed 
between lymphoedema location subgroups. A higher proportion of those with LLL 
who had private health insurance (79%) used self-massage compared with those who 
did not have any form of private health insurance (59%), while for people with ULL 
the difference was clinically irrelevant (84% versus 77%). 
Manual lymph drainage 
Amongst those with LLL, MLD was used by a lower proportion (41%) of people in 
the older age group (75+years)  compared with younger age groups (60-70%), while 
there were no clinically important differences in use across age groups (80%, 70%, 
75%, 81% in order of increasing age groups) for those with ULL. The association 
between private health insurance and MLD use also differed between these 
subgroups. Within the LLL group, a higher proportion of those with private health 
insurance (65%) used MLD compared with those without insurance (41%), whereas 
similar proportions with ULL used MLD (75% versus 74%) irrespective of insurance 
status. 
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 Compression bandaging 
The association between age and the use of compression bandaging differed between 
those with ULL and LLL. A lower proportion of older participants (75+ years) with 
LLL (40%) used bandaging, compared with younger age groups (56% under 55 years 
and 60% aged 55-64 years), while there were no significant differences in the use of 
bandaging between age groups in the ULL group (44% under 55 years, 39% 55-64 
years, 40% 65-74 years and 46% 75+ years).  
Interaction terms introduced into the multivariable models based on these bivariate 
findings resulted in unstable models with very wide confidence intervals, due to low 
numbers of participants in some categories. As a result, effect modification was only 
examined at the bivariate level in this study.  
Multivariable Results 
4.6.1 USE OF COMPRESSION GARMENTS 
After adjustment for a range of personal and lymphoedema characteristics, 
employment, income, lymphoedema characterisation (single episode/recurrent or 
persistent) and comorbidities were associated with compression garment use (see 
Table 4.7). These variables were also identified as clinically and/or statistically 
significant at the bivariate level.  
Those with persistent lymphoedema had 2.8 times higher odds of using garments 
compared to those with single episode or recurrent lymphoedema (95%CI=1.21-6.37, 
p=0.02). Although not supported statistically, participants who were retired had 
lower odds of using compression garments compared to those employed full time 
(OR=0.48, 95%CI=0.14-1.71), while the odds were higher for those who did full 
time home duties (OR=2.52, 95%CI=0.41-15.42). Relative to participants with 
household income < $20,799, those with income of <$20,800-$36,399 had higher 
odds of using compression garments (OR=2.46, 95%CI= 0.72-8.44, p=0.14). The 
odds of using garments were higher for those suffering from 2 or more than 4 
comorbid conditions (OR=3.03, 95%CI=1.10-8.35 and OR=2.52, 95%CI=0.93-6.82, 
respectively) compared to those with no comorbid conditions.  
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Table 4.7 
Crude and adjusted associations between personal and lymphoedema characteristics and the use of 
compression garments  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Employment    0.13   0.17 
Employed full time 55 1.00 ref  1.00 ref  
Part-time/casual 68 0.75 0.23-2.44  1.06 0.31-3.71  
Full time home duties 45 2.15 0.40-11.65  2.52 0.41-15.42  
Retired 209 0.45 0.17-1.20  0.48 0.14-1.71  
Other 44 0.63 0.18-2.23  0.75 0.18-3.11  
Income    0.07   0.14 
<$20 799 69 1.00 ref  1.00 ref  
$20 800- $36 399 61 3.00 0.91-9.86  2.46 0.72-8.44  
$36 400 - $51 999 55 1.72 0.60-4.92  1.47 0.48-4.50  
>$52 000 86 2.05 0.79-5.35  1.25 0.40-3.93  
Did not respond 150 0.88 0.42-1.85  0.68 0.30-1.52  
Lymphoedema characterised    0.02   0.02 
Single episode/recurrent 41 1.00 ref  1.00 ref  
Persistent/missing 380 2.54 1.19-5.39  2.78 1.21-6.37  
Comorbidities    0.12   0.10 
None 64 1.00 ref  1.00 ref  
1 condition 104 0.99 0.44-2.26  1.14 0.48-2.72  
2 conditions 101 2.41 0.91-6.37  3.03 1.10-8.35  
3 conditions 58 0.80 0.32-1.97  1.28 0.48-3.39  
4 + conditions 94 1.74 0.69-4.39  2.52 0.93-6.82  
*All final models adjusted for age 
 
Current use of treatment 
Multivariable analyses were conducted to explore associations between current use of 
treatment (accepted as an indicator for continued use of treatment) and personal and 
lymphoedema characteristics.  
Over three quarters of those who used compression garments were currently using 
them at the time of completing the questionnaire (79%, n=284). Current use of 
compression garments was not associated with any personal or demographic 
characteristics. However, lymphoedema location, characterisation of lymphoedema, 
and comorbidities, were crudely associated with current garment use (see Table 4.8). 
These associations remained clinically and statistically significant in the adjusted 
model. Those with LLL had higher odds of continued garment use (OR=2.35, 
95%CI=1.32-4.19, p<0.01) compared with those with ULL. The odds of current 
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garment use were 2.5 times higher for those with persistent lymphoedema compared 
with single episode or recurrent lymphoedema (95%CI=1.10-5.59, p=<0.01). The 
odds of continued garment use were lower for those with 1, 2, 3 and 4 or more 
comorbid conditions (OR=0.25, 95%CI=0.08-0.80, OR=0.34, 95%CI=0.11-1.10, 
OR=0.22, 95%CI=0.06-0.76, and OR=0.18, 95%CI=0.05-0.56, respectively), when 
compared with those without any comorbidities (p=0.04).   
Table 4.8 
Crude and adjusted associations between personal and lymphoedema characteristics and current use 
of compression garments  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Lymphoedema location   0.01   <0.01 
Upper limb 182 1.00 ref  1.00 ref  
Lower limb 163 2.31 1.33-3.99  2.35 1.32-4.19  
Full body/Other 17 0.91 0.31-2.71  0.71 0.22-2.35  
Lymphoedema characterised    <0.01   0.03 
Single episode/recurrent 30 1.00 ref  1.00 ref  
Persistent/missing 332 3.14 1.45-6.79  2.48 1.10-5.59  
Comorbidities    0.06   0.04 
None 53 1.00 ref  1.00 ref  
1 condition 86 0.29 0.09-0.90  0.25 0.08-0.80  
2 conditions 93 0.34 0.11-1.07  0.34 0.11-1.10  
3 conditions 46 0.21 0.06-0.69  0.22 0.06-0.76  
4 + conditions 84 0.20 0.67-0.63  0.18 0.05-0.56  
*All final models adjusted for age 
 
Impact of acceptability and effectiveness on the current use of compression garments 
The associations between perceived effectiveness, acceptability and continued use of 
treatment were explored using logistic regression. The personal and lymphoedema 
characteristics retained in the final model described above (for each treatment type) 
were entered into the next series of models incorporating effectiveness and 
acceptability variables. Separate models were run for each symptom to ensure 
absence of multicollinearity. For the majority of treatments and symptoms, results 
were consistent, and odds ratios presented and discussed in this chapter are taken 
from the models including the ‘improved swelling’ variable, to include maximum 
available data (i.e., swelling experienced by greatest number of participants). Final 
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models included adjustment for all personal or lymphoedema characteristics that 
were related to continued use of treatment (clinically or statistically significant).  
Characterisation of lymphoedema and presence of comorbidities remained significant 
in the final model of current compression garment use (see Table 4.9). The 
acceptability of discomfort was associated with current treatment use, with those 
stating the discomfort when wearing garments was acceptable having higher odds of 
current treatment use (OR=3.13, 95% CI=1.54-6.36, p=<0.01) compared with those 
who reported the discomfort as unacceptable. Similarly, participants who found the 
time associated with garment use acceptable had 5.2 times the odds of current 
garment use than those who reported the time as unacceptable (95%CI=2.36-11.63, 
p<0.01). Those who reported that the use of compression garments improved their 
swelling had greater odds of reporting current garment use (OR=2.22, 95%CI=1.30-
3.80).  
Table 4.9 
Crude and adjusted associations between personal and lymphoedema characteristics, acceptability, 
effectiveness and use of compression garments  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Lymphoedema location    0.01   0.11 
Upper limb 182 1.00 ref  1.00 ref  
Lower limb 163 2.31 1.33-3.99  2.01 1.00-4.05  
Full body/Other 17 0.91 0.31-2.71  0.80 0.20-3.14  
Lymphoedema characterised  <0.01   <0.01 
Single ep/recurrent 30 1.00 ref  1.00 ref  
Persistent/missing 332 3.14 1.45-6.79  4.31 1.62-11.46  
Comorbidities    0.06   0.10 
None 53 1.00 ref  1.00 Ref  
1 condition 86 0.29 0.09-0.90  0.21 0.05-0.84  
2 conditions 93 0.34 0.11-1.07  0.36 0.09-1.42  
3 conditions 46 0.21 0.06-0.69  0.30 0.07-1.39  
4 + conditions 84 0.20 0.67-0.63  0.17 0.04-0.69  
Acceptability of Time#    <0.01   <0.01 
Unacceptable 59 1.00 ref  1.00 Ref  
Neutral 74 2.00 0.93-4.32  1.77 0.78-4.00  
Acceptable 177 4.60 2.25-9.39  5.24 2.36-11.63  
Acceptability of Discomfort#  <0.01   <0.01 
Unacceptable 106 1.00   1.00 ref  
Neutral 53 1.35 0.63-2.91  1.03 0.45-2.37  
Acceptable 166 3.05 1.61-5.78  3.13 1.54-6.36  
Improved swelling    <0.01   <0.01 
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Not effective 144 1.00 ref  1.00 Ref  
Effective 216 2.36 1.42-3.92  2.22 1.30-3.80  
*All final models adjusted for age 
#Separate models were run for each acceptability variable. Adjusted data presented for all 
other variables is from the final model explaining the most variance. 
 
4.6.2 USE OF SELF-ADMINISTERED MASSAGE 
After adjustment for a range of personal and lymphoedema characteristics, age, 
employment, private health insurance, lymphoedema type, lymphoedema location 
and comorbidities were associated with use of self-administered massage (see Table 
4.10). Age was inversely associated with massage use, with the odds of using 
massage decreasing 0.95 for each year of age (95%CI=0.92-0.98, p=<0.01). Although 
not statistically supported, the odds of using massage were increased for those 
working part-time (OR=2.25, 95%CI=0.82-6.13) or classified as full-time home 
duties (OR=4.59, 95%CI=1.28-16.50), when compared with participants who were 
employed full time (p=0.19). Participants with private health insurance had 1.8 times 
the odds of using massage compared with those without private (95%CI=1.00-3.14, 
p=0.05).  
Participants with secondary lymphoedema had higher odds (OR=2.8, 95%CI=1.44-
5.41) of using massage compared with primary lymphoedema (p<0.01). Similarly, 
participants with 4 or more comorbid conditions had greater odds of using massage 
compared to those with no comorbid conditions (OR=3.00, 95%CI=1.24-7.25, 
p=0.03). Although not statistically supported, compared to those with ULL, 
participants with full body/other lymphoedema had greater odds (OR=2.37, 
95%CI=0.56-9.94) of using massage to treat their lymphoedema.  
Table 4.10 
Crude and adjusted associations between personal and lymphoedema characteristics and use of self-
administered massage  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Age (continuous) 421 0.96 0.94-0.99 <0.01 0.95 0.92-0.98 <0.01 
Employment    0.17   0.19 
Employed full time 55 1.00 ref  1.00   
Part-time/casual 68 1.62 0.64-4.09  2.25 0.82-6.13  
Home duties 45 2.23 0.72-6.90  4.59 1.28-16.50  
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Retired 209 0.82 0.40-1.67  1.91 0.74-4.94  
Other 44 1.09 0.41-2.87  1.81 0.60-5.44  
Private Health Insurance    0.01   0.05 
No 96 1.00 ref  1.00 ref  
Yes 325 2.05 1.22-3.43  1.77 1.00-3.14  
Lymphoedema type    <0.01   <0.01 
Primary 92 1.00 ref  1.00 ref  
Secondary 329 2.38 1.42-3.98  2.80 1.44-5.41  
Lymphoedema location    0.05   0.29 
 Upper limb 216 1.00 ref  1.00 ref  
Lower limb 184 0.57 0.35-0.92  0.84 0.46-1.51  
Full body/Other 21 1.24 0.35-4.43  2.37 0.56-9.94  
Comorbidities    0.14   0.03 
None 64 1.00 ref  1.00 ref  
1 condition 104 1.49 0.70-3.17  1.97 0.87-4.46  
2 conditions 101 1.44 0.68-3.06  1.96 0.87-4.44  
3 conditions 58 0.68 0.31-1.50  0.90 0.38-2.12  
4 + conditions 94 1.63 0.74-3.55  3.00 1.24-7.25  
*All final models adjusted for age 
 
Current use of treatment 
Of those who used self-administered massage (SAM), 68% (n=227) were currently 
using massage when they participated in the study. After adjustment for all 
characteristics, employment was the only variable with a clinically meaningful 
relationship with continued use (see Table 4.11). Participants who reported their 
employment status as full time home duties or retired had lower odds of current 
massage use than those who were employed full-time (OR=0.42, 95%CI=0.15-1.17 
and OR=0.49, 95%CI=0.20-1.23, respectively), but these findings were not 
statistically supported (p=0.43). There were no other clinically relevant or statistically 
significant relationships between current use of SAM and personal or lymphoedema 
characteristics. 
Table 4.11 
Crude and adjusted associations between personal and lymphoedema characteristics and current use 
of self-administered massage  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Employment    0.41   0.43 
Employed full time 43 1.00 ref  1.00 ref  
Part-time/casual 58 0.70 0.27-1.77  0.68 0.26-1.74  
Home duties 40 0.44 0.17-1.17  0.42 0.15-1.17  
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Retired 156 0.53 0.24-1.19  0.49 0.20-1.23  
Other 35 0.45 0.16-1.22  0.44 0.16-1.21  
*All final models adjusted for age 
 
Impact of acceptability and effectiveness on the use of self-administered massage 
The association between employment and current use of self-administered massage 
remained clinically significant in the final model, for those doing full time home 
duties compared with those employed full time (see Table 4.12). The acceptability of 
the time required to conduct self-administered massage was associated with current 
use, with those stating the time involved in self-administering massage was 
acceptable or neutral having greater odds of current use compared to those who found 
the time involved unacceptable (OR=2.66, 95%CI=1.34-5.27 and OR=2.47, 
95%CI=1.00-6.11, respectively). Participants who reported massage as effective in 
improving their swelling had 2.4 times the odds of current use compared to those 
who did not find the treatment helped (95%CI=1.15-5.10, p=0.02).  
Table 4.12 
Crude and adjusted associations between personal and lymphoedema characteristics, acceptability, 
effectiveness and use of self-administered massage  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Employment    0.41   0.49 
Employed full time 43 1.00 ref  1.00 ref  
Part-time/casual 58 0.70 0.27-1.77  0.73 0.27-2.02  
Home duties 40 0.44 0.17-1.17  0.49 0.15-1.62  
Retired 156 0.53 0.24-1.19  0.61 0.22-1.69  
Other 35 0.45 0.16-1.22  0.38 0.13-1.15  
Acceptability of Time    <0.01   0.02 
Unacceptable 56 1.00 ref  1.00 ref  
Neutral 46 2.13 0.91-4.95  2.47 1.00-6.11  
Acceptable 173 3.00 1.55-5.64  2.66 1.34-5.27  
Improved swelling    <0.01   0.02 
Not effective 244 1.00 ref  1.00 ref  
Effective 86 3.34 1.75-6.36  2.42 1.15-5.10  
*All final models adjusted for age 
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4.6.3 USE OF PRESCRIBED EXERCISES 
The use of prescribed exercises was crudely associated with gender, private health 
insurance, education level, employment, lymphoedema type, location, duration, and 
diagnosing health professional. After adjustment for all personal and lymphoedema 
characteristics, gender, employment status and lymphoedema location had significant 
associations with the use of prescribed exercises (see Table 4.13). Although not 
statistically significant, the odds of using exercises amongst men were half those for 
female participants (OR=0.49, 95%CI=0.20-1.22). Those who did full-time home 
duties had greater odds of using exercises to treat lymphoedema than those who were 
employed full-time (OR=2.9, 95%CI=1.04-8.07), but again, these results were not 
statistically supported.  
In the final model, the association between lymphoedema location and the use of 
prescribed exercises was statistically and clinically significant, with participants with 
LLL having half the odds (OR=0.51, 95%CI=0.33-0.79) of using exercises, when 
compared to those with ULL (p=<0.01). 
Table 4.13 
Crude and adjusted associations between personal and lymphoedema characteristics and use of 
prescribed exercises  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Gender    0.02   0.13 
Female 399 1.00 ref  1.00 ref  
Male 22 0.35 0.15-0.83  0.49 0.20-1.22  
Employment    0.11   0.15 
Employed full time 55 1.00 ref  1.00 ref  
Part-time/casual 68 2.01 0.92-4.38  1.89 0.84-4.28  
Home duties 45 2.86 1.12-7.30  2.90 1.04-8.07  
Retired 209 1.25 0.68-2.32  1.33 0.61-2.87  
Other 44 1.08 0.48-2.46  1.01 0.42-2.42  
Lymphoedema location    <0.01   <0.01 
Upper limb 216 1.00 ref  1.00 ref  
Lower limb 184 0.47 0.31-0.72  0.51 0.33-0.79  
Full body/Other 21 1.35 0.43-4.18  1.57 0.49-4.99  
*All final models adjusted for age 
 
Current use of treatment 
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In the final model adjusting for personal and lymphoedema characteristics, income 
and comorbidites were associated with the current use of prescribed exercises (see 
Table 4.14). The association between income and use of exercises was not 
statistically significant, but the odds of current use were higher for participants with 
household income over $52,000 when compared with participants with income 
below $20,799 (OR=2.15, 95%CI=0.91-5.10). Participants with 4 or more comorbid 
conditions had half the odds (OR=0.54) of those with no other medical conditions 
(95%CI=0.24-1.25, p=0.03).  
Table 4.14 
Crude and adjusted associations between personal and lymphoedema characteristics and current use 
of prescribed exercises  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Income    0.09   0.24 
<$20 799 51 1.00 ref  1.00 ref  
$20 800- $36 399 48 1.73 0.78-3.87  1.67 0.73-3.82  
$36 400 - $51 
 
32 1.34 0.55-3.25  1.30 0.51-3.30  
>$52 000 63 2.60 1.20-5.64  2.15 0.91-5.10  
Did not respond 97 2.32 1.16-4.67  2.19 1.06-4.52  
Comorbidities    0.01   0.03 
None 42 1.00 ref  1.00 ref  
1 condition 74 1.16 0.52-2.57  1.18 0.52-2.67  
2 conditions 77 1.48 0.66-3.32  1.68 0.74-3.84  
3 conditions 33 1.28 0.48-3.39  1.50 0.54-4.13  
4 + conditions 65 0.45 0.20-0.99  0.54 0.24-1.25  
*All final models adjusted for age 
 
Impact of acceptability and effectiveness on the use of prescribed exercises 
Income remained clinically significant in the final model (see Table 4.15), after 
adjustment for personal and lymphoedema characteristics, acceptability variables and 
effectiveness. Acceptability of discomfort was associated with current use of 
exercises, with those reporting the discomfort as neutral or acceptable having higher 
odds of current use than those who found the discomfort unacceptable (OR=2.37, 
95%CI=0.80-6.98 and OR=2.23, 95%CI=0.82-6.06). However, these findings were 
not statistically supported. Participants who found exercises effective in improving 
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swelling had 3 times the odds of continuing to use exercises compared with those 
who did not find the treatment effective (OR=3.46, 95%CI=1.67-7.21, p=<0.01).  
Table 4.15 
Crude and adjusted associations between personal and lymphoedema characteristics, acceptability, 
effectiveness and use of prescribed exercises  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Income    0.09   0.05 
<$20 799 51 1.00 ref  1.00 ref  
$20 800- $36 399 48 1.73 0.78-3.87  2.15 0.85-5.46  
$36 400 - $51 999 32 1.34 0.55-3.25  1.32 0.47-3.68  
>$52 000 63 2.60 1.20-5.64  2.83 1.11-7.24  
Did not respond 97 2.32 1.16-4.67  3.36 1.42-7.95  
Acceptability of Discomfort  0.08   0.26 
Unacceptable 20 1.00 ref  1.00 ref  
Neutral 64 2.69 0.96-7.51  2.37 0.80-6.98  
Acceptable 166 2.92 1.14-7.49  2.23 0.82-6.06  
Improved swelling    <0.01   <0.01 
Not effective 212 1.00 ref  1.00 ref  
Effective 78 4.38 2.24-8.58  3.46 1.67-7.21  
*All final models adjusted for age 
 
4.6.4 USE OF MANUAL LYMPHATIC DRAINAGE 
At the bivariate level, the use of MLD was associated with age, private health 
insurance, education level, employment, income, lymphoedema type, whether 
lymphoedema followed cancer, lymphoedema location and duration. After 
adjustment for personal and lymphoedema characteristics, the associations between 
use of MLD and employment, lymphoedema location and comorbidities, remained 
significant (see Table 4.16).  
Participants with LLL had lower odds of using MLD compared to those with ULL 
(OR=0.42, 95%CI=0.27-0.65, p<0.05). Although not statistically supported, 
participants who worked part-time, did home duties or were retired had lower odds of 
using MLD (OR=0.44, 95%CI=0.18-1.07, OR=0.40, 95%CI=0.16-0.98 and 
OR=0.40, 95%CI=0.16-0.98, respectively) than those who were employed full-time 
(p=0.37). The odds of MLD use were lower for those with 3 comorbid conditions 
than those with no comorbidites (OR=0.48, 95%CI=0.21-1.07), however this finding 
was not statistically supported (p=0.14). 
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Table 4.16 
Crude and adjusted associations between personal and lymphoedema characteristics and use of 
manual lymphatic drainage  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Employment    0.20   0.37 
Employed full time 55 1.00 ref  1.00 ref  
Part-time/casual 68 0.47 0.20-1.09  0.44 0.18-1.07  
Home duties 45 0.40 0.16-1.01  0.40 0.15-1.10  
Retired 209 0.41 0.19-0.85  0.40 0.16-0.98  
Other 44 0.53 0.21-1.36  0.54 0.20-1.47  
Lymphoedema location   <0.01   <0.01 
Upper limb 216 1.00 ref  1.00 ref  
Lower limb 184 0.46 0.30-0.71  0.42 0.27-0.65  
Full body/Other 21 1.42 0.46-4.39  0.99 0.31-3.23  
Comorbidities    0.15   0.14 
None 64 1.00 ref  1.00 ref  
1 condition 104 0.58 0.29-1.16  0.64 0.31-1.32  
2 conditions 101 0.87 0.43-1.78  0.92 0.44-1.95  
3 conditions 58 0.44 0.20-0.95  0.48 0.21-1.07  
4 + conditions 94 0.79 0.38-1.61  1.07 0.49-2.31  
*All final models adjusted for age 
 
Current use of treatment 
Over half of the participants who had ever used MLD were currently using MLD at 
the time of the study (58%, n=166). In the final model of current MLD use, the 
continued use of MLD was associated with comorbidities only. Participants with one 
condition (in addition to lymphoedema) had greater odds (OR=2.69, 95%CI=1.23-
5.85) of current MLD use than those with no comorbid conditions. The odds of 
current MLD use for those with more than 2 comorbid conditions compared to those 
with no comorbidities were not clinically meaningful (see Table 4.17).  
Table 4.17 
Crude and adjusted associations between personal and lymphoedema characteristics and current use 
of manual lymphatic drainage  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Comorbidities    0.06   0.06 
None 48 1.00 ref  1.00 ref  
1 condition 66 2.69 1.23-5.85  2.69 1.23-5.85  
2 conditions 73 1.65 0.79-3.44  1.64 0.79-3.44  
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3 conditions 33 0.91 0.37-2.20  0.90 0.37-2.20  
4 + conditions 66 1.39 0.66-2.93  1.38 0.65-2.93  
*All final models adjusted for age 
 
Impact of acceptability and effectiveness on the use of manual lymphatic drainage 
The current use of MLD was associated with the acceptability of the time involved in 
treatment sessions, and the effectiveness of MLD for improving swelling. The odds 
of current use of MLD were greater for those who found the treatment session time 
acceptable or neutral (OR=4.22, 95%CI=1.83-9.71 and OR=3.72), compared with 
those who did not. Participants who reported MLD as effective in improving swelling 
had twice the odds of current MLD use (OR=1.97, 95%CI=1.14-3.39, p=0.02) than 
those who found the treatment did not help their swelling (see Table 4.18).  
Table 4.18 
Crude and adjusted associations between personal and lymphoedema characteristics, acceptability, 
effectiveness and use of manual lymphatic drainage  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Comorbidities    0.06   0.06 
None 48 1.00 ref  1.00 ref  
1 condition 66 2.69 1.23-5.85  2.64 1.09-6.40  
2 conditions 73 1.65 0.79-3.44  1.64 0.71-3.80  
3 conditions 33 0.91 0.37-2.20  0.73 0.27-1.97  
4 + conditions 66 1.39 0.66-2.93  1.22 0.52-2.89  
Acceptability of Time   <0.01   <0.01 
Unacceptable 35 1.00 ref  1.00 ref  
Neutral 42 3.33 1.28-8.66  3.72 1.37-10.09  
Acceptable 178 4.56 2.06-10.11  4.22 1.83-9.71  
Improved swelling    <0.01   0.02 
Not effective 154 1.00 ref  1.00 ref  
Effective 132 2.34 1.44-3.80  1.97 1.14-3.39  
*All final models adjusted for age 
 
4.6.5 USE OF COMPRESSION BANDAGING 
In the final model, the use of bandaging was associated with employment and 
lymphoedema characterisation (see Table 4.19). The odds of using bandaging were 
higher for those employed full-time compared to those employed part-time (OR), and 
retired (=0.62, 95%CI=0.30-1.30 and OR=0.56, 95%CI=0.27-1.16, respectively, 
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p=0.02). Participants with persistent lymphoedema had 2.7 times the odds of using 
compression compared to those with single episode and recurrent lymphoedema 
(95%CI=1.23-5.67, p=0.01).  
Table 4.19 
Crude and adjusted associations between personal and lymphoedema characteristics and use of 
compression bandaging (crude and adjusted results) 
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Age (continuous) 421 0.99 0.97-1.01 0.17 1.00 0.98-1.02 0.89 
Employment    0.01   0.02 
Employed full time 55 1.00 ref  1.00 ref  
Part-time/casual 68 0.55 0.27-1.13  0.62 0.30-1.30  
Home duties 45 0.87 0.40-1.92  0.91 0.39-2.14  
Retired 209 0.51 0.28-0.92  0.56 0.27-1.16  
Other 44 1.61 0.71-3.65  1.81 0.77-4.26  
Lymphoedema characterised   0.01   0.01 
Single episode/recurrent 41 1.00 ref  1.00 ref  
Persistent/missing 380 2.73 1.30-5.73  2.65 1.23-5.67  
*All final models adjusted for age 
 
Current use of treatment 
One third of participants who had used bandages were currently using the treatment 
at the time of completing the questionnaire (30%, n=57). The current use of 
bandaging was associated with gender and lymphoedema location. Men had 4.2 times 
the odds of current bandage use compared to females (95%CI= 1.19-14.85, p=0.02). 
The odds of bandage use were lower for those with full-body/other lymphoedema 
compared to those with ULL (OR=0.28, 95%CI=0.03-2.44). However, this finding 
was not statistically supported (see Table 4.20).  
Table 4.20 
Crude and adjusted associations between personal and lymphoedema characteristics and current use 
of compression bandaging  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Age (continuous) 188 1.00 0.98-1.04 0.47 1.02 0.99-1.04 0.27 
Gender    0.02   0.03 
Female 175 1.00 ref  1.00 ref  
Male 13 4.11 1.28-13.19  4.20 1.19-14.85  
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Lymphoedema location   0.11   0.22 
Upper limb 89 1.00 ref  1.00 ref  
Lower limb 89 1.69 0.89-3.21  1.44 0.73-2.82  
Full body/Other 10 0.32 0.04-2.66  0.28 0.03-2.44  
*All final models adjusted for age 
 
Impact of acceptability and effectiveness on the use of compression bandaging 
The acceptability of the time and discomfort associated with compression bandaging 
were related to current use of bandaging (see Table 4.21). Participants who found the 
time involved with bandaging acceptable or neutral had higher odds of current 
bandage use than those who found the time unacceptable (OR=7.17, 95%CI=2.45-
20.98 and OR=5.04, 95%CI=1.45-17.56, respectively). Similarly, participants who 
found the associated discomfort acceptable or neutral had significantly greater odds 
of current use of bandaging than those who found the discomfort unacceptable 
(OR=6.56, 95%CI=2.55-17.00 and OR=3.39, 95%CI=1.10-10.45, respectively). The 
relationship between current use of bandaging and perceived effectiveness for 
treating swelling was not statistically or clinically meaningful.  
Table 4.21 
Crude and adjusted associations between personal and lymphoedema characteristics, acceptability, 
effectiveness and use of compression bandaging  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Gender    0.02   0.06 
Female 175 1.00 ref  1.00 ref  
Male 13 4.11 1.28-13.19  3.65 0.96-13.82  
Lymphoedema location    0.11   0.34 
Upper limb 89 1.00 ref  1.00 ref  
Lower limb 89 1.69 0.89-3.21  1.16 0.53-2.57  
Full body/Other 10 0.32 0.04-2.66  0.22 0.02-2.18  
Acceptability of Time*    0.00   <0.01 
Unacceptable 51 1.00 ref  1.00 ref  
Neutral 34 3.59 1.18-10.93  5.04 1.45-17.56  
Acceptable 70 5.63 2.12-14.91  7.17 2.45-20.98  
Acceptability of Discomfort    <0.01   <0.01 
Unacceptable 67 1.00 ref  1.00 ref  
Neutral 30 2.76 0.97-7.89  3.39 1.10-10.45  
Acceptable 64 5.69 2.41-13.40  6.56 2.55-17.00  
*All final models adjusted for age 
**Acceptability of time from separate model 
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4.6.6 USE OF COMPLEX PHYSICAL THERAPY 
After adjustment for personal and lymphoedema characteristics, the use of CPT was 
associated with employment, income, and lymphoedema characterisation (see Table 
4.22). Participants with persistent lymphoedema had 2.3 times the odds of using CPT 
compared with those with single episode/recurrent lymphoedema (95%CI=1.10-4.95, 
p=0.03).  Although the odds of using CPT were lower for participants who were 
doing full-time home duties (OR=0.52, 95%CI=0.22-1.26) or retired (OR=0.39, 
95%CI=0.18-0.86) compared to those employed full-time, and lower for participants 
with household income over $20,800 compared to those with household income less 
than $20,799 (OR=0.42, 95%CI=0.20-0.87), these findings were not statistically 
supported.  
Table 4.22 
Crude and adjusted associations between personal and lymphoedema characteristics and use of 
complex physical therapy  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Employment    0.22   0.22 
Employed full time 55 1.00 ref  1.00 ref  
Part-time/casual 68 0.55 0.27-1.13  0.59 0.28-1.24  
Home duties 45 0.61 0.28-1.35  0.52 0.22-1.26  
Retired 209 0.51 0.28-0.92  0.39 0.18-0.86  
Other 44 0.76 0.34-1.69  0.60 0.25-1.47  
Income    0.11   0.08 
<$20 799 69 1.00 ref  1.00 ref  
$20 800- $36 399 61 0.45 0.22-0.92  0.42 0.20-0.87  
$36 400 - $51 999 55 0.62 0.30-1.27  0.58 0.27-1.23  
>$52 000 86 0.75 0.40-1.42  0.55 0.26-1.18  
Did not respond 150 0.50 0.28-0.89  0.43 0.23-0.79  
Lymphoedema characterised  0.04   0.03 
Single episode/recurrent 41 1.00 ref  1.00 ref  
Persistent/missing 380 2.10 1.02-4.30  2.33 1.10-4.95  
*All final models adjusted for age 
 
Current use of treatment 
Of those who had ever used CPT, 32% reported current use of CPT (n=57). The 
current use of CPT was associated with age, gender, employment, income, 
lymphoedema location and comorbidities (see Table 4.23). The odds of using CPT 
increased with age (OR=1.05, 95%CI=1.00-1.11, p=0.04). A number of other 
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variables were considered clinically important. Male participants had lower odds of 
current CPT use compared to females (OR=0.42, 95%CI=0.04-4.77), as did those 
who were employed part-time, did full-time home duties or were retired, compared to 
participants who were employed full-time (OR=0.45, 95%CI=0.11-1.77, OR=0.31, 
95%CI=0.06-1.55 and OR=0.24, 95%CI=0.06-1.00, respectively). However, these 
results were not statistically significant. Participants who had a household income 
between $36,400 and $51,999 had higher odds than those with income less than $20 
799 (OR=2.69, 95%CI=0.69-10.51), but the odds in other income groups were not 
clinically meaningful.  
Participants with LLL and lymphoedema of the full body or other area had lower 
odds of current CPT use than those with ULL (OR=0.40, 95%CI=0.17-0.91 and 
OR=0.45, 95%CI=0.07-2.82). The odds of current CPT use were greater for those 
with 1, 2, 3 or more than 4 comorbid conditions (OR=4.04, 95%CI=0.89-18.42, 
OR=7.23, 95%CI=1.64-31.99, OR=5.09, 95%CI=0.96-26.92 and OR=5.86, 
95%CI=1.23-27.79, respectively) than for those with no comorbidities. However, 
these associations were not statistically supported. 
Table 4.23 
Crude and adjusted associations between personal and lymphoedema characteristics and current use 
of complex physical therapy  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Age (continuous) 176 1.00 1.01-1.08 0.01 1.05 1.00-1.11 0.04 
Gender    0.32   0.48 
Female 169 1.00 ref  1.00 ref  
Male 7 0.34 0.04-2.86  0.42 0.04-4.77  
Employment    0.17   0.09 
Employed full time 30 1.00 ref  1.00 ref  
Part-time/casual 27 1.17 0.38-3.57  0.45 0.11-1.77  
Home duties 19 1.70 0.51-5.63  0.31 0.06-1.55  
Retired 79 1.43 0.58-3.53  0.24 0.06-1.00  
Other 21 0.12 0.01-1.01  0.04 0.00-0.42  
Income    0.07   0.06 
<$20 799 37 1.00 ref  1.00 ref  
$20 800- $36 399 21 1.24 0.37-4.17  1.02 0.26-3.94  
$36 400 - $51 999 23 2.00 0.65-6.16  2.69 0.69-10.51  
>$52 000 40 0.78 0.26-2.29  0.65 0.15-2.80  
Did not respond 55 2.59 1.03-6.50  2.71 0.90-8.18  
Lymphoedema location  0.06   0.08 
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Upper limb 95 1.00 ref  1.00 ref  
Lower limb 70 0.48 0.24-0.95  0.40 0.17-0.91  
Full body/Other 11 0.33 0.07-1.63  0.45 0.07-2.82  
Comorbidities    0.11   0.13 
None 29 1.00 ref  1.00 ref  
1 condition 37 4.16 1.05-16.52  4.04 0.89-18.42  
2 conditions 45 6.33 1.67-24.03  7.23 1.64-31.99  
3 conditions 23 4.62 1.06-20.13  5.09 0.96-26.92  
4 + conditions 42 4.81 1.25-18.60  5.86 1.23-27.79  
*All final models adjusted for age 
 
Impact of acceptability and effectiveness on the use of complex physical therapy 
In the final model incorporating acceptability and effectiveness variables, gender, 
employment, income and comorbidities remained clinically important, and the 
association between lymphoedema location and current use of CPT was both 
statistically and clinically significant (see Table 4.24). Acceptability of discomfort 
and time were also found to be associated with current CPT use. Those who found 
the discomfort acceptable or neutral had 4 times the odds of continued use compared 
with those who found the associated discomfort unacceptable (OR=4.13, 
95%CI=1.18-14.42 and OR=3.93, 95%CI=0.86-17.90, respectively). Similarly, 
participants reporting the time associated with CPT use as acceptable or neutral had 
higher odds of continued use (OR=3.47, 95%CI=1.07-11.20 and OR=2.18, 
95%CI=0.49-9.62, respectively). Effectiveness of CPT for improving swelling was 
not associated with continued CPT use.  
Table 4.24 
Crude and adjusted associations between personal and lymphoedema characteristics, acceptability, 
effectiveness and use of complex physical therapy  
Characteristics  Crude Adjusted* 
 n OR 95%CI p OR 95%CI p 
Age (continuous) 176 1.05 1.01-1.08 0.01 1.05 1.00-1.11 0.07 
Gender    0.32   0.58 
Female 169 1.00 ref  1.00 ref  
Male 7 0.34 0.04-2.86  0.47 0.03-6.74  
Employment    0.17   0.50 
Employed full time 30 1.00 ref  1.00 ref  
Part-time/casual 27 1.17 0.38-3.57  0.58   
Full time home duties 19 1.70 0.51-5.63  0.31   
Retired 79 1.43 0.58-3.53  0.25   
Other 21 0.12 0.01-1.01  -   
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Income    0.07   0.32 
<$20 799 37 1.00 ref  1.00 ref  
$20 800- $36 399 21 1.24 0.37-4.17  0.81 0.19-3.46  
$36 400 - $51 999 23 2.00 0.65-6.16  1.42 0.32-6.18  
>$52 000 40 0.78 0.26-2.29  0.45 0.89-2.35  
Did not respond 55 2.59 1.03-6.50  1.67 0.49-5.69  
Lymphoedema location  0.06  0.04    
Upper limb 95 1.00 ref  1.00 ref  
Lower limb 70 0.48 0.24-0.95  0.34 0.14-0.81  
Full body/Other 11 0.33 0.07-1.63  0.23 0.02-2.64  
Comorbidities    0.11   0.19 
None 29 1.00 ref  1.00 ref  
1 condition 37 4.16 1.05-16.52  4.92 1.00-24.18  
2 conditions 45 6.33 1.67-24.03  5.30 1.11-25.37  
3 conditions 23 4.62 1.06-20.13  2.71 0.44-16.84  
4 + conditions 42 4.81 1.25-18.60  6.54 1.25-34.22  
Acceptability of Discomfort   0.01   0.08 
Unacceptable 38 1.00 ref  1.00 ref  
Neutral 28 4.03 1.09-14.84  3.93 0.86-17.90  
Acceptable 95 5.67 1.86-17.27  4.13 1.18-14.42  
Acceptability of Time**   0.03   0.11 
Unacceptable 35 1.00 ref  1.00 ref  
Neutral 23 2.12 0.56-7.99  2.18 0.49-9.62  
Acceptable 99 3.74 1.34-10.47  3.47 1.07-11.20  
*All final models adjusted for age 
**Acceptability of Time from separate model 
 
4.6.7 FACTORS INFLUENCING CONTINUED USE OF TREATMENT 
To summarise the associations between independent variables and continued use of 
treatrment across the different treatment types, clinicially and statistically significant 
results are presented in Table 4.25. Overall, few personal and lymphoedema 
characteristics were associated with continued treatment use (see Table 4.25). 
Patient-related factors, including acceptability of the time, cost and discomfort 
involved, and perceived effectiveness, were associated with continued use of all six 
treatments, but the specific factors most strongly associated differed for each 
treatment.  
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Table 4.25 
Summary of statistically and clinically significant associations between personal characteristics, lymphoedema characteristics, acceptability and effectiveness of treatment in 
final models for each treatment 
Variable Compression 
garments 
Self-administered 
massage 
Prescribed 
exercises 
Manual lymphatic 
drainage 
Compression 
bandaging 
Complex Physical 
therapy 
Age       
Gender       
Employment       
Income       
Lymphoedema location       
Lymphoedema characterised       
Comorbidities       
Acceptability of time       
Acceptability of cost       
Acceptability of discomfort       
Improved swelling       
Light shading indicates results from final model were clinically significant (OR<0.5 or >2.0); Dark shading indicates results from final model were clinically 
and statistically significant (p<0.05) 
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Chapter 5: Discussion 
Lymphoedema has a significant impact on affected persons’ quality of life, and 
ongoing management is required to prevent worsening of symptoms and/or 
development of complications. This project makes a significant contribution to the 
existing lymphoedema management research by comprehensively describing 
treatment use, effectiveness and acceptability of treatments from the patients’ 
perspective. While previous research has described the detrimental impact of 
lymphoedema, little research has investigated whether current treatment options can 
ease symptom burden.  
Review of the literature revealed a greater research focus on BCRL, highlighting the 
need for consideration of the impact of lymphoedema resulting from other causes. 
The review undertaken as part of this research confirmed that the development of 
lymphoedema following gynaecological cancers has physical, psychological, social 
and financial impacts similar to those experienced by those with BCRL. Further, 
concerns specific to this subgroup were summarised from both quantitative and 
qualitative studies, including difficulties performing daily tasks, sitting and/or 
standing for long periods of time, and concerns about sexuality and intimacy.  
Secondary analysis of data from a cross-sectional study investigating the patient-
reported use of mainstream and CAM treatments by women with lymphoedema 
enabled the first description of CAM use by this population. Previous research had 
identified that a high proportion of people with cancer use CAM. This research found 
that women who developed lymphoedema following breast and gynaecological 
cancers also used a range of CAM treatments to manage symptoms of lymphoedema. 
The findings from this study highlighted the concurrent use of multiple treatments, 
the impact of using multiple treatments on treatment effectiveness, and possible 
reasons patients opt to use a range of treatments beyond mainstream therapies 
commonly prescribed.  
A critique of reviews, evaluating the efficacy of lymphoedema treatments, was also 
undertaken as part of this PhD to summarise the current available evidence. In doing 
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so, the lack of attention given to the burden of treatment and patient-reported 
treatment outcomes was evident. These factors are considered important in 
promoting treatment adherence, which is likely to influence treatment effectiveness 
and thus the long-term management of lymphoedema. To further progress the 
research in this area, a cross-sectional study was designed and conducted, as the final 
component in this program of research. As part of this work, patients’ perceived 
effectiveness of treatments for improving a wide range of symptoms was considered 
for the first time. The barriers to long-term use of various lymphoedema treatments, 
including cost, time and discomfort, were also examined in this quantitative research 
to examine the extent to which these factors influenced treatment use in this 
population. The WHO’s five dimensional approach (social and economic factors, 
treatment-, patient- and condition-related factors, and health care system factors; 
described in more detail in section 2.6) to addressing long-term treatment adherence 
is used to discuss the way these factors relate to continued use of a range of 
lymphoedema treatment modalities.  
This chapter discusses the treatment types and number of treatments used by people 
with lymphoedema, the importance of patient-reported treatment outcomes and 
factors influencing continued treatment use. Patient-related factors, as well as 
treatment-related factors (including variations in treatment prescription) are discussed 
in terms of how they relate to the most commonly prescribed lymphoedema 
treatments (compression garments, self-administered massage, prescribed exercises, 
MLD, bandaging and CPT). The condition-related factors and health care system 
factors likely to influence adherence to lymphoedema treatment are also explored. 
Finally, the strengths and limitations of the study are addressed, the public health 
significance of these findings is discussed and recommendations are made for future 
research directions.  
5.1 LYMPHOEDEMA TREATMENT USE 
Participants used a range of treatment types to manage their lymphoedema, with 
almost two thirds of participants in this study having used more than four treatment 
methods. Treatments most commonly used by participants in this study were 
compression garments, self-massage, prescribed exercises, and MLD. This was 
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consistent with the prescribing practices described by health professionals in the 
study by Langbecker et al. 41. The most commonly prescribed treatments by health 
professionals were garments, bandages, exercises, education, massage, MLD and 
self-massage. Findings were also consistent with a recent study of treatment use by 
women with BCRL, which reported that the greatest proportions of women with 
lymphoedema used self-massage (89%), compression garments (80%), MLD (64%) 
or exercises (62%) 134. In the current study, considering the high proportion of 
participants who continued to use compression garments long-term, it was likely that 
many were using multiple treatments concurrently. This could reflect the fact that as 
yet, research has been unable to determine whether treatments administered by health 
professionals are required on a regular basis or whether intensive periods of treatment 
followed by self-management are equally effective, leading to unclear treatment 
guidelines. It is also unclear whether one treatment is sufficient to control 
lymphoedema or whether a combination is always required.  
Of those participants who had used a particular treatment, the majority were currently 
using compression garments (79%), and over half of those who used garments were 
currently using self-massage (68%), prescribed exercises (64%) or MLD (58%). 
These results suggest a high proportion of people with lymphoedema continue to use 
multiple treatment types to manage their symptoms. Although the proportions of 
participants reporting current use of CPT, bandaging or PCP appear low in 
comparison (32%, 30%, 12%, respectively), this reflects that these treatments are 
often prescribed for an intensive period rather than for long-term use. In this study, it 
could not be determined whether those reporting current use of CPT were continuing 
self-management strategies or currently having intensive professional treatment only.  
The factors associated with treatment use were explored in detail and are discussed in 
the sections below.  
5.2 TREATMENT-RELATED FACTORS ASSOCIATED WITH TREATMENT USE 
Aspects of the treatment program that may influence whether patients will adhere to 
treatment long term include the complexity of treatment and the time involved. It is 
important to note that participants’ descriptions of different treatments varied widely, 
and did not always meet the criteria for each treatment’s definitions used in the 
 135 
Chapter 5: Discussion 135 
current study. The proportions of responses meeting the criteria for each treatment 
definition ranged from 63% for CPT, to 91% for PCP. Although treatment 
descriptions were provided for each treatment type within the questionnaire (see 
Appendix A), confusion about treatments was apparent in the written descriptions 
(see Appendix E). This confusion and inconsistency in treatment description may be 
a result of the overlapping of treatment types, with CPT including bandaging, MLD, 
skin care and exercises. Therefore, participants may have completed all of the above, 
as well as CPT, or may have used those different components but not known it as 
CPT. There is also evidence in the literature of complex treatment types being 
administered in different ways dependent on the health professional 34,41. This can 
make it difficult to compare and synthesise results about treatment effectiveness, with 
the actual prescription of treatment varying significantly.  
5.3 SOCIAL AND ECONOMIC FACTORS ASSOCIATED WITH TREATMENT USE 
A number of social and economic factors have been associated with reduced 
adherence to treatments in other settings, including unemployment, poverty and age 
77. In the current study, there was not sufficient evidence to support the hypothesis 
that lymphoedema treatment use varied between participants with different social and 
economic profiles. There appeared to be gender differences in the odds of continued 
use of compression bandaging and CPT with males having higher odds of continued 
use of bandaging and lower odds of continued CPT use. However, with so few male 
participants in the current study, this would require further investigation in larger 
studies.  
Overall, the associations between continued treatment use and patient- and condition- 
related factors remained, after adjustment for social and economic variables. The 
relevant factors identified were consistent with previous research in treatment 
adherence for other chronic conditions 82. The acceptability of cost of treatment and 
time involved are highly relevant to whether or not people with lymphoedema will 
continue treatment, regardless of differences in income or employment type. Further 
exploration of treatment prescriptions and patients’ ability to complete all aspects of 
a prescribed treatment program is warranted. For example, greater understanding of 
the resources available to patients and the burden of treatment within the contexts of 
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their daily life (including other competing costs, other duties outside of work 
commitments) could offer more insight into the role of social and economic factors in 
influencing lymphoedema treatment adherence.  
5.4 CONDITION-RELATED FACTORS ASSOCIATED WITH TREATMENT USE 
Limited research has been conducted on the relationship between characteristics of 
lymphoedema and treatment adherence. While some suggest lymphoedema severity, 
location (upper- versus lower-limb) and type (cancer related versus non-cancer 
related) influence adherence and treatment effectiveness 34,95,109, many aspects of 
these relationships remain unclear, as described in section 2.8.3 (p. 62).  
Findings from the current study supported the hypothesis that lymphoedema 
treatment use differed between people with different lymphoedema characteristics. 
Frequency of symptoms and lymphoedema location were associated with continued 
use of some treatments, but not others. People who described their lymphoedema as 
persistent more often continued their use of compression garments, than those who 
had a single episode or described their symptoms as recurrent. This was consistent 
with findings from previous research exploring self-management strategies, 
suggesting those who had lymphoedema for longer duration were more likely to 
adhere to prescribed treatment 95. However, persistence of symptoms was not 
associated with continued use of other treatment types.  
Continued use of CPT and bandaging was much less frequent for those with 
lymphoedema affecting the lower-limb (CPT), full body or other area (CPT and 
bandaging) compared with those with ULL. It could not be determined what 
proportion of participants reporting continued use of CPT were referring to 
maintenance strategies performed at home, but participants’ reasons for ceasing 
treatment suggested this difference was, at least in part, due to difficulties applying 
bandages to the lower-limbs.  
Lymphoedema location was also found to be an effect modifier of the associations 
between age, income, private health insurance, and the use of treatment. However, 
due to limited power in multivariable models, these subgroup differences (between 
those with ULL versus LLL) were only able to be explored at the bivariate level. 
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Nevertheless, differences between these subgroups of lymphoedema patients warrant 
further investigation in larger studies.  
In this study, lymphoedema severity was not measured, but previous research 
proposes severity of symptoms can present both as a barrier (if unable to perform 
treatment due to symptoms) and a motivator to treatment (reminding patients to 
perform regular treatment to prevent worsening of symptoms) 65,95,100,107,110. This 
issue would benefit from future adherence research exploring this relationship 
further, incorporating objective and self-reported measures of severity.  
5.5 PATIENT-RELATED FACTORS ASSOCIATED WITH TREATMENT USE 
Patient satisfaction with treatment has been found to influence adherence and 
evidence suggests those who perceive their treatment to be effective are more likely 
to continue with it 112. Associated costs, time and discomfort emerged from the 
literature as factors potentially influencing lymphoedema treatment adherence and 
effectiveness 95,97, but had not been explored in detail prior to the current study. This 
study found that across all treatments, a high proportion of participants reported 
ceasing treatment due to: financial cost, effort involved, time taken to perform 
treatment, and a lack of perceived improvement in symptoms. In addition, 
participants described accessibility, poor experiences with treating health 
professionals, and the discomfort associated with treatment as significant barriers to 
treatment adherence.  
5.5.1 IMPORTANCE OF IMPROVEMENT IN LYMPHOEDEMA SYMPTOMS 
The hypotheses that continued treatment use would be associated with perceived 
effectiveness of treatment and acceptability of treatment were supported for some 
treatment types.  The importance of these factors is highlighted below, followed by 
discussion of their associations with continued treatment use for the most commonly 
prescribed lymphoedema treatments.  
Results from the current study emphasise the need for consideration of patient-
reported outcomes in studies of treatment effectiveness. Improvements in swelling, 
heaviness, tightness and range of movement were reported as very important 
treatment outcomes by 60 to 72% of participants who had each symptom. In addition, 
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improved function, mobility, ability to wear normal clothing, and visual appearance 
were considered very important by around half of the participants. These findings 
highlight the need to consider more than just objective measures of limb size. 
Findings also confirm the previous suggestion by health professionals treating people 
with lymphoedema, that although limb volume measurements are the most common 
outcome in lymphoedema treatment efficacy studies, other issues (increased function, 
softening of tissues, reduced shape distortion and reducing likelihood of infection) 
may be equally important to patients 100.  
5.5.2 TREATMENT ACCEPTABLITY 
Previous research suggests ongoing management is required to maintain 
improvements in symptoms resulting from initial lymphoedema treatment (i.e., after 
a period of intensive CPT) 56. In research settings, extensive efforts may be placed on 
achieving optimal adherence to interventions, but in practice, long-term self-
management is dependent on individuals making the decision to continue treatment 
81. This study explored the factors previously identified by health professionals and 
researchers as barriers to treatment (cost, time and discomfort) 95,97,100, from the 
patient’s perspective.  
The acceptability of different aspects of treatment varied between treatment types. 
Overall, the financial cost and discomfort associated with different modalities were 
the two aspects of treatment considered unacceptable by the highest proportions of 
participants. Half of all participants who had used compression garments and/or 
surgery to treat their lymphoedema reported the cost as unacceptable. Around one in 
three found the cost of CPT and MLD unacceptable.  
Of those who had stopped using garments, CPT, MLD and laser, 26 to 36% reported 
doing so because the treatment was too expensive. Considering that MLD and 
compression garments are amongst the most commonly prescribed and used 
treatments 41, these findings suggest that significant numbers of patients have 
difficulty meeting the costs of their prescribed treatment.  
Around one in three reported unacceptable levels of discomfort associated with 
compression bandaging and garments. Pain, intolerable tightness and other 
descriptions of discomfort associated with compression garment and bandage use 
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were given as reasons for ceasing use of treatment by a significant number of 
participants. This side effect of compression use has been well documented in the 
literature 37,103.  
Half of the participants who underwent surgery found the associated discomfort 
unacceptable. While only a small number of participants had surgery (n=14) and 
between them, a range of surgical techniques was used, this is a potential cause for 
concern and warrants further study to explore the levels of discomfort and recovery 
associated with different types of surgery.  
Compared with cost and discomfort, the time taken to complete treatment sessions, 
and the total duration of treatment periods were considered unacceptable by smaller 
proportions of participants overall. However, amongst those who discontinued use of 
treatment, the time involved was provided as the reason for stopping by up to 40% of 
participants (self-administered massage). It is likely the proportion of people with 
time concerns is lower overall, as those who have continued to use the treatments 
have committed the time required to perform the treatment and may consider it 
necessary to managing their condition.  
5.5.3 TREATMENT EFFECTIVENESS 
Treatment effectiveness has most often been measured by recording changes in limb 
volume before and after a treatment program. This enables validation of 
measurement methods and comparison of effect between treatment types, providing a 
practical outcome measure for intervention research. However, in terms of translating 
evidence into practice and investigating adherence to treatment, it has been noted 
previously that changes to symptoms may be equally as important as reductions in 
limb volume 100.  
This was the first study to consider effectiveness of treatment for eleven different 
symptoms. The symptoms were considered individually as it was considered possible 
that a treatment which improved pain or numbness without having a significant 
impact on limb volume could still be considered as effective and important as a 
treatment which had proven effective in reducing limb size.  
Overall, regardless of treatment type, participants most often experienced 
improvements in swelling, heaviness, tightness and aching. On the other hand, few 
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participants reported improvements in weakness, tingling and numbness following 
any treatment. Across all symptoms, the highest proportions of participants 
consistently reported CPT, compression garments, bandaging and MLD as the most 
effective for symptom improvement. There were some exceptions to this. PCP, for 
example, were reported as effective for improving stiffness and range of movement 
by higher proportions than other types of compression and MLD. Similarly, laser 
therapy was reported as improving tightness by close to half of the participants who 
used this treatment and experienced tightness. It is plausible that people use multiple 
treatments to improve different symptoms and that overall, optimal treatment 
outcomes are achieved when treatments are combined. Notably, fewer participants 
reported improvements in symptoms following self-massage and prescribed 
exercises. Further research is needed to explore whether certain types of massage and 
exercises improve symptoms.  
 
Compression garments 
Compression garments had been used by the majority of participants in the current 
study (86%). Of those, 79% were currently using compression garments at the time 
of the study, indicating very high adherence. Studies investigating the use of 
compression garments to treat ULL and LLL have found consistent reductions in 
limb volume, but the greatest reductions have been reported when garment use was 
combined with other physical therapies. In the current study, 60% of those who had 
used garments reported them as effective for improving swelling, and 39 to 47% 
reported improvements in heaviness, tightness and aching. It was unknown which 
treatments participants were using concurrently, precluding any conclusions about the 
sole contribution of compression garments to symptom improvement.  
Current use of garments was higher amongst those with LLL (compared with ULL) 
and persistent symptoms (compared with single episode or recurrent symptoms), but 
was lower for those with multiple comorbid conditions (compared with no 
comorbidities). This could be a reflection of the impact of lower-limb symptoms on 
daily activities (e.g., walking, standing), motivating people to continue treatment to 
avoid worsening of symptoms. The lower current use amongst people with 
comorbidities could be due to the effort required and difficulty managing multiple 
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medical needs. Low adherence has been associated with comorbidities and resulting 
complex treatment programs for a range of chronic health problems, including 
diabetes, hypertension, obesity and depression 77. Patients with multiple medical 
conditions may weigh up the burden of lymphoedema treatment against the severity 
of symptoms and impact on daily life. 
Perceived effectiveness and acceptability of treatment were associated with continued 
use of compression garments. The odds of continued garment use were higher for 
those who found the time and discomfort acceptable, compared to those who found 
these aspects of the treatment unacceptable. Participants described the discomfort as 
being intolerable in hot weather, and when wearing incorrectly sized garments. In 
addition, the odds of current garment use were higher for those who reported the 
treatment as effective at improving their swelling. These findings raise a number of 
issues to be further investigated. For those who found garments ineffective and/or 
experienced significant discomfort, it would be valuable to  investigate whether there 
were differences between the types of compression garments, frequency of fittings (to 
ensure the correct size), and severity of lymphoedema.  
A recent study reported those with moderate and severe lymphoedema, on average, 
reported compression garments as “very helpful” in reducing limb size, compared to 
those with mild lymphoedema reporting the effect as only “helpful” 134. However, 
that study described “severe” lymphoedema as swelling that “anyone would notice”, 
which could include a wide range of limb volume differences. The same study found 
no association between effectiveness and garment type (off-the-shelf vs custom-
made). However, these findings were limited by the small number of participants 
with custom-made garments (n = 28), all of whom had ULL. Also of note, the 
majority of women (n=82) were only using garments for “at risk” activities, as 
opposed to daily use. The number of participants reporting unacceptable discomfort 
in the current study, and the association with discontinued use, suggest a need for 
further research into the causes of discomfort.  
For those who found the time involved in using compression garments unacceptable, 
it was unclear whether this referred to the time taken to apply and/or wear the 
garments, the time taken to attend appointments to be fitted and order garments, or 
some other aspect of garment use. Prescriptions of garment use vary, with some 
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patients only advised to wear garments for travel, others for daytime use only, and 
some advised to wear garments day and night. These factors could have a significant 
impact on the acceptability of treatment time and long-term use, and would be 
important to investigate in future studies. It is also an important consideration for 
health professionals, to be aware of individual circumstances and what may be 
realistic in the context of the patient’s daily life (i.e., communicating that wearing 
garments on non-work days may still be more effective than not using the garment at 
all).  
 
Self-administered massage 
Self-administered massage had been used by over three quarters of participants, and 
almost 70% had continued use. Research into self-management of lymphoedema is 
minimal, compared to other treatment types, which may reflect the difficulty 
measuring the type and frequency of self-administered treatments, as well as 
adherence. Findings from the only previous study exploring the use of self-massage 
and skin care (in the absence of other treatments) suggested improvement in 
symptoms and some reductions in arm volume 135. 
Around one in four participants in the current study who used self-administered 
massage found it effective in improving swelling, heaviness and tightness. The high 
adherence is quite surprising given the low proportion of participants reporting 
symptom improvements. The acceptability of treatment however, is high, with less 
than 10% considering the cost or discomfort unacceptable. As treatments were 
considered effective when participants indicated the treatment helped ‘quite a lot’ or 
‘very much’, it is possible that using self-administered massage did induce some 
improvements, and the low cost and discomfort makes the treatment worthwhile to 
patients.  
 
Prescribed exercises 
Over two thirds of participants reported using prescribed exercises. This was a 
positive finding, considering treatment guidelines in the past have advised against 
exercise (particularly repetitive movements) due to possible risk of worsening 
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symptoms resulting from increased blood and lymphatic flow. However, current 
evidence suggests that exercise has positive effects on both physical and 
psychological wellbeing, and does not exacerbate the condition 2,7,44.  
The description of prescribed exercises in the questionnaire referred to ‘limb 
exercises prescribed by a health professional’. However, it was clear from the 
responses to the open ended question asking participants to describe their treatment, 
that some patients (9% LAV participants, see Table 4.2) were using whole body 
exercise as a lymphoedema management strategy. This information was not available 
for LAQ+ participants who completed the first questionnaire, so the groups were not 
separated. Further, while studies of exercise interventions have carefully defined 
exercise protocols 65,72,73,105,136,137, it is difficult to determine the impact of exercises 
in the context of patients’ daily lives, where their adherence to what has been 
prescribed could vary greatly over time. The following findings related to 
acceptability and effectiveness should be considered in the context of these 
limitations.  
Prescribed exercises were considered acceptable to the majority of participants, with 
less than 10% finding the associated cost and discomfort unacceptable. As there 
would be no expected costs involved with limb exercises performed by the patients 
themselves, it is assumed some patients were referring to either the cost of sessions 
with a health professional where they were taught the exercises, or the cost of 
sessions using whole body exercise (i.e., hydrotherapy). Of those who stopped using 
exercises, a third reported ceasing use due to the time involved, and around one in 
four felt the effort required was too great, or that they had no improvement in 
symptoms.  
One in four reported improved range of movement following the use of prescribed 
exercises. Given the variation in exercises prescribed, it could not be concluded 
whether particular types of exercise are associated with greater perceived 
improvements in range of movement. This would be worth exploring in future 
studies, considering 85% of participants said improvement in range of movement 
was either important or very important to them. While findings from previous 
research suggest exercise does not exacerbate lymphoedema, it is acknowledged that 
more high quality RCTs are needed to determine whether exercise contributes to 
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reductions in limb volume. The consideration of a range of lymphoedema symptoms 
and exercise types and doses in such research would enable stronger 
recommendations to patients about potential benefits of using prescribed exercises.  
 
Manual lymphatic drainage 
Over two thirds of participants had used MLD. Based on participants’ comments, the 
exact prescriptions of MLD received by patients in the current study varied markedly 
(see Appendix E). The technique developed by Dr. Vodder, and later adapted by 
Casley-Smith, involves very specific hand movements, applying light pressure, from 
the distal to proximal regions 57,138. In the current study, any description of lymphatic 
drainage performed by a health professional was accepted as meeting the criteria for 
MLD. Details of the methods used by health professionals providing treatment to 
study participants are therefore unknown. In addition, there was considerable 
variation in the frequency of use, with some participants using MLD weekly, and 
others only every 3 months or when symptoms worsened. Nevertheless, over a third, 
and up to half of participants who used MLD in the current study reported 
improvements in swelling, tightness, heaviness and aching, and over half of the 
participants who had ever used MLD were currently using the treatment at the time 
of study participation. The time and discomfort associated with MLD were 
acceptable to the majority (more than 85%) of participants. 
The cost of MLD was considered unacceptable by over a third of participants, and of 
those who were no longer using MLD, 36% reported stopping treatment because it 
was too expensive. These findings likely reflect the need to access private 
physiotherapy and/or massage therapy services. Lack of access to qualified 
practitioners was reported by many participants, and others specifically noted the lack 
of available services through the public system.  
Research investigating the effect of MLD on objective measures of lymphoedema 
suggests it is effective when used in combination with compression therapies 52,55,59, 
but the evidence does not support the use of MLD as a stand-alone treatment 
29,44,51,53. In the current study, between 38 and 46% of participants with each 
symptom reported MLD as effective in reducing swelling, tightness, heaviness, 
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aching. It was unknown whether these participants were using other treatments 
concurrently, but considering 79% of those who had ever used compression garments 
were currently still using these at the time of the study, it is likely that this was the 
case for a significant number of participants.  
Although MLD may not consistently achieve limb volume reductions, the 
improvement in other symptoms may be just as relevant to lymphoedema 
management as changes in actual limb size. Further, regular contact with a trained 
health professional who administers MLD could also reassure patients about the 
progress of their condition and assist with coping; important aspects of dealing with a 
chronic condition.  
 
Compression bandaging 
Compression bandaging had been used by almost half of the study participants, but 
only a third of those were currently using bandaging to treat their lymphoedema. 
Bandaging is often used as one component of CPT, and it was clear from treatment 
descriptions that some patients had used bandaging only in the context of an 
intensive period of treatment. As treatment details were not always provided, those 
who used bandaging alone could not be separated. It is important to consider that for 
those who used compression bandaging as part of a combined treatment program, it 
could not be determined whether aspects of treatment effectiveness and acceptability 
apply to bandaging alone. 
A third of the participants who had used bandaging found the associated cost and 
discomfort unacceptable. Participants further described difficulty applying bandages, 
and impacts such as being unable to drive and/or continue their work when wearing 
bandages. Around a quarter of the participants who had stopped using compression 
bandaging reported doing so because of the effort involved. Some who gave reasons 
for stopping described being unable to apply bandages at all, while others had a 
partner help previously but considered the burden too great to continue long-term. In 
the current study, almost half of all participants (42%) reported needing assistance 
from another person to complete this; of these, 20% did not have a support person 
available who could assist them. These results confirm findings from previous 
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studies, suggesting difficulties applying bandages and garments can result in 
improper use or lower compliance 100,115. This is an important finding and suggests a 
need for treating health professionals to consider individual circumstances and to be 
aware of the possible need for extra support, particularly for those who live alone 
and/or those who have difficulty applying compression bandages and/or garments. 
Bandages were considered effective for improving swelling, heaviness, tightness and 
aching by at least a third, and up to half, of those who had used them. Previous 
research has found significant volume reductions following the use of compression 
bandages 29,44,51,53,55, but the contribution of compression alone is not well 
understood, as bandages are often used in combination with other treatments, as was 
found in the current study. Given the evidence of effectiveness of bandaging for 
reducing swelling and improving other symptoms, the low adherence likely reflects 
the unacceptability of the discomfort and cost, and feasibility of using bandages 
within the context of the patients’ lives.  
 
Complex physical therapy 
Over a third of the participants in the current study reported using CPT. Over half of 
those who experienced each symptom felt CPT was effective in reducing swelling 
(60%), tightness (52%), heaviness (50%), and at least a third reported CPT as 
effective for improving aching (41%), range of movement (36%) and stiffness (33%). 
These positive results for around half of the participants add to the findings from the 
critique of reviews (see Section 2.3.15), suggesting CPT was also effective at 
reducing limb volume. On the other hand, a large number of participants (40 to 70% 
depending on the symptom) did not find CPT helpful for symptom improvement, and 
these results should be considered in light of the intensive nature of treatment, in 
terms of time, effort and cost.  
Of note, almost 40% of the participants who reported using CPT described a program 
of treatment that did not meet the defined criteria, highlighting the vast differences in 
treatment prescription. Considerable variation in CPT treatment protocols was found 
in the previous research, with total treatment periods ranging from 5 days to 4 weeks, 
MLD sessions within CPT lasting 30 to 60 minutes, scheduled between daily to 3 
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times per week, and compression applied with the use of bandages, garments, or PCP 
2,44,51,54,55,58,59. Even more variation was seen in treatment prescriptions reported by 
participants in the current study, with treatment periods ranging from one week to 4 
months, with MLD sessions from 20 to 60 minutes and a range of compression 
therapies applied. The differences in treatment prescription may reflect the burden on 
health professionals and services, limiting what treatment can be provided to 
individual patients. Some treatments are covered by private health insurance, and 
professionals and services may tailor a treatment program to reduce the financial 
burden on patients. Regardless of the reasons for different treatment protocols, the 
variation makes it very difficult to draw conclusions about the effectiveness and 
acceptability of CPT. 
The research so far has been unable to identify the most effective components of 
CPT, and suggests ongoing therapy may be required to maintain intitial reductions 
achieved by intensive CPT 59. Findings from early trials of CPT suggested the only 
patients who experienced a full relapse of symptoms (10%), had not complied with 
the maintenance phase of treatment 56. In the current study, only 32% reported 
current use of CPT. While the defined prescription includes ongoing self-
management through the use of compression garments, skin care and exercises, it is 
clear from participants’ treatment descriptions that this was not always prescribed 
(see Appendix E). Therefore, participants reporting current use could have been 
receiving intensive treatment at the time of the study, or could have been completing 
ongoing maintenance strategies. It is plausible that the differences in perceived 
effectiveness found in the current study are related to different treatment protocols 
and adherence to ongoing maintenance.  
Of all participants who used CPT, between 20-35% found either cost, time, duration 
or discomfort associated with treatment unacceptable. This was anticipated, given the 
significant commitment required of patients to complete intensive treatment 
programs. Around one in five people who had stopped using CPT reported doing so 
because the treatment was too expensive, time consuming and too much effort. 
Accessibility was described as a major barrier, with a significant number of patients 
stating the treatment was not or no longer available at all in their local area.  
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Lack of accessibility and inconsistency of prescription of CPT make it very difficult 
to draw conclusions about the acceptability and effectiveness of combined treatment 
programs. High proportions of participants found the combination of treatments 
effective for symptoms, but it is not clear whether an intensive period of the 
combined treatment (sometimes involving admission to a treatment centre or 
hospital) is any more beneficial than MLD and compression used separately.  Future 
studies are also required to assess whether intervening early could reduce the need for 
intensive programs and improve outcomes.  
5.6 HEALTH CARE SYSTEM FACTORS  
In addition to the patient-, condition- and treatment-related factors discussed above, a 
number of broader issues related to the accessibility of appropriate treatment emerged 
from this research. Accessibility of treatment was depicted as a major barrier to 
treatment by many participants (see Appendix G for examples of participant 
responses). There were two aspects to lack of accessibility: some described being 
unable to physically access treatment because of location and lack of service 
provision in their area (particularly rural areas). Others could not access treatment 
because of the high demand for the services, stating they were able to access limited 
treatment but then were not offered any follow up treatment. Further to this, some 
participants had been able to access treatment but did not feel they had received 
appropriate advice or treatment. Many were dissatisfied with the level of knowledge 
about lymphoedema amongst health professionals treating their lymphoedema 
symptoms (see Appendix G). Similar findings have been reported previously, with 
limited lymphoedema knowledge being cited as a possible reason for inappropriate 
prescribing practices and dismissive attitudes towards patients 3,34,37. The fact that 
lymphoedema management has never belonged to a specific medical speciality has 
been suggested as a reason for the numerous different treatment pathways patients 
describe 3,34. 
Health professionals in Australia have previously identified the lack of support and 
training as a barrier to providing lymphoedema treatment 41. A study in the UK and 
Canada highlighted health professionals’ frustration over the lack of access to 
multidisciplinary care, particularly when treating patients with advanced 
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lymphoedema and complications 100. It is unsurprising given these experiences of 
both health professionals and patients that there is confusion over treatment advice 
and frustration over delayed access to appropriate treatment 100,139. Multidisciplinary 
centres have been established in some areas, and enable standardised diagnostic 
procedures, combined treatment plans based on knowledge and experience of a range 
of health professionals, higher continuity of treatment and improved patient 
satisfaction and compliance, enhancing opportunities for education training research 
and increased awareness of LE across disciplines 98. Further, analysis of the cost 
effectiveness indicates diagnosis and adequate treatment in early stage can 
significantly reduce direct and indirect costs compared with treatment for advanced 
LE resulting from delayed or missed diagnoses 99. The findings from the current 
study confirm those issues raised in previous studies, and emphasise the need for 
more access to information, training, and multidisciplinary care.  
Another barrier related to the health care system was the cost of different treatments. 
Of those who had stopped using MLD, CPT, compression garments and laser 
therapy, at least one in four stopped using the treatment because it was too expensive. 
Participants described private health insurance rebates reducing, needing more 
compression garments than covered under health insurance policies, and having to 
pay for multiple garments before finding one that they were able to wear without too 
much discomfort. The financial burden of lymphoedema treatment has been 
identified in a number of previous studies 37,41,105,106, and findings from this study 
suggest this is a concern for many people, regardless of income or employment 
status.  
In Australia, the level of financial support available for people with lymphoedema 
varies between states. The Victorian Department of Human Services funds the 
Lymphoedema Compression Garment Program administered by Mercy Health 
Lymphoedema Clinic in Melbourne, providing financial assistance to pensioners and 
low income earners to support their access to treatment 140. Similarly, in Western 
Australia, Cancer Council WA offers a Lymphoedema Management Service, 
providing access to MLD, CPT and compression garment subscriptions at subsidised 
rates 141. For those ineligible for these services, and certainly for those in other states 
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where there are no subsidised services and inadequate private health rebates, cost 
may present a major barrier to long-term treatment.  
5.7 IMPACT OF LYMPHOEDEMA ON QUALITY OF LIFE 
The majority of the research investigating the impact of lymphoedema on quality of 
life to date has involved women with BCRL. The review of studies investigating 
quality of life of women with lymphoedema following treatment for gynaecological 
cancers undertaken as part of this research explored the impact of lower-limb 
symptoms (see section 2.2.1). Findings confirmed women with LLL experienced a 
range of physical symptoms that impacted on their ability to perform daily activities, 
which is consistent with previous research conducted in the breast cancer setting. 
Difficulties with walking, sitting, performing self-management components, body 
image and sexual function were of particular concern to women with LLL following 
gynaecological cancer. The impact of limited mobility and restricted activities on 
social and work relationships was highlighted, as well as the need for clothing and 
footwear modifications.  
In the current study, quality of life was assessed using a one-item screening scale. 
Participants had a median quality of life score of 5.0 (min=1.0, max=7.0, 7-point 
visual analogue scale). A significant proportion of participants therefore reported 
quality of life detriments and more work is needed to assess whether early 
intervention could be beneficial for these patients. Previous research has suggested 
quality of life is not related to limb volume 142,143, and psychological morbidity may 
be more closely associated with level of physical function than swelling or limb size 
144. Findings from the current study involving people with primary or secondary 
lymphoedema suggested improvements in function and mobility, the ability to wear 
normal clothing, and visual appearance, were all considered very important outcomes 
of lymphoedema treatment by more than half of all participants, irrespective of 
lymphoedema type or location. A number of participants described feeling upset, 
frustrated and anxious about their condition and the impact it has had on their lives, 
as well as their family’s lives (see Appendix G).  
It is evident the physical and psychological impact of lymphoedema is significant, 
regardless of the cause. As quality of life assessment was not a main aim of this 
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research. It is difficult to synthesise the current results with those of previous studies 
due to differences in quality of life measures used. Future, especially intervention 
research could benefit from using the most relevant and sensitive quality of life 
measures to ascertain the degree of impact.  
5.8 STUDY LIMITATIONS 
This research presented cross-sectional views of the variety of treatments 
lymphoedema patients use, continue to use, and of the factors influencing use of 
lymphoedema treatment. It was the first study to explore patients’ perspectives of the 
range of treatments available for lymphoedema management. While cross-sectional 
studies are often used for this type of exploratory and descriptive research, a 
longitudinal design would enable a more thorough investigation of treatment 
adherence. It is possible that participants who were not using a particular treatment at 
the time of the study responded differently than they may have, if asked during a 
period of treatment use.  
The difficulty with investigating treatment outcomes for a condition like 
lymphoedema, is that patients often use multiple treatments concurrently, making it 
challenging to determine which treatments are having an effect on symptoms. 
Incorporating patient-reported outcomes into descriptive or intervention studies 
where treatment protocols are carefully defined, controlled or monitored could 
address this issue. Further limitations of this research include generalisability of the 
results, possible recall bias and measurement quality, as discussed below.  
5.8.1 GENERALISABILITY 
Study participants were members of the LAQ, LAV, or had attended the ISL patient 
information session. As a result, participants may have more knowledge about their 
condition, or have had more access to information about different treatments, as well 
as support, than those with lymphoedema in the general population. These factors 
could lead to higher levels of treatment use in this patient subgroup and may lead to 
more persistent use of treatments in spite of some inconvenience. This study included 
participants with primary lymphoedema or secondary lymphoedema following any 
type of cancer, or any other trauma to the lymphatic system.  This enabled 
representation of all lymphoedema types and is a strength of the study, considering 
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most intervention studies limit eligibility to secondary lymphoedema, with the 
majority of previous research conducted with women following breast cancer.  
Estimates of lymphoedema prevalence vary significantly, and limited data is 
available regarding characteristics of those who develop lymphoedema. A 
population-based study conducted in the UK 3 enables the most appropriate 
comparison of patient characteristics in this Australian study (considering both are 
developed countries and have comparable incidence and survival rates for the most 
common cancers). Participants in the current study were similar in age (current study 
mean=66.0 years, population-based mean=66.9 years). Men were under-represented 
at 5% of the sample compared to 17% in the population-based study, respectively. 
This is likely due to recruitment being through the Lymphoedema Associations, and 
women typically more likely to join support groups 145. Similar proportions of 
participants with both upper- (45%) and lower-limb (43%) lymphoedema were 
included in this study, while 41% and 58% had ULL and LLL in the population-
based study, respectively. The lower proportions of men and people with LLL 
(compared with the population-based study) may limit the generalizability of our 
findings to these subgroups. There were some significant differences in the use of 
treatments, with only 4% using MLD and 17% using self-massage in the population-
based study, compared with 67% and 79% in the current study. This may either 
reflect true differences in treatment use between the two countries, or reflect 
increased use of treatments options amongst members of a support group. This 
finding could suggest that patterns of treatment may have limited generalizability to 
people with lymphoedema in the general population. The much lower levels of 
treatment use in the population-based study could also suggest lymphoedema 
treatment availability or adherence is an even greater problem in the general 
population than was established in this study.  
The study included participants predominantly from Queensland and Victoria, with a 
small number living in New South Wales. Personal characteristics did not vary 
significantly between states, so data were combined for all analyses. Findings may be 
limited in generalisability to other states and territories, and internationally, given 
possible differences in available treatment, health care system practices, and patient 
needs.  
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5.8.2 RECALL BIAS 
Study participants may have had lymphoedema for a long period of time and were 
asked questions about all treatment types they had ever used to manage their 
symptoms. However, as participants were unlikely to have forgotten using a given 
treatment the impact of recall bias on the prevalence of treatments used was 
considered limited. It also seems unlikely that people would forget treatments which 
make a great difference to their symptoms. However, given the maximum age of 
participants of 91 years, it is possible there could be some loss of data due to memory 
loss. Results related to the acceptability and effectiveness could be subject to recall 
bias, as those who were no longer using treatment may have responded differently 
(i.e., considering a treatment more unacceptable or less effective because they had 
stopped) than they would have whilst still using the treatment. Prospective studies 
incorporating patient-reported measures of acceptability and treatment effect would 
minimise recall bias.  
5.8.3 MEASUREMENT QUALITY 
The study utilised a newly developed questionnaire. Personal characteristics were 
collected using questions used in previous research, but variables relating to 
lymphoedema and treatment types involved the development of new questions. 
Senior researchers, a physiotherapist and people with lymphoedema completed the 
questionnaire prior to distribution to help establish face and content validity. 
Participants in this process did identify that limited accessibility to treatment was 
missing as a potential reason for stopping treatment, and this was confirmed by a 
number of participants describing reasons related to accessibility in the open ended 
question about reasons for ceasing use. Considering the size of the questionnaire and 
the time taken to complete it, particularly for those who had undertaken several 
different treatments, it is possible some may not have responded to open-ended 
questions requiring a written response, even when their experience wasn’t reflected 
completely in the closed reponses. This may have led to under-reporting of reasons 
for stopping, for those options not included (e.g., accessibility).  Only six participants 
responded to the request to complete the questionnaire a second time, precluding any 
formal quantitative repeatability testing. However, among those six, consistency was 
excellent.  
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It is possible the title of the questionnaire “The issues faced in the treatment and 
management of lymphoedema” introduced reporting bias by implying people with 
lymphoedema inherently have problems accessing and adhering to treatment. In 
future work, care should be taken to ensure neutral wording of all aspects of the 
questionnaire.  
Effectiveness for improving symptoms was measured by asking participants to rank 
how much a treatment had helped with each symptom, and providing categories 
ranging from ‘very little’ to ‘very much’. The category ‘not applicable’ was available 
for participants who did not have a particular symptom. These responses assumed 
that if a participant had a symptom, that the treatment would at least help ‘very little’, 
but it is possible that a participant may have felt the treatment did not help at all or 
made symptoms worse. This may have forced responses into an effectiveness 
category, where the treatment was not considered by participants to be effective. 
However, in this case, it is likely participants would opt for the lowest category 
available. As results for treatment effectiveness were based on those who indicated 
treatment helped ‘quite a lot’ or ‘very much’ the analysis ascertained that treatment 
effectiveness was not over-reported.  
Treatment use questions asked participants to indicate which treatments they had 
used, what each treatment entailed (LAV only) and whether they were currently using 
each treatment. Although LAV participants were asked for how long they had been 
using a treatment, it is not known whether or not they had used the treatment during 
the whole period or had stopped and started again. In addition, participants who were 
not currently using a treatment may have previously used it for a significant period of 
time. It was considered inappropriate to use the data as an accurate reflection of 
treatment duration, when these details could not be clarified. Further, it was unknown 
whether participants were currently continuing with the treatment as prescribed, or 
only to some level. It is important that future research in the field considers the 
multiple aspects of prescribed treatments and the change of treatment use over time 
when measuring adherence to long-term therapies.  
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5.9 PUBLIC HEALTH SIGNIFICANCE OF FINDINGS 
This cross-sectional study included over 400 participants from three different states 
of Australia, providing data on a range of treatments accessed by people with 
lymphoedema in different locations and health systems. The following figure 
summarises the findings from the current study, as they relate to the conceptual 
summary presented in Chapter 2 and the results presented in Chapter 4. 
 
Figure 5.1 Conceptual summary with key findings from the current study and 
recommendations for future research 
 
The study explored the use, acceptability and effectiveness of a range of 
lymphoedema treatment types, including intensive treatments, those performed by 
health professionals, and self-management strategies. The findings provide useful 
information for health professionals about the barriers faced by people undertaking 
long-term lymphoedema treatment, and the factors that are considered important by 
this patient group, relating to treatment outcomes.  
Results from this study suggest that the majority of people with lymphoedema use 
some type of ongoing treatment to manage their condition, and many use a 
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combination of treatment modalities, including CAM (see section 2.4). While 
adherence was high for some treatments, a significant proportion of people face 
numerous barriers to accessing and continuing appropriate treatment. Findings from 
this study provide knowledge about treatment use, patients’ experiences of treatment, 
and areas needing attention, both in future research and practice. The barriers 
identified here (see Figure 2.1) highlight that many people with lymphoedema face 
difficulties when trying to incorporate treatment into their daily lives on a long-term 
basis, as is needed to manage this chronic condition. This is also reflected in the 
impact lymphoedema has on quality of life (see section 2.2).  
Similar patterns of treatment use have been reported interstate and internationally 
134,146. Of note, proportions of people using each treatment type in the present study 
were comparable to results from two other studies. Both of these also recruited 
participants through organisations designed to offer information and support; Breast 
Cancer Network Australia 134, The Lymphoedema Support Network 146. The use of 
all types of treatment reported in these three studies was higher than those reported in 
a population-based study conducted in the UK 3. This demonstrates the importance of 
such organisations for providing information and support, and highlights the 
significant impact this may have on patients’ management of their condition. 
Informing patients about such supportive community organisations could be 
integrated into health professionals’ treatment of lymphoedema, considering the 
chronic nature of the condition and importance of treatment adherence and self-
management to maximise treatment success.  
A recent Australian study of treatment use by women with BCRL suggested even 
amongst those with consistent lymphoedema type and location, experiences of 
treatment varied and no single treatment was of benefit to all women 134. Results 
from a UK study relating to patients’ experiences of treatments were similar to those 
found in the current study, with 80 to 90% reporting benefits following the use of 
compression garments and MLD, and less but still a high proportion (60 to 70%) 
reporting benefits of self-massage and exercises. It is likely these high figures reflect 
a single choice of ‘benefit’ or ‘no benefit’ offers to participants, compared to the 
more stringent criteria of ‘quite a lot’ or ‘very much’ benefit in the current study. 
Together with findings from the current study, these results suggest a combination of 
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treatment modalities may offer the greatest benefit to patients in terms of symptom 
improvements. Considering the impact of chronic symptoms on aspects of daily life 
(i.e., employment, shopping, driving, coping with chronic pain), results from this 
study emphasise the need for health professionals to consider improvement in 
individuals symptoms, and to explore the availability of alternative treatment options 
when patients are unable to adhere to what has been prescribed.  
Access to appropriate treatment remains a significant barrier for some people with 
lymphoedema. Physical access to health services is likely to be a bigger issue for 
those in rural and remote areas, and may require careful consideration of which 
modalities can be most easily performed by a patient themselves, or with the help of 
another person (i.e., partner or other family member). A need for more awareness of 
lymphoedema amongst health professionals and more training in treatment provision 
(e.g., performing MLD) was described frequently by participants. This issue is not 
unique to Australia, with health professionals in the UK and Canada also 
acknowledging a lack of adequate training and knowledge, particularly for the 
management of complications associated with lymphoedema 100.  
The development of multidisciplinary lymphoedema treatment centres has been 
shown to have widespread benefits, including improved diagnostic procedures, 
combined treatment plans, higher continuity of treatment and higher levels of patient 
satisfaction. Although considerable resources are required initially, analysis of the 
cost-effectiveness indicates early diagnosis and treatment can significantly reduce 
direct and indirect costs 99. Participants who were able to access such services 
through Mercy Health Lymphoedema Clinics in Victoria for example, described 
positive experiences, but some were unable to access ongoing treatment, presumably 
due to the high demand for services, or eligibility requirements. Considering the 
benefits to patients and the evidence of cost-effectiveness, the development of 
multidisciplinary centres for the management of lymphoedema should be seen as a 
priority by those responsible for developing health services in other states.  
5.10 FUTURE RESEARCH DIRECTIONS 
Through this research, a number of factors related to lymphoedema treatment 
adherence were identified, which would benefit from further exploration. For 
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example, more thorough investigation of whether treatment needs differ for the main 
subgroups of lymphoedema (ULL/LLL/full body) would be beneficial. This study did 
not consider symptom severity, which could influence adherence in at least two 
ways: as a motivating reminder to continue treatment, or as a barrier to performing 
treatment (i.e., inability to apply compression or massage the affected area due to 
severe swelling). In future, where possible, it is recommended that validated tools be 
used to measure lymphoedema status, such as the one developed by Norman and 
colleagues147. Consistency in the measurement of lymphoedema will enable 
comparisons between future studies and strengthen the available evidence. Living 
area may influence accessibility of treatment, with available treatment options likely 
being limited in regional and rural areas. The impact of this on treatment adherence is 
worthy of further exploration.  
A difficulty in exploring what really works to support treatment adherence for 
chronic conditions is finding the balance between measuring compliance in 
longitudinal intervention studies, and measuring peoples’ use of treatment outside of 
a controlled study environment. Many aspects of intervention studies, including 
clearly defined treatment protocols, support through regular contact with research 
staff and reminders to perform treatment, are all likely to result in higher levels of 
adherence than may be expected outside of the research setting. Ideally, future 
intervention studies would include patient-reported treatment outcomes, 
acknowledging the importance of these factors to those being asked to use the 
treatment on a long-term basis. In addition, when findings from such studies suggest 
the given treatment is effective and treatment recommendations are made, follow up 
studies should explore whether such recommendations are acceptable and feasible for 
patients, in their less structured day to day environment.  
5.11 CONCLUSION 
This research has explored the impact of lymphoedema on patients’ daily lives, and 
examined the issues faced by patients in managing lymphoedema long term. A 
comprehensive review of the literature confirmed that symptoms of LLL, like ULL, 
have a significant impact on physical function and mobility and can have widespread 
social and psychological implications. Managing symptoms long term often requires 
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a significant commitment by patients to complex treatment programs. This research 
examined the considerable burden of a range of commonly prescribed treatments and 
found that many had less than optimal effect. It was therefore not surprising that 
many people with lymphoedema had used a range of treatments, including various 
CAM treatments, in the hope of finding relief from their symptoms.  
The key findings of this research provided information about the widespread 
symptoms suffered by many people with lymphoedema, and highlighted the need to 
consider these in addition to measures of limb volume in future intervention research. 
For many people with lymphoedema, available treatment options including 
compression garments and MLD were considered acceptable and effective for 
improving symptoms. Many reported using the treatments on a long-term basis. 
However, findings from this research suggested barriers such as accessibility, time 
commitments, symptom severity, and discomfort led to discontinued treatment, 
which is known to increase the risk of lymphoedema progression and complications. 
It is important for researchers, health care services and health professionals to 
consider individual circumstances and responses to treatment to maximise long-term 
adherence and treatment effectiveness. 
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APPENDIX A 
Letter to participants and Questionnaire: The issues faced in the treatment 
and management of lymphoedema 
 Dear LAV members, 
 
Researchers at the Queensland University of Technology are trying to better understand the 
factors which motivate and prevent people from adhering to treatment for lymphoedema. 
Ultimately, the information collected will be used to inform future management of 
lymphoedema, so that it takes into better account the key concerns for those living with 
lymphoedema.  
 
The Lymphoedema Association of Victoria has kindly offered to distribute this research 
package to potentially eligible people on our behalf. If you choose to participate in this 
project, we ask that you complete the enclosed questionnaire and return it to us using the 
reply-paid envelope within the next 2 weeks.  Your participation is voluntary, we ask for no 
identifying information and returning the questionnaire implies you are consenting to 
participate.  
 
Following completion of the study, the results will be published in LAV’s newsletter, Swell 
News. We look forward to hearing back from you and your support in our research 
endeavours.  
 
Anna Finnane 
Masters (Research) Student 
School of Public Health 
Queensland University of Technology 
 
  
 
 
 
 
The issues faced in the treatment and 
management of lymphoedema 
 
A Questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PARTICIPANT INFORMATION for QUT RESEARCH PROJECT 
The use, acceptability and perceived effectiveness of prescribed treatments for the 
management of lymphoedema 
 
Research Team Contacts 
Dr. Sandi Hayes - Senior Research Fellow 
School of Public Health, Institute of Health and 
Biomedical Innovation, Queensland University of 
Technology 
Anna Finnane – PhD student 
Queensland University of Technology,  
School of Public Health 
Victoria Park Rd, Kelvin Grove, QLD 4059 
Phone     07 3138 9164  Phone 07 3138 5817 
Email sc.hayes@qut.edu.au Email   a.finnane@student.qut.edu.au 
Description 
This project is being undertaken as part of a postgraduate research project by Anna Finnane at 
Queensland University of Technology (QUT) under the supervision of Dr. Sandi Hayes. The purpose of this 
study is to develop an understanding of factors which motivate and prevent people who have, or have 
experienced lymphoedema, from adhering to prescribed treatments and therapies.  
 
The research team requests your assistance because the information you provide could enable better 
planning and prescribing of long term treatment strategies which meet the needs of people with 
lymphoedema. 
 
Participation 
Your participation will involve completing a questionnaire, either in writing or by telephone. If you choose 
to participate, all information you provide will be anonymous. Therefore, it will not be possible to 
withdraw once you have submitted the questionnaire. 
 
Expected benefits 
It is expected that participation in this project will provide no immediate benefit to you. However, this project may inform future 
research and contribute to the planning of treatment strategies, ultimately benefiting lymphoedema patients. 
 
Risks 
The research team acknowledges that disclosing personal and health information may induce anxiety for some people. If you do not 
feel comfortable answering certain questions, you can skip these. An incomplete survey will still be of use to us. 
 
QUT provides limited free counselling for research participants of QUT projects, who may experience discomfort or distress as 
a result of their participation in the research.  Should you wish to access this service please contact the Clinic Receptionist of 
the QUT Psychology Clinic on 3138 0999.  Please indicate to the receptionist that you are a research participant. 
 
Confidentiality 
All comments and responses are anonymous and will be treated confidentially.  The names of individual persons are not required in 
any of the responses. 
 
Consent to Participate 
Submitting the completed questionnaire is accepted as an indication of your consent to participate in this project. 
 
Questions / further information about the project 
Please contact the researcher team members named above to have any questions answered or if you require further information 
about the project. 
 
Concerns / complaints regarding the conduct of the project 
QUT is committed to researcher integrity and the ethical conduct of research projects.  However, if you do have any concerns or 
complaints about the ethical conduct of the project you may contact the QUT Research Ethics Officer on 3138 2091 
or ethicscontact@qut.edu.au. The Research Ethics Officer is not connected with the research project and can facilitate a resolution to 
your concern in an impartial manner. 
 
 
 
 
 
 
 
 
 
 
 
The issues faced in the treatment and 
management of lymphoedema 
 
 
 
Questionnaire Instructions 
 
 
The questionnaire is contained in this booklet. Please try to answer all of the questions in the 
questionnaire that are relevant to you. If you are not sure of the correct answer, please give us 
your best estimate. Some questions may not directly relate to lymphoedema treatment, but will 
provide us with important information relating to the barriers you may face in treating your 
lymphoedema. If you do not feel comfortable answering certain questions, you can skip these. 
An incomplete questionnaire will still be of use to us. 
 
Some of the questions have check boxes. Please read these questions carefully as some require 
you to tick the most correct answer, while others require you to tick all boxes that apply to you. 
Questions requiring a short written answer give you the opportunity to provide information you 
think is relevant to your experience of lymphoedema and lymphoedema treatment, which has not 
already been covered in the questionnaire. 
 
Sometimes your answer to one question will allow you to skip other questions. Please read the 
“go to” statements carefully to ensure you are answering the questions appropriate for you. If you 
are uncertain about any of the questions do not hesitate to contact us: 
 
Anna Finnane 07 3138 5817 
 
 
Thank you for taking the time to complete this survey. 
 
 
QUT is committed to researcher integrity and the ethical conduct of research projects. However, if you do 
have any concerns or complaints about the ethical conduct of the  project  you  may  contact  the  QUT  
Research Ethics Officer on 07 3138 2340 or ethicscontact@qut.edu.au. The Research Ethics Officer is 
not connected with the research project and can facilitate a resolution to your concern in an impartial 
manner.  
 
 
 
 
 Before you start, please write today’s date:  ____/_____/____ 
   
1 Age:   
        ___________ years  
   
2 Are you: 
 Female  Male  
   
3 Do you have children?    
  Yes  If yes, continue below 
  No  If no, go to question 4 
   
 How many children are younger than 5 years?    
 
 How many children are aged between 5 and 14 years?    
  
 How many children are older than 14 years?    
   
 How many children, of any age, are living in your care?    
   
   
4 Currently, what is your main work arrangement? (please tick one box) 
 Employed/Self-employed – full-time  
 Employed/Self-employed – part-time  
 Employed/Self-employed – casual  
 Full-time home duties  
 Student  
 Unemployed or looking for work  
 Retired  
 Permanently ill/unable to work  
 Unpaid work in a family business or farm  
 Unpaid voluntary worker  
 Other (please specify)  ____________________  
   
5 What side do you consider your dominant side (usually the hand that you write with)? 
 Right   Left   Both    
   
6 Have you ever been diagnosed with lymphoedema (swelling) in the arm, breast, trunk, groin 
area or legs? 
 Yes  No   
7 If you have been diagnosed with lymphoedema, please complete the following table: 
      
 Where? 
(mark with 
an ‘x’ all that 
apply) 
Date of 
diagnosis 
(approx. 
month and 
year) 
Who diagnosed you? 
(physiotherapist 
surgeon, GP, 
massage therapist, 
self, other) 
Did your 
lymphoedema 
last for 3 
months or 
longer? 
(yes/no) 
How would you 
characterise your 
lymphoedema? 
Single episode, 
Recurrent (comes 
and goes) or 
Persistent (almost 
always there) 
right arm      
right hand      
right breast      
right trunk      
right leg      
right foot      
left arm      
left hand      
left breast      
left trunk      
left leg      
left foot      
groin area      
other      
   
8 Do you currently have lymphoedema? 
 Yes  No  
  
9 Was the lymphoedema you were diagnosed with considered primary (inherited) or 
secondary (following cancer or injury to the lymphatic system)? 
 Primary   If primary, go to Question 11 
 Secondary   
  
10 Did your lymphoedema occur following treatment for cancer? 
 Yes    
 No  Did your lymphoedema follow Injury  
  Other  _______________ 
 
 
 
11 Have you ever been diagnosed with cancer?  
    
 Yes  If yes, please indicate which cancer (tick all that apply): 
 Breast  Cervix  
 Prostate  Vulva  
 Uterus  Bladder               
 Ovary  Melanoma  
 Other (please specify)   _______________________  
    
 No   If no, go to Question 14 
 
12 When were you first diagnosed with cancer?      
 ____ /____ / ____ 
 
 13 What treatment have you had for your cancer? 
      
  Yes No Don’t know When (mm/yyyy)? 
 Surgery     ________________ 
 Chemotherapy    ________________ 
 Radiation therapy    ________________ 
 Hormone therapy    ________________ 
 Other (please specify) 
____________________ 
   ________________ 
 
14 Have you had any of the following conditions? If yes, please state the approximate date you 
were first diagnosed with this condition. 
      
  Yes No Don’t know Date of diagnosis 
 Heart attack (coronary, myocardial infarction)    __________ 
 Angina pectoris    __________ 
 High blood pressure    __________ 
 High cholesterol    __________ 
 Other heart condition (specify):_____________    __________ 
 Stroke    __________ 
 Diabetes    __________ 
 Asthma     __________ 
 Chronic Bronchitis    __________ 
 Emphysema of the lungs    __________ 
 Stomach or duodenal ulcer    __________ 
 Migraine headaches    __________ 
 Osteoporosis    __________ 
 Rheumatoid arthritis    __________ 
 Depression    __________ 
 Any other prolonged serious illness – if yes, 
please specify: _________________________ 
    
__________ 
  
 
The questions on the following 10 pages relate specifically to treatments you 
may have used to treat your lymphoedema. Each page has a series of 
questions about a specific treatment, which appear on both sides of the 
page. Please answer the yes/no question at the beginning of each page, and 
continue with the following questions only if you have used that treatment. 
 
To help you determine which treatment strategies you have used, brief 
descriptions are provided below. If you tick a box, then you know to proceed 
to the coloured page that is listed. 
 
Complex physical therapy    Questions 15 a-h  
Involves 2-4 weeks of manual lymph drainage (described below), followed by compression 
bandaging, skin care and prescribed limb exercises undertaken by the patient.  If you have used 
these in combination, please tick here; if you only use one or two of the treatments mentioned, 
then do not tick here, but rather tick below for each single treatment. 
 
Manual lymphatic drainage  Questions 16 a-h 
Administered by a health professional, manual lymphatic drainage uses various light massage 
techniques moving up and down the limb. 
 
Self massage     Questions 17 a-h 
Involves a simplified version of manual lymph drainage using ‘sweeping’ strokes applied by you 
or someone else. 
 
Laser therapy     Questions 18 a-h 
Uses a device that emits low-intensity wavelengths, also known as a scanning or spot laser. 
 
Pneumatic pumps    Questions 19 a-h 
Uses pumps (with single or multiple chambers) that surround the limb, inflating and deflating at 
different cycles and pressures. 
 
Compression bandaging   Questions 20 a-h 
Consists of a gauze sleeve, soft cotton wrap or high-density foam and two or three layers of 
short-stretch bandaging. 
 
Compression garment   Questions 21 a-h 
Provides greatest compression at the furthest end of the limb and least at the end closest to the 
trunk. 
 
Prescribed exercises    Questions 22 a-h 
Limb exercises prescribed by a health professional to reduce excess fluid and improve range of 
movement.  
 
Surgery      Questions 23 a-h 
Any surgical procedure used to treat lymphoedema.  
 
Other      Questions 24 a-h 
Any other treatment method used to treat your lymphoedema.  
 
 
 
15a Have you used complex physical therapy to treat your lymphoedema? 
     
 Yes  No  Please go to Question 16  
  
b Who prescribed this treatment? 
       
 Physiotherapist  Massage Therapist  GP   
      
 Self   Other (please specify)  __________________ 
 
  
c In your own words, please tell us what this treatment entails (i.e., tell us what was 
prescribed, how often you attended sessions, how long each session was and the length of 
the total prescribed treatment period): 
  
 
  
 
  
 
d Were you able to complete this treatment as prescribed? 
         
 Yes, always  Yes, sometimes  Rarely  Never  
  
e Are you currently using this treatment? 
     
 Yes  No  
  
f How acceptable do/did you find the following aspects of complex physical therapy as a 
treatment for lymphoedema? 
  
 Financial Cost: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Time required per session/day: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Duration of total prescribed treatment period (months/years/ongoing): 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Level of discomfort during treatment: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
      
 
g Did complex physical therapy help with the following symptoms of lymphoedema? If you 
do not experience any of the symptoms, mark the “not applicable” box. 
 
 Very little/ 
Little 
Somewhat/ 
Moderately 
Quite a lot/ 
Very much 
 
      
Swelling    Not applicable  
      
Heaviness    Not applicable  
      
Tightness    Not applicable  
      
Aching    Not applicable  
      
Tenderness    Not applicable  
      
Stiffness    Not applicable  
      
Weakness    Not applicable  
      
Numbness    Not applicable  
 
Tingling (pins & needles) 
 
 
 
 
 
 
 
Not applicable 
 
 
      
Pain    Not applicable  
      
Range of movement    Not applicable  
  
h If you are not currently using complex physical therapy, please indicate why not by ranking 
all that apply (eg. number 1 to 7) where 1 = the main reason: 
 
 No longer needed (treatment was effective)  Did not improve symptoms  
     
 Too expensive  Stopped improving symptoms  
     
 Too much effort  Made symptoms worse  
     
 Too time consuming  Stopped due to side effects  
     
 
 
If there was another reason you are not currently using complex physical therapy, please 
tell us here: 
  
 
 
 
 
 
 
 
 
16a Have you used manual lymphatic drainage to treat your lymphoedema? 
     
 Yes  No  Please go to Question 17 
  
b Who prescribed this treatment? 
       
 Physiotherapist  Massage Therapist  GP   
      
 Self   Other (please specify)  __________________ 
 
  
c In your own words, please tell us what this treatment entails (i.e., tell us what was 
prescribed, how often you attended sessions, how long each session was and the length of 
the total prescribed treatment period): 
  
 
  
 
  
 
d Were you able to complete this treatment as prescribed? 
         
 Yes, always  Yes, sometimes  Rarely  Never  
  
e Are you currently using this treatment? 
     
 Yes  No  
  
f How acceptable do/did you find the following aspects of manual lymphatic drainage as a 
treatment for lymphoedema? 
  
 Financial Cost: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Time required per session/day: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Duration of total prescribed treatment period (months/years/ongoing): 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Level of discomfort during treatment: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
      
g Did manual lymphatic drainage help with the following symptoms of lymphoedema? If you 
do not experience any of the symptoms, mark the “not applicable” box. 
 
 Very little/ 
Little 
Somewhat/ 
Moderately 
Quite a lot/ 
Very much 
 
      
Swelling    Not applicable  
      
Heaviness    Not applicable  
      
Tightness    Not applicable  
      
Aching    Not applicable  
      
Tenderness    Not applicable  
      
Stiffness    Not applicable  
      
Weakness    Not applicable  
      
Numbness    Not applicable  
 
Tingling (pins & needles) 
 
 
 
 
 
 
 
Not applicable 
 
 
      
Pain    Not applicable  
      
Range of movement    Not applicable  
  
h If you are not currently using manual lymphatic drainage, please indicate why not by 
ranking all that apply (eg. number 1 to 7) where 1 = the main reason: 
 
 No longer needed (treatment was effective)  Did not improve symptoms  
     
 Too expensive  Stopped improving symptoms  
     
 Too much effort  Made symptoms worse  
     
 Too time consuming  Stopped due to side effects  
     
 If there was another reason you are not currently using manual lymphatic drainage, please 
tell us here: 
  
 
 
 
 
 
 
 
 
17a Have you used self massage (applied by you or someone else) to treat your lymphoedema? 
     
 Yes  No  Please go to Question 18 
  
b Who prescribed this treatment? 
       
 Physiotherapist  Massage Therapist  GP   
      
 Self   Other (please specify)  __________________ 
  
c In your own words, please tell us what this treatment entails (i.e., tell us what was 
prescribed, how often you attended sessions, how long each session was and the length of 
the total prescribed treatment period): 
  
 
  
 
  
 
d Were you able to complete this treatment as prescribed? 
         
 Yes, always  Yes, sometimes  Rarely  Never  
  
e Are you currently using this treatment? 
     
 Yes  No  
  
f How acceptable do/did you find the following aspects of self massage as a treatment for 
lymphoedema? 
  
 Financial Cost: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Time required per session/day: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Duration of total prescribed treatment period (months/years/ongoing): 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Level of discomfort during treatment: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
      
      
g Did self massage help with the following symptoms of lymphoedema? If you do not 
experience any of the symptoms, mark the “not applicable” box. 
 
 Very little/ 
Little 
Somewhat/ 
Moderately 
Quite a lot/ 
Very much 
 
      
Swelling    Not applicable  
      
Heaviness    Not applicable  
      
Tightness    Not applicable  
      
Aching    Not applicable  
      
Tenderness    Not applicable  
      
Stiffness    Not applicable  
      
Weakness    Not applicable  
      
Numbness    Not applicable  
 
Tingling (pins & needles) 
 
 
 
 
 
 
 
Not applicable 
 
 
      
Pain    Not applicable  
      
Range of movement    Not applicable  
  
h If you are not currently using self massage, please indicate why not by ranking all that apply 
(eg. number 1 to 7) where 1 = the main reason: 
 
 No longer needed (treatment was effective)  Did not improve symptoms  
     
 Too expensive  Stopped improving symptoms  
     
 Too much effort  Made symptoms worse  
     
 Too time consuming  Stopped due to side effects  
     
 If there was another reason you are not currently using self massage, please tell us here: 
 
  
 
 
 
 
 
 
 
 
 
18a Have you used laser therapy to treat your lymphoedema? 
     
 Yes  No  Please go to Question 19 
  
b Who prescribed this treatment? 
       
 Physiotherapist  Massage Therapist  GP   
      
 Self   Other (please specify)  __________________ 
 
  
c In your own words, please tell us what this treatment entails (i.e., tell us what was 
prescribed, how often you attended sessions, how long each session was and the length of 
the total prescribed treatment period): 
  
 
  
 
  
 
d Were you able to complete this treatment as prescribed? 
         
 Yes, always  Yes, sometimes  Rarely  Never  
  
e Are you currently using this treatment? 
     
 Yes  No  
  
f How acceptable do/did you find the following aspects of laser therapy as a treatment for 
lymphoedema? 
  
 Financial Cost: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Time required per session/day: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Duration of total prescribed treatment period (months/years/ongoing): 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Level of discomfort during treatment: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
      
 
g Did laser therapy help with the following symptoms of lymphoedema? If you do not 
experience any of the symptoms, mark the “not applicable” box. 
 
 Very little/ 
Little 
Somewhat/ 
Moderately 
Quite a lot/ 
Very much 
 
      
Swelling    Not applicable  
      
Heaviness    Not applicable  
      
Tightness    Not applicable  
      
Aching    Not applicable  
      
Tenderness    Not applicable  
      
Stiffness    Not applicable  
      
Weakness    Not applicable  
      
Numbness    Not applicable  
 
Tingling (pins & needles) 
 
 
 
 
 
 
 
Not applicable 
 
 
      
Pain    Not applicable  
      
Range of movement    Not applicable  
  
h If you are not currently using laser therapy, please indicate why not by ranking all that apply 
(eg. number 1 to 7) where 1 = the main reason: 
 
 No longer needed (treatment was effective)  Did not improve symptoms  
     
 Too expensive  Stopped improving symptoms  
     
 Too much effort  Made symptoms worse  
     
 Too time consuming  Stopped due to side effects  
     
 If there was another reason you are not currently using laser therapy, please tell us here: 
  
 
 
 
 
 
 
 
 
 
 
19a Have you used pneumatic pumps to treat your lymphoedema? 
     
 Yes  No  Please go to Question 20 
  
b Who prescribed this treatment? 
       
 Physiotherapist  Massage Therapist  GP   
      
 Self   Other (please specify)  __________________ 
 
  
c In your own words, please tell us what this treatment entails (i.e., tell us what was prescribed, 
how often you attended sessions, how long each session was and the length of the total 
prescribed treatment period): 
  
 
  
 
  
 
d Were you able to complete this treatment as prescribed? 
         
 Yes, always  Yes, sometimes  Rarely  Never  
  
e Are you currently using this treatment? 
     
 Yes  No  
  
f How acceptable do/did you find the following aspects of pneumatic pumps as a treatment for 
lymphoedema? 
  
 Financial Cost: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Time required per session/day: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Duration of total prescribed treatment period (months/years/ongoing): 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Level of discomfort during treatment: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
      
 
g Did pneumatic pumps help with the following symptoms of lymphoedema? If you do not 
experience any of the symptoms, mark the “not applicable” box. 
 
 Very little/ 
Little 
Somewhat/ 
Moderately 
Quite a lot/ 
Very much 
 
      
Swelling    Not applicable  
      
Heaviness    Not applicable  
      
Tightness    Not applicable  
      
Aching    Not applicable  
      
Tenderness    Not applicable  
      
Stiffness    Not applicable  
      
Weakness    Not applicable  
      
Numbness    Not applicable  
 
Tingling (pins & needles) 
 
 
 
 
 
 
 
Not applicable 
 
 
      
Pain    Not applicable  
      
Range of movement    Not applicable  
  
h If you are not currently using pneumatic pumps, please indicate why not by ranking all that 
apply (eg. number 1 to 7) where 1 = the main reason: 
 
 No longer needed (treatment was effective)  Did not improve symptoms  
     
 Too expensive  Stopped improving symptoms  
     
 Too much effort  Made symptoms worse  
     
 Too time consuming  Stopped due to side effects  
     
 If there was another reason you are not currently using pneumatic pumps, please tell us 
here: 
  
 
 
 
 
 
 
 
 
20a Have you used compression bandaging to treat your lymphoedema? 
     
 Yes  No  Please go to Question 21 
  
b Who prescribed this treatment? 
       
 Physiotherapist  Massage Therapist  GP   
      
 Self   Other (please specify)  __________________ 
 
  
c In your own words, please tell us what this treatment entails (i.e., tell us what was prescribed, 
how often you attended sessions, how long each session was and the length of the total 
prescribed treatment period): 
  
 
  
 
  
 
d Were you able to complete this treatment as prescribed? 
         
 Yes, always  Yes, sometimes  Rarely  Never  
  
e Are you currently using this treatment? 
     
 Yes  No  
  
f How acceptable do/did you find the following aspects of compression bandaging as a 
treatment for lymphoedema? 
  
 Financial Cost: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Time required per session/day: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Duration of total prescribed treatment period (months/years/ongoing): 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Level of discomfort during treatment: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 
g Did compression bandaging help with the following symptoms of lymphoedema? If you do 
not experience any of the symptoms, mark the “not applicable” box. 
 
 Very little/ 
Little 
Somewhat/ 
Moderately 
Quite a lot/ 
Very much 
 
      
Swelling    Not applicable  
      
Heaviness    Not applicable  
      
Tightness    Not applicable  
      
Aching    Not applicable  
      
Tenderness    Not applicable  
      
Stiffness    Not applicable  
      
Weakness    Not applicable  
      
Numbness    Not applicable  
 
Tingling (pins & needles) 
 
 
 
 
 
 
 
Not applicable 
 
 
      
Pain    Not applicable  
      
Range of movement    Not applicable  
  
h If you are not currently using compression bandaging, please indicate why not by ranking 
all that apply (eg. number 1 to 7) where 1 = the main reason: 
 
 No longer needed (treatment was effective)  Did not improve symptoms  
     
 Too expensive  Stopped improving symptoms  
     
 Too much effort  Made symptoms worse  
     
 Too time consuming  Stopped due to side effects  
     
 If there was another reason you are not currently using compression bandaging, please tell 
us here: 
  
 
 
 
 
 
 
 
 
21a Have you used compression garments to treat your lymphoedema? 
     
 Yes  No  Please go to Question 22 
  
b Who prescribed this treatment? 
       
 Physiotherapist  Massage Therapist  GP   
      
 Self   Other (please specify)  __________________ 
 
  
c In your own words, please tell us what this treatment entails (i.e., tell us what was prescribed, 
how often you attended sessions, how long each session was and the length of the total 
prescribed treatment period): 
  
 
  
 
  
 
d Were you able to complete this treatment as prescribed? 
         
 Yes, always  Yes, sometimes  Rarely  Never  
  
e Are you currently using this treatment? 
     
 Yes  No  
  
f How acceptable do/did you find the following aspects of compression garments as a 
treatment for lymphoedema? 
  
 Financial Cost: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Time required per session/day: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Duration of total prescribed treatment period (months/years/ongoing): 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Level of discomfort during treatment: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 
g Did compression garments help with the following symptoms of lymphoedema? If you do 
not experience any of the symptoms, mark the “not applicable” box. 
 
 Very little/ 
Little 
Somewhat/ 
Moderately 
Quite a lot/ 
Very much 
 
      
Swelling    Not applicable  
      
Heaviness    Not applicable  
      
Tightness    Not applicable  
      
Aching    Not applicable  
      
Tenderness    Not applicable  
      
Stiffness    Not applicable  
      
Weakness    Not applicable  
      
Numbness    Not applicable  
 
Tingling (pins & needles) 
 
 
 
 
 
 
 
Not applicable 
 
 
      
Pain    Not applicable  
      
Range of movement    Not applicable  
  
h If you are not currently using compression garments, please indicate why not by ranking all 
that apply (eg. number 1 to 7) where 1 = the main reason: 
 
 No longer needed (treatment was effective)  Did not improve symptoms  
     
 Too expensive  Stopped improving symptoms  
     
 Too much effort  Made symptoms worse  
     
 Too time consuming  Stopped due to side effects  
     
 If there was another reason you are not currently using compression garments, please tell 
us here: 
  
 
 
 
 
 
 
 
 
 
22a Have you used prescribed exercises to treat your lymphoedema? 
     
 Yes  No  Please go to Question 23 
  
b Who prescribed this treatment? 
       
 Physiotherapist  Massage Therapist  GP   
      
 Self   Other (please specify)  __________________ 
 
  
c In your own words, please tell us what this treatment entails (i.e., tell us what was prescribed, 
how often you attended sessions, how long each session was and the length of the total 
prescribed treatment period): 
  
 
  
 
  
 
d Were you able to complete this treatment as prescribed? 
         
 Yes, always  Yes, sometimes  Rarely  Never  
  
e Are you currently using this treatment? 
     
 Yes  No  
  
f How acceptable do/did you find the following aspects of prescribed exercises as a 
treatment for lymphoedema? 
  
 Financial Cost: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Time required per session/day: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Duration of total prescribed treatment period (months/years/ongoing): 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Level of discomfort during treatment: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
  
g Did prescribed exercises help with the following symptoms of lymphoedema? If you do not 
experience any of the symptoms, mark the “not applicable” box. 
 
 Very little/ 
Little 
Somewhat/ 
Moderately 
Quite a lot/ 
Very much 
 
      
Swelling    Not applicable  
      
Heaviness    Not applicable  
      
Tightness    Not applicable  
      
Aching    Not applicable  
      
Tenderness    Not applicable  
      
Stiffness    Not applicable  
      
Weakness    Not applicable  
      
Numbness    Not applicable  
 
Tingling (pins & needles) 
 
 
 
 
 
 
 
Not applicable 
 
 
      
Pain    Not applicable  
      
Range of movement    Not applicable  
  
h If you are not currently using prescribed exercises, please indicate why not by ranking all 
that apply (eg. number 1 to 7) where 1 = the main reason: 
 
 No longer needed (treatment was effective)  Did not improve symptoms  
     
 Too expensive  Stopped improving symptoms  
     
 Too much effort  Made symptoms worse  
     
 Too time consuming  Stopped due to side effects  
     
 If there was another reason you are not currently using prescribed exercises, please tell us 
here: 
  
 
 
 
 
 
 
 
 
23a Have you had surgery to treat your lymphoedema? 
     
 Yes  No  Please go to Question 24 
  
  
b In your own words, please tell us what this treatment entailed (i.e., tell us what was 
prescribed and whether this involved one surgical procedure or more): 
  
 
  
 
  
 
c Were you able to complete this treatment as prescribed? 
  
 Yes, always  Yes, sometimes  Rarely  Never  
  
d Have you already completed this treatment? 
  
 Yes  No  
  
e Do you expect to have more surgery to treat your lymphoedema? 
  
 Yes  No  
  
f How acceptable do/did you find the following aspects of surgery as a treatment for 
lymphoedema? 
  
 Financial Cost: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Length of treatment and recovery period: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Level of discomfort during recovery: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
  
  
  
  
 
 
g Did surgery help with the following symptoms of lymphoedema? If you do not experience 
any of the symptoms, mark the “not applicable” box. 
 
 Very little/ 
Little 
Somewhat/ 
Moderately 
Quite a lot/ 
Very much 
 
      
Swelling    Not applicable  
      
Heaviness    Not applicable  
      
Tightness    Not applicable  
      
Aching    Not applicable  
      
Tenderness    Not applicable  
      
Stiffness    Not applicable  
      
Weakness    Not applicable  
      
Numbness    Not applicable  
 
Tingling (pins & needles) 
 
 
 
 
 
 
 
Not applicable 
 
 
      
Pain    Not applicable  
      
Range of movement    Not applicable  
  
h If you did not complete the surgical treatment that was prescribed (if more than one 
procedure was involved), please indicate why not by ranking all that apply (eg. number 1 to 
7) where 1 = the main reason: 
 
 No longer needed (treatment was effective)  Did not improve symptoms  
     
 Too expensive  Stopped improving symptoms  
     
 Too much effort  Made symptoms worse  
     
 Too time consuming  Stopped due to side effects  
     
 If there was another reason, please tell us here: 
 
  
 
 
 
 
 
 
 
 
24a Have you used another type of treatment (not already listed) to treat your lymphoedema? 
     
 Yes  No  Please go to Question 25 
  
b Who prescribed this treatment? 
       
 Physiotherapist  Massage Therapist  GP   
      
 Self   Other (please specify)  __________________ 
 
  
c In your own words, please tell us what this treatment entails (i.e., tell us what was 
prescribed, how often you attended sessions, how long each session was and the length of 
the total prescribed treatment period): 
  
 
  
 
  
 
d Were you able to complete this treatment as prescribed? 
         
 Yes, always  Yes, sometimes  Rarely  Never  
  
e Are you currently using this treatment? 
     
 Yes  No  
  
f How acceptable do/did you find the following aspects of this treatment as a treatment for 
lymphoedema? 
  
 Financial Cost: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Time required per session/day: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Duration of total prescribed treatment period (months/years/ongoing): 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 Level of discomfort during treatment: 
                
 Unacceptable Somewhat unacceptable Neutral Somewhat acceptable Very acceptable 
  
 
g Did this treatment help with the following symptoms of lymphoedema? If you do not 
experience any of the symptoms, mark the “not applicable” box. 
 
 Very little/ 
Little 
Somewhat/ 
Moderately 
Quite a lot/ 
Very much 
 
      
Swelling    Not applicable  
      
Heaviness    Not applicable  
      
Tightness    Not applicable  
      
Aching    Not applicable  
      
Tenderness    Not applicable  
      
Stiffness    Not applicable  
      
Weakness    Not applicable  
      
Numbness    Not applicable  
 
Tingling (pins & needles) 
 
 
 
 
 
 
 
Not applicable 
 
 
      
Pain    Not applicable  
      
Range of movement    Not applicable  
  
h If you are not currently using this treatment, please indicate why not by ranking all that apply 
(eg. number 1 to 7) where 1 = the main reason: 
 
 No longer needed (treatment was effective)  Did not improve symptoms  
     
 Too expensive  Stopped improving symptoms  
     
 Too much effort  Made symptoms worse  
     
 Too time consuming  Stopped due to side effects  
     
 If there was another reason you are not currently using this treatment, please tell us here: 
 
  
 
 
 
 
 
 
 
 
 
The following questions relate to your overall experience of lymphoedema 
treatments. 
 
25 Do/did you need another person to assist you with doing the treatment that has been 
prescribed for your lymphoedema? 
       
 Yes, all the time  Yes, sometimes  No  
 
26 When you need assistance, do you have someone who is able to provide it? 
     
     
 Yes, all the time  Yes, sometimes  No  
 
 
27 How important is it to you that a particular treatment results in an improvement in the 
following symptoms in order for you to continue with that treatment? 
  
Swelling 1 2 3 4 5 
 Not important at all Not very important Does not bother me Important Very important 
 
Heaviness 1 2 3 4 5 
 Not important at all Not very important Does not bother me Important Very important 
 
Tightness 1 2 3 4 5 
 Not important at all Not very important Does not bother me Important Very important 
 
Aching 1 2 3 4 5 
 Not important at all Not very important Does not bother me Important Very important 
 
Tenderness 1 2 3 4 5 
 Not important at all Not very important Does not bother me Important Very important 
 
Stiffness 1 2 3 4 5 
 Not important at all Not very important Does not bother me Important Very important 
 
Weakness 1 2 3 4 5 
 Not important at all Not very important Does not bother me Important Very important 
 
Numbness 1 2 3 4 5 
 Not important at all Not very important Does not bother me Important Very important 
 
Tingling  1 2 3 4 5 
 Not important at all Not very important Does not bother me Important Very important 
 
Pain 1 2 3 4 5 
 Not important at all Not very important Does not bother me Important Very important 
 
Range of 
movement 
1 2 3 4 5 
Not important at all Not very important Does not bother me Important Very important 
  
 
28 In your own words, could you describe the level of change in your lymphoedema that you 
would need to see to consider a given form of treatment as being successful (e.g., “want to 
see a size reduction of more than 10%”; ”just want a reduction in the severity of my pain”, 
etc) 
  
 
 
 
 
 
 
29 Circle the response which most accurately reflects how important the following factors 
relating to lymphoedema status are to you. 
 
Improvement in visual appearance 
1 2 3 4 5 
Not important at all Not very important Neutral Quite important Very important 
 
Able to wear normal clothing 
1 2 3 4 5 
Not important at all Not very important Neutral Quite important Very important 
 
Improvement in function  
1 2 3 4 5 
Not important at all Not very important Neutral Quite important Very important 
 
Improvement in mobility  
1 2 3 4 5 
Not important at all Not very important Neutral Quite important Very important 
 
     
 
Finally, a little about you: 
     
30 Which ONE of the following best describes your current living arrangement? 
 Living alone with no children  
 Single parent living with one or more children  
 Single and living with friends or relatives  
 Couple (married or defacto) living with no children  
 Couple (married or defacto) living with one or more children  
 Other (please specify):  __________________ 
   
31 Do you have private health insurance?  
 No  
 Yes, hospital only  
 Yes, extras only  
 Yes, hospital + extras  
  
32 What is the highest educational qualification you have completed? (Tick one only) 
     
 Year 10 or less  Associate or undergraduate diploma  
 Year 11  Bachelor degree  
 Year 12  Post-graduate diploma  
 Trade or business certificate  Masters degree or Doctorate  
 
Apprenticeship 
 
Other (please specify): __________
_ 
  
33 Please add up the amount of BEFORE-TAX income received by ALL members of your 
household, and tick the box that comes closest to this number. Please indicate income either 
per year, per fortnight or per week. 
   
 Per year  Per week  
 less than $15,600  less than $300  
 $15,600-20,799  $300-399  
 $20,800-25,999  $400-499  
 $26,000-31,199  $500-599  
 $31,200-36,399  $600-699  
 $36,400-41,599  $700-799  
 $41,600-51,999  $800-999  
 $52,000-72,799  $1,000-1,399  
 $72,800-93,599  $1,400-1,799  
 $93,600-$129,999  $1,800-2,499  
 $130,000 or more  $2,500 or more  
     
 Do not know  I do not want to answer this question  
   
  
  
  
 
 
34 What is your height, without shoes on?    
 __________ cm 
  
35 How much did you weigh: 
 When your lymphoedema was diagnosed? ___________kg 
 When you were at your heaviest since diagnosis of your lymphoedema? ___________kg 
 Now? ___________kg 
  
36 Please circle the number between 1 and 7 that best applies to you. 
   
 How would you rate your overall health during the past week? 
 1 2 3 4 5 6 7 
 Very Poor      Excellent 
  
 How would you rate your overall quality of life during the past week? 
 1 2 3 4 5 6 7 
 Very Poor      Excellent 
   
37 Do you have anything else you would like to tell us about your lymphoedema and/or 
treatment you have used? Please do so here:  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for completing this questionnaire! 
 
  
 
 
 
APPENDIX B 
Participant responses providing additional information about 
lymphoedema and/or treatment 
Exercise 
Hydrotherapy - twice weekly, in a group specifically for lymphoedema patients helps 
incredibly with symptoms. Overcomes embarassment in wearing bathers because everyone 
there has swollen limbs. Good social event, lots of laughs! 
I have been doing hydro for the past 2 or 3 years and found that this by far was the most 
successful treatment of my lymphoedema, but could always fall back on the garments when 
not being able to participate in hydro. 
Support groups 
Being part of a support group led by a qualified lymphoedema therapist makes a huge 
difference. Gives better understanding of the condition, advice available as required on a 
weekly basis and friendship and understanding from other people facing the same 
discomforts. 
I go to a help group once a month it makes me feel good after as I know that I am not on my 
own. 
Long time to diagnosis preventing early intervention 
I wish I had been informed following surgery for breast cancer that I could get lymphoedema 
and what symptoms to be aware of. I could then have got treatment earlier and my arm 
might have been more reduced in size. 
I wish I had had more information that you could get lymphoedema from surgery following 
removal of lymph nodes and that a massage be given following the operation. 
The size of my left arm has never been less than when it was diagnosed by a physio approx. 2 
years after surgery. Therefore early identification and treatment of lymphoedema are 
needed to prevent this initial swelling. Could NHMRC guidelines recommend arm 
measurements beofre breast surgery and at 6/12 intervals afterwards? Maybe BreastScreen 
could take these measurements prior to surgery. I think early detection and intervention 
could have helped me greatly to manage it successfully. 
The worst part was taking so long to get diagnosed, and not knowing what the swelling was. I 
had 2 lots of clothes and shoes, one for when it was bad and another for when it was a bit 
better. I try to handle things myself now. 
Accessing appropriate information 
There doesn't appear to be much information about treatments. I hadn't heard of treatments 
mentioned in this survey. 
Treatment and advice given was very haphazard, sometimes conflicting and confusing. 
Since 2001, it has been extremely difficult to find out more about treatment options and 
professionals that can help me. 
Cost 
I have been hospitalised many times because of cellulitis in my lymphoedema.Being a 
pensioner, I would find it very helpful to receive some financial help to buy the garments I 
need to manage my lymphoedema. Presently I pay over $120 for each garment. 
The cost of garments and treatment makes it very difficult to adequately manage my 
condition. 
I would very much like to try the bandaging, but distance and cost do not make this possible. 
I also believe the Government should help with the cost of the compression sleeve. The 
hospital benefits return some, but still very expensive $285 twice a year. 
Accessing health professionals (time, location and suitably qualified) 
Finding a qualified private practitioner is very hard. Regular massage by physio or therapist is 
vital - it may be possible to self massage with an arm only, but it is virtually impossible to self 
massage trunk and legs properly. 
For me the biggest issue is time! I work full time and cannot undertake much of my work 
outside of standard business hours. Treaters need to understand that working less thatn F/T 
is not an option. 
Have tried a number of lymphoedema physios and have found their treatment to be very 
varied. Some beneficial, others waste of time (and money). Matter of shopping around 
although not many to choose from. 
Living in a rural area, there is no real treatment choice. It is not possible to have complex 
physical therapy as there is not the staff or the room to carry it out. Our nearest clinic is over 
3 hours drive away. Education re self massage and exercises is barely adequate at our public 
facilities and most lymphoedema clients have to work out their own treatments. 
I have found some practioners to be more helpful than others, which I suppose is normal in 
most areas of life. Some were basically not interested or I consider to be incompetent. 
Experiences with health professionals 
I would especially like leaders in the lymphoedema industry such as Neil Piller stop using 
abusive, derogatory and demeaning language to describe us and our body parts. My lymph 
system is NOT lazy, sluggish or broken down - not AM I! My limbs are not swampy, teeming 
of bacteria or backed up. Nor am I with language like that its no wonder a majority of us are 
depressed! 
Medical professionals (oncologists/breast surgeons) fail or underestimate the effects of 
lymphoedema - this risk was never mentioned pre-surgery/after diagnosis nor suitable 
treatment offered. 
It would be nice to get a bit more understanding from the medical professionals. Because we 
conceal our unglamourous legs and hopefully don't complain too much as we try to live an 
active life, doesn't mean we don't suffer, especially in the hot weather. 
Weather 
My lymphoedema is totally controlled by daily wearing of a compression stocking. It is a 
much more difficult condition to live with in summer due to the heat. The garments are hot 
and harder to hide in a skirt/dress than in trousers in winter. 
My feet and ankles swell in hot/warm weather. Generally speaking, the hotter the weather, 
the worse the swelling. 
Stress, anxiety, distress, frustration 
I am also very bitter about the reality that since my first child was born (1992) I have had 
limited opportunities to share in family experiences due to my lymphoedema. It is on my 
mind 24/7 - TRUE! 
To go through cancer and end up having lymphoedema was, to say the least, very upsetting. 
Being diagnosed with lymphoedema was probably worse than my cancer diagnosis! Cancer 
can often be cured, but you can never forget you had it with lymphoedema, 
I feel anxious that the condition will worsen. 
In the early days of diagnosis I was depressed upset and angry that it changed and affected 
my life - young children, working on the farm in cattle yards was out and treatment was too 
hard to access. 
Focus on breast cancer 
Overall, a greater awareness of lymphoedema in medical circles, and most emphasis seems 
to be on post breast ops - how about us 'legs'? 
Selfishly, those of us with leg problems (let alone more esoteric cases) get tired of the major 
stress on arm treatments. At least they don't have to stand and walk on arm. 
I would like to see primary lymphoedema researched as thoroughly and passionately  as 
breast cancer-related lymphoedema, and for people of primary lymphoedema to be no 
longer 'blamed' for their condition or treatment as an inferior class of lymphoedema citizen. 
My lymphoedema is related to melanoma not breast cancer. Most assistance programs are 
aimed at the breast cancer survivor and my isolation after diagnosis was debilitating in itself. 
Public awareness 
I would just like the general public to understand what lymphoedema really is. Also more 
medical people. 
I would like people made more aware of lymphoedema, especially GPs. 
More information should be available to educate the general public about possibilities 
available to relieve their discomfort. 
 
 
  
 
 
 
APPENDIX C 
Letter to participants and validity questions 
        
 
 
Dear LAQ members, 
 
Last year you may have been contacted by researchers at the Queensland University of 
Technology and invited to participate in a study of the factors which motivate and prevent 
people from adhering to treatment for lymphoedema. The information collected will be used to 
inform future management of lymphoedema, so that it takes into better account the key 
concerns for those living with lymphoedema.  
 
The second stage of this project involves checking whether the questionnaire used for this 
study collects information about all relevant factors that influence decisions regarding 
treatment for lymphoedema. If you choose to participate in this project, please read through 
the Participant Information Sheet and instructions at the beginning of the questionnaire.  
 
Your participation is voluntary, we ask for no identifying information and returning the 
questionnaire implies you are consenting to participate.  
 
Thank you for your ongoing support in our research endeavours.  
 
 
Anna Finnane 
PhD Student 
School of Public Health 
Queensland University of Technology 
a.finnane@student.qut.edu.au 
(07) 3138 5817 / 0438 722 547 
The issues faced in the treatment and management of lymphoedema 
 
Validity and Reliability of the Questionnaire 
About the Questionnaire 
 
For the questions about different treatment types (starting on Page 5): 
 
1. Was there any aspect of the acceptability of lymphoedema treatment 
that has impacted on you and was not addressed on the questionnaire? 
(ie. apart from cost, time, duration and discomfort) 
________________________________________________________________
________________________________________________________________
________________________________________________________________ 
 
2. Have you had physical symptoms of lymphoedema that were not listed 
on the questionnaire? If so, what were they? 
________________________________________________________________
________________________________________________________________ 
“Question 29. Circle the response which most accurately reflects how 
important the following factors relating to lymphoedema status are to you” 
 
3. Are there any other factors that are important to you in terms of 
treatment effectiveness, that were not listed? (ie. apart from 
improvement in visual appearance, ability to wear normal clothing, 
improvement in function and mobility) 
________________________________________________________________
________________________________________________________________
________________________________________________________________ 
 
  
 
 
 
APPENDIX D 
Follow-up reminder postcard 
 A friendly reminder 
Hi, 
 
Around two weeks ago you would have  
received a survey from us in the mail.  
 
Thankyou to all those who have already  
completed and returned it, we appreciate 
your time and participation. 
 
To those who have not yet completed the  
survey, we would be very grateful if you could 
take the time to do so - your information is 
important to us. If you have not received a 
survey or have misplaced it, please call me on 
(07) 3138 5677. 
 
Regards,  
For more information, please contact Anna Finnane (07) 3138 5677 or a.finnane@student.qut.edu.au 
  
 
 
 
APPENDIX E 
Participants’ treatment descriptions 
Met criteria Did not meet criteria 
Complex Physical Therapy 
MLD daily (for approx 1 hour) for 2 weeks, followed by application of 
compression bandaging. Self exercise 1-2 times p/day. Skin care is a daily 
ritual for me.  
Compression bandaging x2 6 months apart. Now wear a support sleeve. 
Massage every 6-12 months.  
Manual lymph drainage – weekly, 30 mins. Compression bandaging – 
fortnightly. Total period – 6 weeks. 
Manual lymph massage weekly for 6 weeks by physiotherapist followed 
by 6 monthly visits.  
3 times a week, one hour sessions for 4 months, massage and compression 
bandaging. 
Body flow machine (my own) daily 20 mins. Two days of hydrotherapy 1 
hour.  
Manual Lymphatic Drainage 
Clearance of lymph nodes, manual drainage of lymph fluid – arm, hand and 
breast area – right hand side – also other areas of body e.g., legs, trunk, 
stomach, left arm – by trained massage therapist. Began treatments in 2009. 
Sessions are monthly, last approx 1 hr each and are ongoing indefinitely.  
Exercises for arm mobility and general good health. To massage from arm 
across the chest. Self-treated. 
Treated by 2 people, one every 2 weeks. Physio – light drainage and organises 
compression garment – 20 minutes. Lymphatic trained masseur – 1 hour – 
solid massage, most beneficial.  
Stretching and stroking exercises after attending classes suggested by 
hospital physio.  
Massage by physio – 3 monthly, 30 mins each session, 5 years.  Given crystals to try in evening, could not keep them in place.  
Self-administered massage  
Gentle massage under axilla over shoulders across chest, deep breathing. 
Gentle sweeping strokes 5-10 mins most days, ongoing.  
Just initial 6 weeks – massage followed by pressure bandaging approx 1 
hr/day 
Activating drainage points and lightly massage stroking towards poi nt. 
Draining strokes etc. time approx 15 minutes.  
Massage, bandaging, exercise 
I was shown by physio to do at home.   The exercises take approx 20 minutes.  
Laser Therapy  
Every 4 to 5 weeks lying on a table having both overhead and hand held laser. 
Mainly for fibrosis which causes restriction/pain etc which blocks and causes 
lymphoedema.  
Started with Body Flow, found it helped.  
Laser beam applied to affected limb. Session was for 20-30 mins daily for 1 
month.  
 
Spot laser is occasionally used depending on the state of my arm at each 
massage session.  
 
Pneumatic compression pumps  
I purchased a pump at great expense in 2000 when lymphoedema first 
diagnosed. It is a noisy box that blows air into a plastic leg sheath an squeezes 
the leg then releases the air and builds up the air pressure again etc. 
I used a body flow machine 5 times a week. It helps to keep the limb soft 
but does not decrease the circumference.  
Purchased my own pump and use it twice a day for 1 hour. Suction cups are placed on the limb in certain points and it generates a 
vibration and suction for about 10 minutes every month. 
Was able to use pump at home for 2 weeks. Applied each night for 1 hour. I go to the Mercy Lymphoedema Clinic every 6 months to measure and 
have new compression stocking.  
Compression bandaging  
Start with measurement of arms and fingers. Different grades of pressure to 
ends area of fingers and arm up to shoulder. This is done over 6 weeks every 
day until measurements plateau then measured for compression glove and 
sleeve.  
The physiotherapist recommended I wear a compression bandage and 
stockings. I only had one session for 1 hour.  
1 month, x3 daily, 2 layers of soft bandages and 1 outer stretchy firmer 
bandage.  
Compression sleeve on long air flights.  
Changing bandages every couple of days and seeing therapist 1 to 2 weeks.  To help with pain and swelling.  
Compression garments  
Waist high tights, both legs compression 20-30mmHg. Worn continually when 
not in bed, daily use.  
Massaging, then shower, then full compression bandaging. This was 
initially done once a week for a month, very rarely now but stronger 
bandaging 3 times a week.  
Arm and hand compression garments. Nearly always wear them except in hot 
weather. Leg too uncomfortable to wear. Have worn garment on and off for 6 
years.  
The bandaging was very painful and used 4 days every few months. 
Compression stocking which I use regularly.   Just do it. 
Prescribed exercises  
Most days for 3-5 minutes, 3-4 times a day, left arm stretches, rotation, 
pressure against wall. Still do exercises prescribed in 2001.  
Gentle massage of lymph system.  
Exercises from education session at Mercy Lymphoedema Clinic. Generally 
incorporated throughout the day e.g., when sitting – moving feet in heel-toe 
action, e.g., like walking, sitting down, standing at regular intervals, standing 
up on balls of feet. 
Physiotherapist was trained to manage lymphoedema. 1 hour sessions 
weekly. I now have massage fortnightly.  
Range of exercises to improve lymphatic drainage twice a day for approx 10 
mins ongoing.  
There was no long session, part of  check up.  
Surgery  
Venous anastomosis for right (unsuccessfully as lymphoedema present for 
14+ years and lymph vessels withered). Left arm successful and does not 
require compression garment.  
Lumpectomy and revision lumpectomy, sentinel node biopsy 
Liposuction to right arm followed by 10 days of compression bandaging and 
compression garments.  
 
Debulking of scrotal area. Plastic surgeon removed fibrous tissue. Only 
bottom of scrotal area was operated on removing approx 1.6kg of tissue. 
Second operation is required to reduce tissue on top half of scrotal area.  
 
 
  
 
 
 
APPENDIX F 
Results: Acceptability of cost, time, duration and discomfort for all 
treatments 
Appendix F1 
Proportions of participants reporting the acceptability of the financial cost of lymphoedema treatment 
Treatment Unacceptable Somewhat 
unacceptable 
Neutral Somewhat 
acceptable 
Very acceptable Missing 
Complex physical therapy 26 (14.8%) 33 (18.8%) 28 (15.9%) 33 (18.8%) 38 (21.6%) 18 (10.2) 
Manual lymphatic drainage 36 (12.6) 64 (22.5) 33 (11.6) 71 (24.9) 47 (16.5) 34 (11.9) 
Self administered massage 4 (1.2) 11 (3.3) 60 (18.1) 33 (9.9) 150 (45.2) 74 (22.3) 
Laser therapy 9 (11.7) 12 (15.6) 19 (24.7) 11 (14.3) 20 (26.0) 6 (7.8) 
Pneumatic pumps 3 (5.9) 5 (9.8) 12 (23.5) 8 (15.7) 11 (21.6) 12 (23.5) 
Compression bandaging 24 (12.7) 33 (17.5) 35 (18.5) 35 (18.5) 33 (17.5) 29 (15.3) 
Compression garments 92 (25.4) 98 (27.1) 32 (8.8) 75 (20.7) 48 (13.3) 17 (4.7) 
Prescribed exercises 3 (1.0) 12 (4.1) 62 (21.2) 38 (13.0) 126 (43.2) 51 (17.5) 
Surgery 2 (14.3) 5 (35.7) 2 (14.3) 3 (21.4) 0 (0.0) 2 (14.3) 
Appendix F2 
Proportions of participants reporting the acceptability of the time required per session of lymphoedema treatment 
Treatment Unacceptable Somewhat 
unacceptable 
Neutral Somewhat 
acceptable 
Very acceptable Missing 
Complex physical therapy 11 (6.3%) 24 (13.6%) 23 (13.1%) 49 (27.8%) 50 (28.4%) 19 (10.8) 
Manual lymphatic drainage 6 (2.1) 29 (10.2) 42 (14.7) 89 (31.2) 88 (30.9) 31 (10.9) 
Self administered massage 18 (5.4) 38 (11.4) 46 (13.9) 82 (24.7) 91 (27.4) 57 (17.2) 
Laser therapy 3 (3.9) 6 (7.8) 18 (23.4) 22 (28.6) 23 (29.9) 5 (6.5) 
Pneumatic pumps 1 (2.0) 10 (19.6) 8 (15.7) 15 (29.4) 7 (13.7) 10 (19.6) 
Compression bandaging 22 (11.6) 29 (15.3) 35 (18.5) 43 (22.8) 27 (14.3) 33 (17.5) 
Compression garments 17 (4.7) 42 (11.6) 74 (20.4) 72 (19.9) 105 (29.0) 52 (14.4) 
Prescribed exercises 9 (3.1) 37 (12.7) 52 (17.8) 77 (26.4) 80 (27.4) 37 (12.7) 
Surgery 1 (25.0) 0 (0.0) 1 (25.0) 0 (0.0) 1 (25.0) 1 (25.0) 
Appendix F3 
Proportions of participants reporting the acceptability of the duration of the treatment period 
Treatment Unacceptable Somewhat 
unacceptable 
Neutral Somewhat 
acceptable 
Very acceptable Missing 
Complex physical therapy 10 (10.3%) 11 (11.3%) 18 (18.6%) 20 (20.6%) 25 (25.8%) 13 (13.4) 
Manual lymphatic drainage 15 (8.2) 17 (9.9) 34 (18.7) 41 (22.5) 48 (26.4) 26 (14.3) 
Self administered massage 13 (5.9) 18 (8.2) 45 (20.5) 45 (20.5) 54 (24.7) 44 (20.1) 
Laser therapy 1 (3.1) 6 (18.8) 6 (18.8) 9 (28.1) 7 (21.9) 3 (9.4) 
Pneumatic pumps 1 (6.7) 0 (0.0) 3 (20.0) 4 (26.7) 1 (6.7) 6 (40.0) 
Compression bandaging 13 (12.6) 11 (10.7) 21 (20.4) 23 (22.3) 17 (16.5) 18 (17.5) 
Compression garments 22 (9.3) 31 (13.1) 44 (18.6) 41 (17.3) 60 (25.3) 39 (16.5) 
Prescribed exercises 8 (4.0) 17 (8.6) 36 (18.2) 40 (20.2) 59 (29.8) 38 (19.2) 
Surgery 2 (20.0) 1 (10.0) 1 (10.0) 5 (50.0) 1 (10.0) 0 (0.0) 
Appendix F4 
Proportions of participants reporting the acceptability of the discomfort of lymphoedema treatment 
 
Treatment Unacceptable Somewhat 
unacceptable 
Neutral Somewhat 
acceptable 
Very acceptable Missing 
Complex physical therapy 11 (6.3%) 27 (15.3%) 28 (15.9%) 38 (21.6%) 57 (32.4%) 15 (8.5) 
Manual lymphatic drainage 5 (1.8) 6 (2.1) 43 (15.1) 61 (21.5) 146 (51.4) 23 (8.1) 
Self administered massage 6 (1.8) 10 (3.0) 70 (21.1) 56 (16.9) 144 (43.4) 46 (13.9) 
Laser therapy 1 (1.3) 3 (3.9) 10 (13.0) 10 (13.0) 47 (61.0) 6 (7.8) 
Pneumatic pumps 2 (3.9) 3 (5.9) 15 (29.4) 11 (21.6) 10 (19.6) 10 (19.6) 
Compression bandaging 26 (13.8) 41 (21.7) 31 (16.4) 36 (19.0) 28 (14.8) 27 (14.3) 
Compression garments 28 (7.7) 78 (21.5) 53 (14.6) 86 (23.8) 80 (22.1) 37 (10.2) 
Prescribed exercises 3 (1.0) 17 (5.8) 65 (22.3) 64 (21.9) 102 (34.9) 41 (14.0) 
Surgery 3 (21.4) 5 (35.7) 1 (7.1) 5 (35.7) 0 (0.0) 0 (0.0) 
  
 
 
 
APPENDIX G 
Participants’ reasons for discontinuing use of treatment 
Reasons for discontinued use of treatment 
Complex Physical Therapy 
As a country resident (150km from Melbourne) access is restricted. Local 
hospital physio has been trained but does not have time for CPT. 
It is no longer available at RPA. My massage therapist cannot afford the time, 
and I could not afford to pay her. 
The time per day and total period of duration are fine, but working full time, it's 
hard to take the time off work to do it! The benefits for me were amazing!! 
Assistance with daily living and getting to and from appointments is also a 
barrier. (If I can't drive, how do I get there? Public transport in full bandages = 
not so easy) 
Manual Lymphatic Drainage 
Cannot afford to keep taking too much time off work. Most practitioners only 
work within standard business hours. 
My therapist retired and I have been unable to locate a suitable replacement. I 
have tried a few and find the level of training and ability varies greatly. 
I have not been able to find another physio offering this service - plenty of 
people who think they know - really shonky, and very worrying! 
Self-administered massage 
Difficult to massage back and chest well 
Due to age I am finding it hard to do now, looking for a therapist in this area. 
Finding it hard to stretch to do the strokes up and down the leg 
My husband did complete the 1 month as directed but found it very hard and 
time consuming to continue with the lymphoedema 'milking' process of my legs. 
It was very effective though. Trying to do it myself seemed ineffective. 
Laser Therapy 
Laser therapy is not available in all states. Distance to travel is too far. 
Physio at hospital do not have time to do it - too expensive at private practice. 
Distance to therapist - however certainly improved fibrotic areas. 
Pneumatic compression pumps 
No longer available to me. 
Not recommended by everyone, can make condition worse evidentally. 
Told not to use outside of complex physical therapy, which I only had for 10 
sessions in 1 month. Would like to have more. 
Compression bandaging 
Definitely too time consuming and a lot of effort involved with putting bandage 
on, taking it off, washing them all and rolling the 12 individual rolls up to use 
again. Of all the treatments I've tried this is the worst 
Too hard to work in full bandages. I drive for work, cannot drive in full bandages. 
Finding pants and shoes to fit very difficult. 
It's very hard to do - to know whether you are doing it right or not. It needs to be 
done by a professional. 
Compression garments 
Found them very uncomfortable they ride down and then dig in under the knee 
causing pain. 
Have just received compression garment for left leg and that is help 
considerably with my leg. Arm only - compression garment for arm/hand is too 
inhibiting to use as it cuts off circulation to tips of fingers despite exhaustive 
attempts to rectify by manufacturer. I have back and left shoulder injury which 
makes it impossible to put on garments. I live alone. 
Stockings too difficult to get on/off for minimal improvement. Wear them when 
flying more than 4 hours. 
Prescribed exercises 
Lack of time. Am my husband's carer and this year I have been busy but intend 
restarting exercises and massage very soon. 
To make a worthwhile improvement in me I think I would have to do the 
exercises morning noon and night and I still may not improve. I have tried upon 
occasion to really do them to no great avail. 
At the age of 82 and having a range of health issues I no longer have the energy 
to do exercises. Osteoarthritis in knees, hips, arms, shoulders, hands, neck, 
feet. 
 
  
 
 
 
APPENDIX H 
Results: Bivariate effect modification tables 
 
Table 1 Bivariate associations between independent variables and use of compression garments, 
stratified by lymphoedema location 
 
Table 2 Bivariate associations between independent variables and use of self-massage, stratified by 
lymphoedema location 
 All locations pooled Upper Lower Full body/Other 
 n(%) p-value n(%) p-value n(%) p-value n(%) p-value 
Total participants 332 (78.9)  179 (82.9)  135 (73.4)  18 (85.7)  
Private Health Insurance 
No/DVA 
card/Missing 
66 (68.8)  30 (76.9)  29 (59.2)  7 (87.5)  
Yes 266 (81.8)  149 (84.2)  106 (78.5)  11 (84.6)  
  .018  .024  .017  .854 
Categories with under 20 cases are italicised; effect modification was not considered. 
 
 All locations pooled Upper Lower Full body/Other 
 n(%) p-value n(%) p-value n(%) p-value n(%) p-value 
Total participants 362 (86.0)  182 (84.3)  163 (88.6)  17 (81.0)  
Age 
Under 55 years 55 (88.7)  21 (84.0%)  29 (90.6)  5 (100.0)  
55-64 years 107 (87.7)  62 (89.9%)  38 (86.4)  7 (77.8)  
65-74 years 130 (87.2)  73 (85.9%)  54 (91.5)  3 (60.0)  
75 and 
over/missing 
70 (79.5)  26 (70.3%)  42 (85.7)  2 (100.0)  
  .556  0.165  0.918  0.140 
Household income 
<$20 799 57 (82.6)  26 (76.5)  28 (90.3)  3 (75.0)  
$20 800 – 36 399 57 (93.4)  30 (90.9)  23 (95.8)  4 (100.0)  
$36 400 – 51 999 49 (89.1)  24 (85.7)  21 (91.3)  4 (100.0)  
$52 000+ 78 (90.7)  45 (91.8)  30 (90.9)  3 (75.0)  
Not known/not 
answering/Missing 
121 (80.7)  57 (79.2)  61 (83.6)  3 (60.0)  
  .185  0.270  0.809  0.634 
Categories with under 20 cases are italicised; effect modification was not considered. 
Table 3 Bivariate associations between independent variables and use of manual lymph drainage, 
stratified by lymphoedema location 
 
Table 4 Bivariate associations between independent variables and use of compression bandaging 
stratified by lymphoedema location 
 All locations pooled Upper Lower Full body/Other 
Total participants 188 (44.7) 89 (41.2) 89 (48.4) 10 (47.6) 
     
Age n(%) p-value n(%) p-value n(%) p-value n(%) p-value 
Under 55 years 32 (51.6)  11 (44.0)  18 (56.3)  3 (60.0)  
55-64 years 57 (46.7)  27 (39.1)  26 (59.1)  4 (44.4)  
65-74 years 62 (41.6)  34 (40.0)  26 (44.1)  2 (40.0)  
75 and 
over/missing 
37 (42.0)  17 (45.9)  19 (38.8)  1 (50.0)  
 CS .593 NS .981 CS .251  .719 
Categories with under 20 cases are italicised; effect modification was not considered. 
 
 All locations pooled Upper Lower Full body/Other 
 n(%) p-value n(%) p-value n(%) p-value n(%) p-value 
Total participants 286 (67.9)  162 (75.0)  107 (58.2)  17 (81.0)  
Age         
Under 55 years 45 (72.6)  20 (80.0)  21 (65.6)  4 (80.0)  
55-64 years 88 (72.1)  48 (69.6)  31 (70.5)  9 (100.0)  
65-74 years 101 (67.8)  64 (75.3)  35 (59.3)  2 (40.0)  
75 and over/missing 52 (59.1)  30 (81.1)  20 (40.8)  2 (100.0)  
  .390  .788  .127  .119 
Private Health Ins 
No/DVA 
card/Missing 
55 (57.3)  29 (74.4)  20 (40.8)  6 (75.0)  
Yes 231 (71.1)  133 (75.1)  87 (64.4)  11 (84.6)  
  .034  .814  .007  .862 
Categories with under 20 cases are italicised; effect modification was not considered. 
